


<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2025-09-09T13:49:21Z</responseDate>
    <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:12405325" metadataPrefix="pmc">https://pmc.ncbi.nlm.nih.gov/api/oai/v1/mh/</request>
    
    <GetRecord>
        <record>
    <header>
    <identifier>oai:pubmedcentral.nih.gov:12405325</identifier>
    <datestamp>2025-09-04</datestamp>
    
        
        <setSpec>pmc-open</setSpec>
        
    
</header>
    <metadata>
        
        <article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.4/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.4/ https://jats.nlm.nih.gov/archiving/1.4/xsd/JATS-archivearticle1-4.xsd" article-type="review-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Neurol</journal-id><journal-id journal-id-type="iso-abbrev">J Neurol</journal-id><journal-id journal-id-type="pmc-domain-id">365</journal-id><journal-id journal-id-type="pmc-domain">springeropen</journal-id><journal-title-group><journal-title>Journal of Neurology</journal-title></journal-title-group><issn pub-type="ppub">0340-5354</issn><issn pub-type="epub">1432-1459</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Springer</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12405325</article-id><article-id pub-id-type="pmcid-ver">PMC12405325.1</article-id><article-id pub-id-type="pmcaid">12405325</article-id><article-id pub-id-type="pmcaiid">12405325</article-id><article-id pub-id-type="pmid">40892138</article-id><article-id pub-id-type="doi">10.1007/s00415-025-13314-7</article-id><article-id pub-id-type="publisher-id">13314</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Advancing personalized spinal muscular atrophy care: matching the right biomarker to the right patient at the right time</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-5425-969X</contrib-id><name name-style="western"><surname>Corti</surname><given-names initials="S">Stefania</given-names></name><address><email>stefania.corti@unimi.it</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ottoboni</surname><given-names initials="L">Linda</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Sansone</surname><given-names initials="V">Valeria</given-names></name><address><email>valeria.sansone@centrocliniconemo.it</email></address><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00wjc7c48</institution-id><institution-id institution-id-type="GRID">grid.4708.b</institution-id><institution-id institution-id-type="ISNI">0000 0004 1757 2822</institution-id><institution>Dino Ferrari Centre, Department of Pathophysiology and Transplantation (DEPT), </institution><institution>Universit&#224; Degli Studi Di Milano, </institution></institution-wrap>Milan, Italy </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/016zn0y21</institution-id><institution-id institution-id-type="GRID">grid.414818.0</institution-id><institution-id institution-id-type="ISNI">0000 0004 1757 8749</institution-id><institution>SC Neurology Unit, Department of Neurosciences and Mental Health, </institution><institution>Fondazione IRCCS Ca&#8217; Granda Ospedale Maggiore Policlinico, </institution></institution-wrap>Milan, Italy </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/016zn0y21</institution-id><institution-id institution-id-type="GRID">grid.414818.0</institution-id><institution-id institution-id-type="ISNI">0000 0004 1757 8749</institution-id><institution>SSD Neuromuscular and Rare Diseases, Department of Neurosciences and Mental Health, </institution><institution>Fondazione IRCCS Ca&#8217; Granda Ospedale Maggiore Policlinico, </institution></institution-wrap>Milan, Italy </aff><aff id="Aff4"><label>4</label>NeMO Clinical Center, Milan, Italy </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00wjc7c48</institution-id><institution-id institution-id-type="GRID">grid.4708.b</institution-id><institution-id institution-id-type="ISNI">0000 0004 1757 2822</institution-id><institution>Department of Neurorehabilitation, </institution><institution>University of Milan, </institution></institution-wrap>Milan, Italy </aff></contrib-group><pub-date pub-type="epub"><day>2</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="ppub"><year>2025</year></pub-date><volume>272</volume><issue>9</issue><issue-id pub-id-type="pmc-issue-id">496088</issue-id><elocation-id>605</elocation-id><history><date date-type="received"><day>4</day><month>7</month><year>2025</year></date><date date-type="rev-recd"><day>31</day><month>7</month><year>2025</year></date><date date-type="accepted"><day>1</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>02</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-04 00:25:59.930"><day>04</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="415_2025_Article_13314.pdf"/><abstract id="Abs1"><p id="Par1">With the advent of survival motor neuron (SMN)-enhancing therapies, the natural course of spinal muscular atrophy (SMA) has been reshaped, unveiling new patient phenotypes. As therapeutic options expand, there is an increasing demand for robust biomarkers to enhance prognostic accuracy, anticipate treatment response, track disease progression, and support personalized clinical decision-making. This narrative review critically examines the literature and discusses the role and appropriate application of key biomarkers across different age groups, ranging from presymptomatic newborns to adults with chronic disease. Genetic testing remains the diagnostic gold standard, with <italic toggle="yes">SMN2</italic> copy number serving as the strongest prognostic indicator. However, substantial phenotypic variability exists among individuals with the same <italic toggle="yes">SMN2</italic> copy number. Neurophysiological measures, including compound muscle action potential (CMAP) and motor unit number estimation (MUNE), accurately inform about motor neuron integrity, often anticipating clinical changes and potentially predicting treatment responsiveness. Circulating neurofilaments (NF) are increasingly recognized as sensitive biomarkers of active neurodegeneration. While NF holds promise in infants and younger children, its relevance in adolescents and adults remains limited. Conversely, quantitative muscle imaging techniques, such as MRI and ultrasound, may be valuable tools in adolescent and adult patients, capturing long-term muscle structural changes. By reviewing the current evidence across age groups, we provide an overview of biomarker application in newborns, children and adolescents/adults for diagnostic, prognostic, predictive, and monitoring purposes to help advance individualized management across all SMA stages.</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Spinal muscular atrophy</kwd><kwd>Biomarker</kwd><kwd>Neurophysiology</kwd><kwd>Neurofilament</kwd><kwd>Prognosis</kwd><kwd>Monitoring</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100005614</institution-id><institution>Biogen</institution></institution-wrap></funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Springer-Verlag GmbH Germany, part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par2">Spinal muscular atrophy (SMA) is a rare neuromuscular degenerative disorder characterized by the progressive loss of motor neurons and consequent muscle atrophy [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. It is an autosomal recessive genetic disorder primarily caused by homozygous deletions (or, less frequently, mutations) in the <italic toggle="yes">SMN1</italic> gene, which encodes for the survival motor neuron (SMN), an essential protein for the survival of motor neurons [<xref ref-type="bibr" rid="CR3">3</xref>]. The disease presents with continuous and incremental symptom severity, and patients are typically classified into four main types (0&#8211;IV) according to age of onset, symptom severity and motor milestones achievement. Type 0 SMA is embryonically lethal, while type IV represents the mildest form, characterized by mild muscle weakness, while types I&#8211;III show a range of symptom severity [<xref ref-type="bibr" rid="CR4">4</xref>&#8211;<xref ref-type="bibr" rid="CR9">9</xref>].</p><p id="Par3">The loss of functional SMN protein is partially compensated by the presence of <italic toggle="yes">SMN2</italic>, a paralogous gene of <italic toggle="yes">SMN</italic>. Compared to <italic toggle="yes">SMN1</italic>, <italic toggle="yes">SMN2</italic> carries a single nucleotide substitution (C&#8201;&gt;&#8201;T) in exon 7, which causes aberrant splicing in the pre-mRNA. As a result, most <italic toggle="yes">SMN2</italic> transcripts skip exon 7, yielding a truncated SMN protein (SMN&#916;7). Despite the altered <italic toggle="yes">SMN2</italic> splicing pattern, approximately 10% of <italic toggle="yes">SMN2</italic> transcripts include exon 7 and produce functional SMN protein [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>]. Overall, the amount of SMN functional protein expressed in patients with SMA varies depending on the individual's number of <italic toggle="yes">SMN2</italic> copies [<xref ref-type="bibr" rid="CR11">11</xref>&#8211;<xref ref-type="bibr" rid="CR14">14</xref>].</p><p id="Par4">Recent years have witnessed groundbreaking advancements in the treatment of this disease. Three transformative, gene-targeting therapies have been approved, each aimed at increasing the availability of SMN protein: the splice-modifying drugs nusinersen and risdiplam, acting on <italic toggle="yes">SMN2</italic> pre-mRNA splicing to favor exon 7 inclusion, and onasemnogene abeparvovec (AVXS-101), a gene therapy delivering <italic toggle="yes">SMN1</italic> transgene through an adeno-associated virus (AAV9) vector [<xref ref-type="bibr" rid="CR15">15</xref>&#8211;<xref ref-type="bibr" rid="CR19">19</xref>]. Beyond SMN-targeting therapies, SMN-independent therapeutic strategies are also under investigation. These emerging approaches aim to modulate alternative pathways involved in muscle function, neuromuscular junction integrity, neuroprotection, cell survival, and epigenetic regulation. When used in combination with the approved SMN-enhancing treatments, these novel molecules may provide complementary benefits by addressing distinct pathophysiological mechanisms [<xref ref-type="bibr" rid="CR20">20</xref>]. The advent of these SMN-enhancing therapies has substantially improved outcomes across all SMA severities, especially in presymptomatic infants and children [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR22">22</xref>], younger patients [<xref ref-type="bibr" rid="CR23">23</xref>], and patients with some residual motor function [<xref ref-type="bibr" rid="CR24">24</xref>]. With the introduction of these treatments, the natural history of SMA has undergone a profound transformation, unveiling novel SMA phenotypes which differ across age of onset and show different residual symptom severity and motor milestone achievement [<xref ref-type="bibr" rid="CR25">25</xref>]. Upon treatment, some patients initially categorized as type I or type II have achieved unexpected milestones for their SMA type, thereby exceeding the limits of the classification system [<xref ref-type="bibr" rid="CR26">26</xref>]. As a result, the traditional classification of SMA into types 0&#8211;IV has become increasingly outdated and less reflective of patient outcomes, based on functional status [<xref ref-type="bibr" rid="CR26">26</xref>&#8211;<xref ref-type="bibr" rid="CR29">29</xref>]. To overcome the barriers associated with this classification, patients are now referred to as non-sitters, sitters, and walkers, thus allowing the inclusion of new phenotypes emerged with the introduction of the new treatments.</p><p id="Par5">Because of the effective delay in the progression of SMA, many patients, including adults with severe disabilities and parents or caregivers of pediatric patients, report meaningful improvements following treatment. However, profound inter-individual variability in treatment response has been observed in patients despite similar baseline characteristics [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR31">31</xref>]. Growing evidence from clinical trials and real-world evidence [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR32">32</xref>&#8211;<xref ref-type="bibr" rid="CR48">48</xref>] provides refined clinical information and relatively adequate data on the advantages and limitations of each treatment available. However, the degree of variability between patients underscores the need for additional information to guide clinical practice. In general, there is consensus that the number of <italic toggle="yes">SMN2</italic> copies, the initial level of disability when treatment is started, and the age at which this occurs are the most significant determinants of the outcome. Yet, this information does not fill the gap that still exists when considering treatment choices, prognosis, and patient trajectories over time. In some cases, therapies stabilize the patient's condition, preventing further decline in function, while in other cases, they may lead to significant improvements, by either partially restoring muscle functions or enhancing overall motor performance. Systemically administered therapies such as risdiplam and AVXS-101 may have effects beyond the central nervous system. Indeed, it is not unusual to see that impact on neuromotor, respiratory, or swallowing functions, which may follow different timelines. Conversely, nusinersen is expected to have primarily CNS-mediated effects, due to its intrathecal administration and pharmacokinetic properties. Nevertheless, preliminary evidence suggests that systemic outcomes may also occur with this molecule [<xref ref-type="bibr" rid="CR49">49</xref>&#8211;<xref ref-type="bibr" rid="CR51">51</xref>]. Importantly, in a relentlessly progressive disease, such as SMA, and considering that current treatments may not completely block disease progression, maintaining stability is increasingly recognized as a meaningful therapeutic success. This leads to a discussion of patients&#8217; expectations, which is crucial in guiding care and management.</p><p id="Par6">The development of multimodal assessments, ideally tailored to the unique characteristics of different patient populations, is becoming increasingly necessary to fully capture the diverse therapeutic responses to these treatments. While standardized tools remain valuable, they often lack the sensitivity to detect subtle but meaningful changes in disease progression or improvements in less commonly measured functional domains [<xref ref-type="bibr" rid="CR52">52</xref>]. This is often an additional limitation in the clinic to guide treatment choices and manage expectations.</p><p id="Par7">In this regard, the integration of multiple biomarkers is anticipated to play a central role, serving different purposes throughout the course of the disease. Diagnostic biomarkers are essential for early detection and confirmation of the disease, which is particularly crucial in presymptomatic cases identified through newborn screening (NBS). Prognostic biomarkers predict symptom severity and disease progression, while predictive biomarkers help identify patients most likely to benefit from specific interventions. Pharmacodynamic biomarkers enable the assessment of treatment responses and may support clinicians in ongoing management during follow-up monitoring [<xref ref-type="bibr" rid="CR53">53</xref>, <xref ref-type="bibr" rid="CR54">54</xref>].</p><p id="Par8">This narrative review examines the evolving role of selected biomarkers (genetic biomarkers, neurophysiological measures, neurofilaments, and imaging techniques) in guiding clinical decision-making and supporting patients throughout the SMA journey, from diagnosis to treatment and long-term monitoring. These biomarkers have been selected because they are routinely used in clinical practice and/or are supported by a substantial body of evidence in the literature. Other biomarkers have not been included either because they are not commonly used in clinical practice or because data about their long-term clinical significance are limited.</p><p id="Par9">To illustrate the practical application of these biomarkers in clinical practice, we present a series of hypothetical clinical case studies. By providing pragmatic examples, we show how biomarkers can empower clinicians and patients, address unmet needs, and shape the future of SMA care.</p></sec><sec id="Sec2"><title>The role of SMA biomarkers in presymptomatic newborns</title><sec id="Sec3"><title>Genetic biomarkers</title><p id="Par10">In presymptomatic newborns, diagnosis depends exclusively on genetic testing to identify deletions or mutations in the <italic toggle="yes">SMN1</italic> gene through NBS [<xref ref-type="bibr" rid="CR55">55</xref>&#8211;<xref ref-type="bibr" rid="CR57">57</xref>]. Given the demonstrated effectiveness of current therapies in altering the disease course, particularly when initiated early, population-wide screening programs and extended access to genetic testing to search for <italic toggle="yes">SMN1</italic> gene alterations have become increasingly available. Indeed, treatment initiation during the presymptomatic phase is associated with improved outcomes, enhanced long-term prognosis, and the potential to substantially alter the course of the disease [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR58">58</xref>].</p><p id="Par11">Once a presymptomatic newborn is diagnosed with SMA through NBS, knowing the <italic toggle="yes">SMN2</italic> copy number becomes essential for prognosis. Although limited, the production of functional SMN protein from the <italic toggle="yes">SMN2</italic> gene plays a significant role in modulating disease severity and progression [<xref ref-type="bibr" rid="CR59">59</xref>, <xref ref-type="bibr" rid="CR60">60</xref>]. In general, a higher number of <italic toggle="yes">SMN2</italic> copies is associated with a milder clinical phenotype. Patients with the most severe form, type 0 SMA, typically have a single <italic toggle="yes">SMN2</italic> copy, while those with type III and IV SMA have three or four copies [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR55">55</xref>, <xref ref-type="bibr" rid="CR61">61</xref>&#8211;<xref ref-type="bibr" rid="CR65">65</xref>]. As such, the <italic toggle="yes">SMN2</italic> copy number currently stands as the strongest prognostic biomarker in SMA, especially in presymptomatic patients [<xref ref-type="bibr" rid="CR27">27</xref>].</p><p id="Par12">However, emerging evidence indicates that identical <italic toggle="yes">SMN2</italic> copy numbers can be seen across patients with varying degrees of symptom severity, SMA types and progression rates [<xref ref-type="bibr" rid="CR64">64</xref>, <xref ref-type="bibr" rid="CR66">66</xref>&#8211;<xref ref-type="bibr" rid="CR69">69</xref>], suggesting that the relationship between <italic toggle="yes">SMN2</italic> copy number and phenotype is more complex than initially perceived [<xref ref-type="bibr" rid="CR70">70</xref>&#8211;<xref ref-type="bibr" rid="CR72">72</xref>]. The study by Ricci et al. [<xref ref-type="bibr" rid="CR68">68</xref>] investigated the clinical phenotypes of pediatric and adult patients who possessed four copies of the <italic toggle="yes">SMN2</italic> gene. Among 169 patients, most (66%) were classified as type IIIb SMA, with smaller proportions having type IIIa (24%) and 5% II or IV. Despite the presence of four <italic toggle="yes">SMN2</italic> copies, patients displayed a wide range of SMA types and clinical severity. Functional decline was common, with loss of ambulation occurring in 35% of type III and 25% of type IV patients. However, the cohort also included six presymptomatic individuals and two asymptomatic adults. By highlighting the considerable phenotypic variability in disease progression within this genetic subgroup, these findings indicate that relying solely on <italic toggle="yes">SMN2</italic> copy number to predict disease severity may be insufficient [<xref ref-type="bibr" rid="CR68">68</xref>]. Potential modifiers of disease severity have been identified and include, among others, <italic toggle="yes">SMN2</italic> gene variants, such as the c.859G&#8201;&gt;&#8201;C variant, associated with the mildest phenotypes [<xref ref-type="bibr" rid="CR59">59</xref>]; Plastin 3 (PLS3), which acts as a protective modifier particularly in females [<xref ref-type="bibr" rid="CR73">73</xref>, <xref ref-type="bibr" rid="CR74">74</xref>]; and neurocalcin delta (NCALD), whose reduction protects against SMA by restoring impaired endocytosis [<xref ref-type="bibr" rid="CR75">75</xref>]. These modifiers may contribute to the phenotypic variability observed among patients with identical <italic toggle="yes">SMN2</italic> copy numbers.</p></sec><sec id="Sec4"><title>Neurophysiological measurements in presymptomatic newborns</title><p id="Par13">The use of supplementary biomarkers beyond genetic testing for <italic toggle="yes">SMN1</italic> and <italic toggle="yes">SMN2</italic> copies becomes increasingly important, especially in presymptomatic newborns diagnosed with SMA through NBS. Although long-term data (with follow-up of up to 5&#160;years in treated presymptomatic children [<xref ref-type="bibr" rid="CR36">36</xref>]) suggest that motor function is maintained, additional measurements over time are necessary to confirm the extent to which early treatment prevents phenoconversion, and assess the &#8220;health&#8221; of the motor neuron pool. Among neurophysiological assessments, compound muscle action potential (CMAP) amplitude effectively informs about motor neuron integrity and predicts disease progression [<xref ref-type="bibr" rid="CR76">76</xref>, <xref ref-type="bibr" rid="CR77">77</xref>]. Its values vary according to SMA type and&#160;<italic toggle="yes">SMN2</italic>&#160;copy number [<xref ref-type="bibr" rid="CR76">76</xref>] and correlate with motor function [<xref ref-type="bibr" rid="CR78">78</xref>, <xref ref-type="bibr" rid="CR79">79</xref>]. CMAP amplitude can enhance initial clinical assessment [<xref ref-type="bibr" rid="CR80">80</xref>], as reduced values often precede the onset of overt motor symptoms [<xref ref-type="bibr" rid="CR55">55</xref>, <xref ref-type="bibr" rid="CR81">81</xref>].</p></sec><sec id="Sec5"><title>Neurofilaments in presymptomatic newborns</title><p id="Par14">In addition to neurophysiological measures, there is consensus that neurofilaments (NFs) can be considered as biomarkers of active neurodegeneration; upon cellular damage, NFs are released from neurons and can be found in both cerebrospinal fluid (CSF) and blood [<xref ref-type="bibr" rid="CR82">82</xref>, <xref ref-type="bibr" rid="CR83">83</xref>]. Indeed, elevated levels of phosphorylated NF-heavy chain (pNF-H) and NF-light chain (NF-L) have been found in several neurologic disorders [<xref ref-type="bibr" rid="CR83">83</xref>&#8211;<xref ref-type="bibr" rid="CR86">86</xref>], including SMA [<xref ref-type="bibr" rid="CR87">87</xref>]. Nowadays, there is significant interest within the scientific community in advancing the understanding and utilization of NFs as a prognostic and predictive biomarker in patients with SMA [<xref ref-type="bibr" rid="CR54">54</xref>]. Although not routinely performed in clinical practice, measurement of NF levels may complement the prognostic information obtained from genetic and neurophysiological biomarkers. Notably, serum pNF-H and NF-L concentrations have been shown to correlate with <italic toggle="yes">SMN2</italic> copy number, earlier age of symptom onset, and CMAP amplitude values [<xref ref-type="bibr" rid="CR88">88</xref>]. Beyond their sensitivity in detecting active neurodegeneration and identifying subclinical pathological changes, measuring NF levels offers added value through their emerging role in predicting response to treatment. In general, both blood and CSF NF levels are higher in SMA newborns compared to healthy controls [<xref ref-type="bibr" rid="CR87">87</xref>, <xref ref-type="bibr" rid="CR89">89</xref>, <xref ref-type="bibr" rid="CR90">90</xref>], and both decline following nusinersen treatment [<xref ref-type="bibr" rid="CR87">87</xref>, <xref ref-type="bibr" rid="CR89">89</xref>]. A strong correlation has been reported between serum and CSF NF-L levels in pediatric patients [<xref ref-type="bibr" rid="CR90">90</xref>]. Given their less invasive nature, blood-based NF measurements are generally preferred in clinical practice. However, when nusinersen is the selected treatment, its intrathecal administration can be leveraged to assess NF levels in the CSF.</p><p id="Par15">The NURTURE study [<xref ref-type="bibr" rid="CR89">89</xref>] was pivotal in revealing that plasma pNF-H levels at baseline and day 64 after nusinersen initiation effectively predicted both Hammersmith Infant Neurological Examination&#160;- Section <xref rid="Sec2" ref-type="sec">2</xref> (HINE-2) total motor milestone achievement and early independent walking. Compared with CMAP amplitude and age, pNF-H was the strongest predictor of motor function [<xref ref-type="bibr" rid="CR89">89</xref>]. While this study suggests that NFs may be considered useful biomarkers for predicting the response to nusinersen, this does not seem to be applicable to predict outcomes using other treatments, such as AXVS-101. After dosing in patients started on gene therapy, NFs show a rapid, transitory increase [<xref ref-type="bibr" rid="CR88">88</xref>, <xref ref-type="bibr" rid="CR91">91</xref>]. Intriguingly, the rise in NF-L was minor or null in infants who were pre-treated with nusinersen before AXVS-101 administration. The initial increase in NF levels could be due to an inflammatory response triggered by the infection of neuronal cells by AAV9 particles [<xref ref-type="bibr" rid="CR91">91</xref>]. No data are currently available on the effects of risdiplam on NF levels [<xref ref-type="bibr" rid="CR88">88</xref>].</p><p id="Par16">The key studies assessing the role of biomarkers in newborns are summarized in Table&#160;<xref rid="Tab1" ref-type="table">1</xref> [<xref ref-type="bibr" rid="CR55">55</xref>, <xref ref-type="bibr" rid="CR57">57</xref>, <xref ref-type="bibr" rid="CR80">80</xref>, <xref ref-type="bibr" rid="CR81">81</xref>, <xref ref-type="bibr" rid="CR88">88</xref>, <xref ref-type="bibr" rid="CR89">89</xref>].<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table&#160;1</label><caption><p>Main studies assessing the role of biomarkers in newborns</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Study (first author, year)</th><th align="left" colspan="1" rowspan="1">Study design</th><th align="left" colspan="1" rowspan="1">Number of patients</th><th align="left" colspan="1" rowspan="1">Age</th><th align="left" colspan="1" rowspan="1">Biomarker(s)</th><th align="left" colspan="1" rowspan="1">Role</th><th align="left" colspan="1" rowspan="1">Main findings</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Vill et al., 2019 [<xref ref-type="bibr" rid="CR55">55</xref>]</td><td align="left" colspan="1" rowspan="1">Prospective newborn screening study</td><td align="left" colspan="1" rowspan="1">165,525 screened; 22 SMA cases identified</td><td align="left" colspan="1" rowspan="1">Newborns (median treatment initiation: 24&#160;days)</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">SMN1</italic> exon 7 deletion, <italic toggle="yes">SMN2</italic> copy number, CMAP amplitude</td><td align="left" colspan="1" rowspan="1">Diagnostic, Prognostic, Predictive</td><td align="left" colspan="1" rowspan="1">Early diagnosis through NBS led to presymptomatic treatment. <italic toggle="yes">SMN2</italic> copy number and CMAP values correlated with disease severity; low CMAP values preceded motor function decline</td></tr><tr><td align="left" colspan="1" rowspan="1">Kariyawasam et al., 2020 [<xref ref-type="bibr" rid="CR80">80</xref>]</td><td align="left" colspan="1" rowspan="1">Prospective newborn screening study</td><td align="left" colspan="1" rowspan="1">103,903 screened; 9 SMA cases identified</td><td align="left" colspan="1" rowspan="1">Newborns</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">SMN1</italic> exon 7 deletion, <italic toggle="yes">SMN2</italic> copy number</td><td align="left" colspan="1" rowspan="1">Diagnostic, Prognostic</td><td align="left" colspan="1" rowspan="1">Early diagnosis through NBS enabled early treatment initiation. Lower <italic toggle="yes">SMN2</italic> copy numbers correlated with earlier symptom onset and more severe phenotypes</td></tr><tr><td align="left" colspan="1" rowspan="1">Berzal-Serrano et al., 2025 [<xref ref-type="bibr" rid="CR57">57</xref>]</td><td align="left" colspan="1" rowspan="1">Newborn screening study</td><td align="left" colspan="1" rowspan="1">31,560 screened; 4 SMA cases identified</td><td align="left" colspan="1" rowspan="1">Newborns</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">SMN1</italic> exon 7 deletion, SMN2 copy number</td><td align="left" colspan="1" rowspan="1">Diagnostic, Prognostic</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">SMN1</italic> deletion confirmed SMA diagnosis; <italic toggle="yes">SMN2</italic> copy number guided early treatment decisions</td></tr><tr><td align="left" colspan="1" rowspan="1">De Vivo et al., 2019 [<xref ref-type="bibr" rid="CR89">89</xref>]</td><td align="left" colspan="1" rowspan="1">Phase II clinical trial</td><td align="left" colspan="1" rowspan="1">25</td><td align="left" colspan="1" rowspan="1">&#8201;&#8804;&#8201;6&#160;weeks old at first nusinersen dose</td><td align="left" colspan="1" rowspan="1">NF (pNF-H), SMN2 copy number</td><td align="left" colspan="1" rowspan="1">Prognostic, Predictive</td><td align="left" colspan="1" rowspan="1">Early nusinersen treatment improved motor function; NF levels declined with treatment</td></tr><tr><td align="left" colspan="1" rowspan="1">Weng et al., 2021 [<xref ref-type="bibr" rid="CR81">81</xref>]</td><td align="left" colspan="1" rowspan="1">Newborn screening study</td><td align="left" colspan="1" rowspan="1">21</td><td align="left" colspan="1" rowspan="1">Newborns</td><td align="left" colspan="1" rowspan="1">CMAP amplitude, <italic toggle="yes">SMN2</italic> copy number</td><td align="left" colspan="1" rowspan="1">Predictive, Prognostic</td><td align="left" colspan="1" rowspan="1">CMAP drop predicted symptom onset; higher pretreatment CMAP correlated with better response to nusinersen</td></tr><tr><td align="left" colspan="1" rowspan="1">Alves et al., 2021 [<xref ref-type="bibr" rid="CR88">88</xref>]</td><td align="left" colspan="1" rowspan="1">Longitudinal cohort study</td><td align="left" colspan="1" rowspan="1">68 untreated, 22 treated</td><td align="left" colspan="1" rowspan="1">0&#8211;3&#160;years (range)</td><td align="left" colspan="1" rowspan="1">NF (pNF-H, NF-L)</td><td align="left" colspan="1" rowspan="1">Prognostic, Predictive</td><td align="left" colspan="1" rowspan="1">Higher NF levels were associated with disease severity; nusinersen reduced NF levels, but onasemnogene abeparvovec increased them</td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">CMAP</italic> Compound muscle action potential, <italic toggle="yes">MRI</italic> Magnetic resonance imaging, <italic toggle="yes">MUNE</italic> Motor unit number estimation, <italic toggle="yes">MUNIX</italic> Motor unit number index, <italic toggle="yes">MUSIX</italic> Motor unit size index, <italic toggle="yes">NF-L</italic> Neurofilament light chain, <italic toggle="yes">pNF-H</italic> Phosphorylated neurofilament heavy chain, <italic toggle="yes">SMA</italic> Spinal muscular atrophy, <italic toggle="yes">SMN</italic> Survival motor neuron</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec6"><title>Case study 1</title><p id="Par17">A. was the first child born to parents who were unaware of being carriers of a <italic toggle="yes">SMN1</italic> deletion, in a country where NBS is available. After 72&#160;h from dried blood spot (DBS) screening, confirmation of <italic toggle="yes">SMN1</italic> deletion was available, and three <italic toggle="yes">SMN2</italic> copies were detected. On day 3, A. was seen by a multidisciplinary team involving a neurologist, a child neurologist, a neonatologist, and a pediatrician, and the diagnosis was discussed with the parents. Data from clinical trials and real-world evidence were presented to contextualize the prognosis and treatment options. CMAP was also discussed as important to define motor neuron integrity. After having obtained informed consent from both parents, the ulnar nerve CMAP was tested and provided values within the normal range (amplitude&#8201;&gt;&#8201;5.9&#160;mV, distal latency&#8201;&lt;&#8201;3.8&#160;ms for age). A blood sample was obtained for anti-AAV9 antibodies and was also stored for future testing, including NFs levels. Treatment options were discussed with the parents. Follow-up was planned for 1 week later or as needed, based on clinical signs that may arise, and treatment was started.</p><p id="Par18">In this case, the clinical status, the number of <italic toggle="yes">SMN2</italic> copies, and the CMAP values were the key determinants used to discuss the prognosis, the treatment options, and expected outcomes, based on available evidence.</p></sec><sec id="Sec7"><title>Case study 2</title><p id="Par19">B. was born to parents who were known SMA carriers and was the second child in the family. The family resided in a country where NBS was not available. The older sibling had received the diagnosis of SMA at 3&#160;years of age, manifesting progressive lower limb weakness and reduced walking abilities. He was found to have four&#160;<italic toggle="yes">SMN2</italic> copies. Blood was collected to assess the level of anti-AAV9 antibodies and stored for additional testing. CMAP testing of the ulnar nerve was performed, and values were within the normal range. Parents decided to proceed with treatment. Follow-up was planned based on the selected treatment and would be adapted based on any emerging clinical symptoms.</p><p id="Par20">In this case, the clinical status, the number of <italic toggle="yes">SMN2</italic> copies, the CMAP values, and the sibling&#8217;s phenotype were the main factors used to discuss the prognosis, the most appropriate treatment, and the expected outcomes, based on available evidence.</p></sec><sec id="Sec8"><title>Case study 3</title><p id="Par21">C. was born in a country where NBS is available. Parents were unaware of being carriers of an <italic toggle="yes">SMN1</italic> deletion. On day 3, genetic test results confirmed SMA in the newborn; C. presented only one copy of <italic toggle="yes">SMN</italic>2. The high risk of rapid disease progression and potentially life-threatening symptoms was clearly communicated to the family. C. was admitted for close clinical monitoring and initiation of a treatment plan. Anti-AAV9 antibody levels were tested, and a blood sample was stored for future testing, including the quantification of exploratory biomarkers. CMAP amplitude of the ulnar nerve was measured and found to be below the normal threshold for age. Treatment was discussed and planned based on clinical status, prioritizing the stabilization of the disease and implementation of standard of care (SoC) in response to any emerging symptom of neurodegeneration.</p><p id="Par22">In this case, the clinical status and the number of <italic toggle="yes">SMN2</italic> copies were critical to discuss the need for careful monitoring, prioritizing clinical management and pharmacological treatment as an &#8220;add-on&#8221; treatment to improve prognosis and expected outcomes, based on available evidence. Neurophysiology data were acquired as a potential tool to monitor disease progression and to support long-term clinical decision-making.</p></sec></sec><sec id="Sec9"><title>The role of SMA biomarkers in children</title><p id="Par23">Studies focusing on children with SMA cover a broad age range, spanning from a few months to 12 years of age; unsurprisingly, this patient's setting exhibits a wide spectrum of disease severity. This heterogeneous population presents unique challenges, as the trajectory of disease progression differs considerably depending on multiple factors, including the time of treatment initiation and overall disease severity. Most children with type I, II, and III SMA who have already developed symptoms are currently receiving treatment, and their response varies widely.</p><sec id="Sec10"><title>Neurophysiological measurements in children</title><p id="Par24">Neurophysiological tests can help reveal subclinical changes in motor units, which may not necessarily correspond to subjective and objective measures of motor function. Among these, CMAP and motor unit number estimation (MUNE) have been widely studied; other measurements, such as motor unit number index (MUNIX) and motor unit size index (MUSIX), may provide additional information [<xref ref-type="bibr" rid="CR92">92</xref>, <xref ref-type="bibr" rid="CR93">93</xref>].</p><p id="Par25">CMAP measurement may serve to assess disease severity and predict disease progression and treatment response. In children, CMAP amplitudes vary according to disease severity and correlate with motor function [<xref ref-type="bibr" rid="CR77">77</xref>, <xref ref-type="bibr" rid="CR94">94</xref>], though variability exists across SMA types [<xref ref-type="bibr" rid="CR95">95</xref>&#8211;<xref ref-type="bibr" rid="CR97">97</xref>]. Nusinersen increases CMAP amplitudes over time, consistently with improved motor function [<xref ref-type="bibr" rid="CR94">94</xref>, <xref ref-type="bibr" rid="CR98">98</xref>]. Higher baseline CMAP values have been associated with better treatment outcomes for both nusinersen and AVXS-101 [<xref ref-type="bibr" rid="CR94">94</xref>, <xref ref-type="bibr" rid="CR99">99</xref>&#8211;<xref ref-type="bibr" rid="CR101">101</xref>]. Greater improvements in CMAP amplitudes may be observed in younger children and those receiving early treatment, possibly because they retain more viable motor units than older patients or children receiving treatment at an older age [<xref ref-type="bibr" rid="CR98">98</xref>, <xref ref-type="bibr" rid="CR99">99</xref>, <xref ref-type="bibr" rid="CR102">102</xref>].</p><p id="Par26">MUNE is considered more sensitive than CMAP for detecting subtle changes in motor unit loss or reinnervation, as it identifies changes at the level of individual motor units [<xref ref-type="bibr" rid="CR94">94</xref>, <xref ref-type="bibr" rid="CR103">103</xref>]. Like CMAP, MUNE values also generally correlate with <italic toggle="yes">SMN2</italic> copy number and vary according to SMA types [<xref ref-type="bibr" rid="CR76">76</xref>, <xref ref-type="bibr" rid="CR94">94</xref>, <xref ref-type="bibr" rid="CR97">97</xref>, <xref ref-type="bibr" rid="CR103">103</xref>, <xref ref-type="bibr" rid="CR104">104</xref>]. MUNE also correlates with motor function, although the strength of this association varies. This variability is likely due to MUNE's ability to detect"silent"denervation, where the significant motor unit loss occurs without noticeable declines in motor function, which is possibly maintained by compensatory mechanisms, such as nerve sprouting and enlargement of surviving motor units [<xref ref-type="bibr" rid="CR97">97</xref>]. Interestingly, Kang et al. observed a longitudinal increase in MUNE values in treatment-na&#239;ve patients, especially those aged 5&#8211;10&#160;years old, suggesting spontaneous motor unit development [<xref ref-type="bibr" rid="CR97">97</xref>]. This is in contrast with the study by Swoboda et al., who also considered untreated patients but reported a progressive decline in MUNE values over time. Several factors may explain this discrepancy, including differences in both the age of patients at the start of longitudinal monitoring and the proportion of patients with SMA type I, II, and III [<xref ref-type="bibr" rid="CR76">76</xref>, <xref ref-type="bibr" rid="CR97">97</xref>]. In children treated with nusinersen, MUNE is often one of the earliest neurophysiological measures to show improvement following treatment initiation. The magnitude of this initial increase is associated with a greater likelihood of achieving clinically meaningful motor function gains [<xref ref-type="bibr" rid="CR94">94</xref>]. MUNE is a valuable tool for tracking disease progression in SMA, especially in early or less severe stages where motor function is preserved and CMAP may fail to detect meaningful changes. However, MUNE values should be interpreted with caution as multiple variables, including patients'age, disease duration, extent of denervation, and types and locations of nerves tested, may affect MUNE changes over time.</p><p id="Par27">Other neurophysiological parameters derived from CMAP measurement, including N50, A50, and largest single motor unit potential (LSMUP), should be evaluated in children alongside CMAP and MUNE, as they offer insights into motor unit remodeling and reinnervation. In the pivotal study by Kariyawasam et al., N50 values increased over time in children treated with nusinersen, suggesting that denervation is reduced within larger motor unit pools, and the extent of N50 improvement from baseline was associated with a higher probability of motor function improvement. In contrast, A50 and LSMUP, surrogates of collateral reinnervation, did not change [<xref ref-type="bibr" rid="CR94">94</xref>].</p></sec><sec id="Sec11"><title>Neurofilaments in children</title><p id="Par28">A substantial body of evidence supports the multiple roles of NFs in infants and young children with SMA, including their use as diagnostic, prognostic, predictive, monitoring, treatment response, and potential risk biomarkers [<xref ref-type="bibr" rid="CR87">87</xref>, <xref ref-type="bibr" rid="CR89">89</xref>, <xref ref-type="bibr" rid="CR90">90</xref>, <xref ref-type="bibr" rid="CR105">105</xref>, <xref ref-type="bibr" rid="CR106">106</xref>]. NF levels are elevated in pediatric patients compared to age-matched healthy controls [<xref ref-type="bibr" rid="CR90">90</xref>, <xref ref-type="bibr" rid="CR106">106</xref>, <xref ref-type="bibr" rid="CR107">107</xref>]; they also progressively decline with age and vary according to SMA severity, disease duration, and are usually higher in the acute than chronic phase [<xref ref-type="bibr" rid="CR88">88</xref>, <xref ref-type="bibr" rid="CR90">90</xref>, <xref ref-type="bibr" rid="CR107">107</xref>, <xref ref-type="bibr" rid="CR108">108</xref>]. As they influence the baseline levels of NF, age and disease severity are also the main factors that determine the extent of NF changes upon nusinersen treatment. Overall, nusinersen reduces NF-L levels in both the CNS and serum, with the most significant decline occurring in children with the most severe SMA phenotypes [<xref ref-type="bibr" rid="CR88">88</xref>, <xref ref-type="bibr" rid="CR90">90</xref>, <xref ref-type="bibr" rid="CR106">106</xref>, <xref ref-type="bibr" rid="CR107">107</xref>, <xref ref-type="bibr" rid="CR109">109</xref>]. Given this growing body of literature, the European Medicines Agency (EMA) has endorsed the potential use of NF-L as a biomarker for pediatric neurological diseases, including SMA, emphasizing its importance for clinical management and research [<xref ref-type="bibr" rid="CR110">110</xref>]. As elevated NF-L levels reflect disease activity and can be considerably decreased by nusinersen treatment [<xref ref-type="bibr" rid="CR90">90</xref>, <xref ref-type="bibr" rid="CR107">107</xref>], they can serve as valuable indicators for guiding therapeutic decisions, particularly regarding the timing of intervention. Although further research is needed to determine the most suitable biomarker &#8211; whether NF-L or pNF-H &#8211; the optimal biological fluid (CSF or plasma), and the most appropriate patient subset (children with SMA type I or all children with&#8201;&#8804;&#8201;2 <italic toggle="yes">SMN2</italic> copies), NF remains a promising biomarker that could indicate therapeutic success even in the absence of obvious motor unit score improvement.</p></sec><sec id="Sec12"><title>Imaging techniques in children</title><p id="Par29">Imaging techniques, including muscle ultrasound and magnetic resonance imaging (MRI), can inform about the status of muscle composition and/or architecture in SMA patients. In children, muscle pathology is dynamic and rapidly changing, making it harder to capture meaningful changes with static imaging. Although the role of muscle imaging in tracking SMA progression is still unclear, ultrasound and MRI have been shown to discriminate against children with SMA based on disease severity, thus constituting a potential biomarker for disease monitoring [<xref ref-type="bibr" rid="CR111">111</xref>&#8211;<xref ref-type="bibr" rid="CR116">116</xref>]. Quantitative MRI applied to children with SMA types II and III receiving nusinersen showed an increase in the fat fraction (FF) in the majority of tight muscles. Despite the progressive fat infiltration, children showed clinical improvement. In contrast to FF, improvements in other exploratory parameters obtained from diffusion tensor imaging (DTI) were observed, highlighting a potential role for these parameters as biomarkers to follow treatment outcomes. Although preliminary, these data may suggest that nusinersen may positively affect muscle microstructure, potentially decreasing muscle atrophy and restoring abnormal but viable muscle rather than preventing fat infiltration [<xref ref-type="bibr" rid="CR117">117</xref>]. Despite these encouraging findings, the rapid neurodegeneration taking place in children with SMA makes neurophysiological parameters and NF measurement more informative biomarkers than muscle imaging techniques to assess disease activity. Moreover, MRI is both time and cost intensive, further justifying the use of neurophysiological parameters and NF level measurement in this age group in routine clinical practice.</p></sec><sec id="Sec13"><title>Clinical significance of biomarkers in pediatric patients</title><p id="Par30">As discussed above, biomarker values tend to fluctuate with age, possibly indicating different scenarios (e.g., acute neurodegeneration, motor neuron preservation, compensatory reinnervation, etc.) in patients within the same age category. Therefore, the clinical relevance of each SMA biomarker may differ between early and late childhood; the use of biomarkers should be tailored according to the child's age and result interpretation requires great caution due to underlying heterogeneity in disease stage and prior treatment history. In the pediatric setting, the primary treatment goal should be symptom improvement, particularly in young children diagnosed and treated early, but again, this is highly dependent on the baseline clinical characteristics of the child, especially if respiratory and swallowing functions are affected.</p><p id="Par31">Discussion on expectations is a crucial step in the care process and should be fully integrated into the treatment pathway. It deserves adequate recognition and sufficient time, as communication and active listening are fundamental components of the care and cure of each individual. In these discussions, it is important to explain that different domains may improve at different times (e.g., motor&#8201;&gt;&#8201;respiratory muscles&#8201;&gt;&#8201;swallowing function, in different orders) and may require different timelines. Data from clinical trials and real-world studies suggest that 6&#8211;12&#160;months more are required to see more clinically significant changes [<xref ref-type="bibr" rid="CR89">89</xref>, <xref ref-type="bibr" rid="CR94">94</xref>, <xref ref-type="bibr" rid="CR98">98</xref>]. These changes need to be weighed against what would have been the natural course without treatment, from previous literature studies. Potential achievements or progression should always be discussed based on expectations. Patients&#8217; and families&#8217; preferences should always be considered [<xref ref-type="bibr" rid="CR118">118</xref>&#8211;<xref ref-type="bibr" rid="CR120">120</xref>].</p><p id="Par32">Recent consensus guidelines [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR27">27</xref>] indicate that add-on or switch therapy should generally be considered only after a prolonged period of monotherapy, also considering country-specific regulatory approvals and reimbursement policies. Special consideration should be given to potential worsening and greater need for rehabilitation programs after spine surgery, which typically occurs at this stage [<xref ref-type="bibr" rid="CR121">121</xref>&#8211;<xref ref-type="bibr" rid="CR123">123</xref>].</p><p id="Par33">The main studies assessing the role of biomarkers in children with SMA are reviewed in Table&#160;<xref rid="Tab2" ref-type="table">2</xref> [<xref ref-type="bibr" rid="CR90">90</xref>, <xref ref-type="bibr" rid="CR94">94</xref>, <xref ref-type="bibr" rid="CR99">99</xref>, <xref ref-type="bibr" rid="CR101">101</xref>, <xref ref-type="bibr" rid="CR106">106</xref>, <xref ref-type="bibr" rid="CR107">107</xref>, <xref ref-type="bibr" rid="CR117">117</xref>].<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table&#160;2</label><caption><p>Main studies assessing the role of biomarkers in children</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Study (first author, year)</th><th align="left" colspan="1" rowspan="1">Study design</th><th align="left" colspan="1" rowspan="1">Number of patients</th><th align="left" colspan="1" rowspan="1">Age</th><th align="left" colspan="1" rowspan="1">Biomarker(s)</th><th align="left" colspan="1" rowspan="1">Role</th><th align="left" colspan="1" rowspan="1">Main findings</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Kariyawasam et al., 2021 [<xref ref-type="bibr" rid="CR94">94</xref>]</td><td align="left" colspan="1" rowspan="1">Prospective cohort study</td><td align="left" colspan="1" rowspan="1">20</td><td align="left" colspan="1" rowspan="1">99 months (median) (range: 4&#8211;193)</td><td align="left" colspan="1" rowspan="1">CMAP, MUNE, N50</td><td align="left" colspan="1" rowspan="1">Prognostic Predictive</td><td align="left" colspan="1" rowspan="1">Baseline CMAP and MUNE correlated with <italic toggle="yes">SMN2</italic> copies and motor function. Nusinersen increased CMAP, MUNE, and N50 values. CMAP increases&#8201;&#8805;&#8201;4.5 mV and MUNE increases&#8201;&#8805;&#8201;15 units correlated with a higher likelihood of motor improvements in patients with type II and III SMA</td></tr><tr><td align="left" colspan="1" rowspan="1">Barrois et al., 2023 [<xref ref-type="bibr" rid="CR101">101</xref>]</td><td align="left" colspan="1" rowspan="1">Prospective cohort study</td><td align="left" colspan="1" rowspan="1">25</td><td align="left" colspan="1" rowspan="1"><p>227 days (median, Cohort 1) (range: 114&#8211;334)</p><p>247 days (median, Cohort 2) (range: 26&#8211;496)</p></td><td align="left" colspan="1" rowspan="1">CMAP amplitude</td><td align="left" colspan="1" rowspan="1">Predictive</td><td align="left" colspan="1" rowspan="1">CMAP combined with motor scores predicted motor improvement during treatment with AVXS-101</td></tr><tr><td align="left" colspan="1" rowspan="1">Richard et al., 2024 [<xref ref-type="bibr" rid="CR99">99</xref>]</td><td align="left" colspan="1" rowspan="1">Longitudinal study</td><td align="left" colspan="1" rowspan="1">10</td><td align="left" colspan="1" rowspan="1">From 11 months to 10 years</td><td align="left" colspan="1" rowspan="1">CMAP amplitude</td><td align="left" colspan="1" rowspan="1">Predictive</td><td align="left" colspan="1" rowspan="1">Increased CMAP values correlated with motor improvements in SMA type II patients treated with nusinersen. Patients aged&#8201;&lt;&#8201;5 years showed more pronounced CMAP and motor improvements than older children</td></tr><tr><td align="left" colspan="1" rowspan="1">Olsson et al., 2019 [<xref ref-type="bibr" rid="CR106">106</xref>]</td><td align="left" colspan="1" rowspan="1">Prospective cohort study</td><td align="left" colspan="1" rowspan="1">12 patients, 11 controls</td><td align="left" colspan="1" rowspan="1">14.4 months&#8201;&#177;&#8201;24.0 (mean&#8201;&#177;&#8201;SD) (range: 1.2&#8211;92.4)</td><td align="left" colspan="1" rowspan="1">NF-L</td><td align="left" colspan="1" rowspan="1">Predictive, Monitoring</td><td align="left" colspan="1" rowspan="1">CSF NF-L levels decreased and correlated with motor improvement during nusinersen treatment in patients with SMA type I and two <italic toggle="yes">SMN2</italic> copies</td></tr><tr><td align="left" colspan="1" rowspan="1">Nitz et al., 2021 [<xref ref-type="bibr" rid="CR90">90</xref>]</td><td align="left" colspan="1" rowspan="1">Observational study</td><td align="left" colspan="1" rowspan="1">18 patients, 97 controls</td><td align="left" colspan="1" rowspan="1">From 18 days to 17.2 years</td><td align="left" colspan="1" rowspan="1">NF-L</td><td align="left" colspan="1" rowspan="1">Predictive, monitoring</td><td align="left" colspan="1" rowspan="1">Serum NF-L levels decreased and correlated with motor function only in patients with up to two <italic toggle="yes">SMN2</italic> copies during nusinersen treatment</td></tr><tr><td align="left" colspan="1" rowspan="1">Seo et al., 2023 [<xref ref-type="bibr" rid="CR107">107</xref>]</td><td align="left" colspan="1" rowspan="1">Biomarker study</td><td align="left" colspan="1" rowspan="1">8</td><td align="left" colspan="1" rowspan="1">From 1.1 to 270 months</td><td align="left" colspan="1" rowspan="1">NF-L</td><td align="left" colspan="1" rowspan="1">Predictive, monitoring</td><td align="left" colspan="1" rowspan="1">CSF and plasma NF-L levels decreased during nusinersen loading phase, followed by a plateau in patients with SMA type I and II</td></tr><tr><td align="left" colspan="1" rowspan="1">Otto et al., 2024 [<xref ref-type="bibr" rid="CR117">117</xref>]</td><td align="left" colspan="1" rowspan="1">Longitudinal MRI study</td><td align="left" colspan="1" rowspan="1">8</td><td align="left" colspan="1" rowspan="1">9 years (mean) (range: 7.7&#8211;13.8)</td><td align="left" colspan="1" rowspan="1">Quantitative MRI</td><td align="left" colspan="1" rowspan="1">Monitoring</td><td align="left" colspan="1" rowspan="1">MRI detects ongoing fat infiltration and improvement in muscle microstructure during nusinersen treatment</td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">CMAP</italic> Compound muscle action potential, <italic toggle="yes">MRI</italic> Magnetic resonance imaging, <italic toggle="yes">MUNE</italic> Motor unit number estimation, <italic toggle="yes">NF-L</italic> Neurofilament light chain, <italic toggle="yes">SMA</italic> Spinal muscular atrophy, <italic toggle="yes">SD</italic> Standard deviation, <italic toggle="yes">SMN</italic> Survival motor neuron</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec14"><title>Case study 4</title><p id="Par34">D. was a 2&#160;year-old child diagnosed with SMA type II at 8&#160;months of age due to progressive motor weakness and delayed motor milestones. The child had three copies of <italic toggle="yes">SMN2</italic>. At diagnosis, neurophysiological studies revealed significant motor neuron loss: CMAP amplitude of the ulnar nerve was reduced (2.1&#160;mV, below normal range for age), and MUNE showed only 15 motor units (normal&#8201;&gt;&#8201;40 for age). Blood was drawn for NF-L measurement, which showed elevated levels (85&#160;pg/ml, above normal age range of 2.73&#8211;25.00&#160;pg/mL). Treatment with a disease-modifying treatment was initiated. During follow-up at 6, 12, and 18&#160;months, serial neurophysiological assessments provided evidence of motor neuron pool recovery through collateral sprouting mechanisms. While MUNE remained relatively stable, increasing modestly to 18 motor units, CMAP amplitude improved significantly to 6.8&#160;mV. The key evidence for collateral sprouting came from motor unit remodeling parameters: A50 increased from 0.8 to 2.1&#160;mV, and LSMUP increased from 2.5 to 4.8&#160;mV, indicating that surviving motor neurons had significantly enlarged their innervation territories by sprouting to reinnervate orphaned muscle fibers. Additionally, single motor unit potential (SMUP) analysis showed increased amplitude and duration, confirming enlarged motor unit size. These neurophysiological changes preceded clinical motor improvements by several months, with the child eventually showing gains in motor function scores. At 18&#160;months, NF-L levels had decreased to 28&#160;pg/ml. This case demonstrates how detailed neurophysiological analysis can reveal compensatory reinnervation as the primary mechanism of functional recovery, where surviving motor neurons expand their innervation through collateral sprouting to partially compensate for motor neuron loss, providing valuable insights into treatment response mechanisms in pediatric SMA.</p></sec></sec><sec id="Sec15"><title>The role of SMA biomarkers in adolescents and adults</title><p id="Par35">Most patients with SMA who reach adolescence and enter adulthood have less severe SMA types [<xref ref-type="bibr" rid="CR124">124</xref>] and are characterized by a chronic phase of gradual motor neuron loss and progressive muscle weakness. In contrast to younger children, where early intervention can substantially modify disease trajectory, treatment-related improvements in older SMA patients may take longer to manifest, likely due to the slower progression of the disease and the extent of pre-existing neuromuscular impairment. Therefore, the main goal is stabilization or reduction in the rate of progression in most functions. Evaluation of biomarker dynamics is pivotal to help stratify patients and depict treatment responses.</p><p id="Par36">However, it is important to note that patients who reach adulthood may frequently present pronounced musculoskeletal deformities and neuromuscular impairment, which significantly limit the applicability of commonly used motor scales, such as the Hammersmith Functional Motor Scale &#8211; Expanded (HFMSE) and Revised Upper Limb Module (RULM). Many adult patients show either a floor or, more rarely, a ceiling effect on these scales. This highlights the importance of identifying reliable biomarkers capable of capturing subtle disease progression and treatment response that existing functional scales may not detect in this specific population.</p><sec id="Sec16"><title>Neurophysiological measurements in adult patients</title><p id="Par37">Like in other settings, neurophysiology techniques can be used to monitor adolescent and adult patients and may deepen our understanding of motor unit remodeling. Overall, reduced CMAP values appear to be more visible in the most damaged muscles. Using MScanFit, CMAP values from the abductor pollicis brevis (APB) muscle were similar between adult patients with type III SMA and healthy controls [<xref ref-type="bibr" rid="CR125">125</xref>, <xref ref-type="bibr" rid="CR126">126</xref>]. However, these studies also showed that there was a reduction in D50, indicating substantial axonal loss, which was partially compensated by increased single motor unit amplitudes, suggesting that collateral sprouting occurs in adults with SMA [<xref ref-type="bibr" rid="CR125">125</xref>]. Differently, in a population of pediatric and adolescent patients with SMA type II and III (either untreated or receiving nusinersen or risdiplam), CMAP and MUNE values from APB, abductor digiti minimi (ADM), and tibialis anterior muscles varied according to SMA type. In general, measures of collateral reinnervations (median amplitude and LSMUP) were lower in walkers compared to sitters [<xref ref-type="bibr" rid="CR126">126</xref>]. These findings were similar to a previous study of adolescent and adult patients, in which CMAP amplitude, MUNE, and D50 values of median nerves significantly differed across SMA types, and more severe patients showed lower CMAP amplitudes and more pronounced collateral reinnervation [<xref ref-type="bibr" rid="CR103">103</xref>]. Notably, adult patients exhibit a distinct pattern of motor unit degeneration, characterized by greater motor neuron loss in the ADM compared to the APB. This"reversed split-hand"phenomenon is specific to SMA [<xref ref-type="bibr" rid="CR127">127</xref>]; as the APB muscle is relatively well preserved compared to the ADM, measurement of the median nerve CMAP amplitude may be a more suitable neurophysiological biomarker in this population. Neurophysiological parameters were shown to improve following nusinersen treatment, although with some discrepancies [<xref ref-type="bibr" rid="CR114">114</xref>, <xref ref-type="bibr" rid="CR115">115</xref>]. In particular, ulnar CMAP and SMUP values, but not MUNE, improved in both ambulatory and non-ambulatory patients up to 14 months of treatment, implying that the changes in CMAP amplitudes may depend on collateral sprouting rather than an increase in the number of motor units [<xref ref-type="bibr" rid="CR128">128</xref>, <xref ref-type="bibr" rid="CR129">129</xref>]. Recent studies have also investigated neurophysiological changes in adults treated with risdiplam. A significant increases in median nerve CMAP amplitude has been observed in 18 adult patients treated with risdiplam for 10 months, with improvements correlating well with clinical outcome scores [<xref ref-type="bibr" rid="CR130">130</xref>].</p><p id="Par38">MUNIX and MUSIX are promising biomarkers for characterizing the pattern of motor neuron loss in adults, being potentially more sensitive than traditional CMAP measurements in detecting motor neuron degeneration [<xref ref-type="bibr" rid="CR128">128</xref>]. MUNIX values are strongly associated with disease severity [<xref ref-type="bibr" rid="CR129">129</xref>, <xref ref-type="bibr" rid="CR131">131</xref>]; both MUNIX and MUSIX correlate with muscle strength and clinical disability scores [<xref ref-type="bibr" rid="CR132">132</xref>]. Interestingly, the effects of nusinersen were evaluated in CMAP, MUNIX, and MUSIX from the orbicularis oculi muscle; no significant changes in any of the parameters were detected after 10 months, possibly because of the short duration of the observation period [<xref ref-type="bibr" rid="CR133">133</xref>].</p><p id="Par39">Overall, these findings highlight the challenges in monitoring disease progression and treatment response in patients with chronic SMA. Given the broad variability in terms of age, disease severity and duration, and retained motor function in SMA patients, alongside the different techniques used and the distinct muscles assessed in published studies, the results cannot be easily generalized. Nevertheless, neurophysiological measurements are essential to monitor changes in motor unit pools and evaluate the interplay between axonal loss and compensatory collateral sprouting at the individual patient level.</p></sec><sec id="Sec17"><title>Imaging techniques in adult patients</title><p id="Par40">Disease progression may also be assessed via muscle MRI and ultrasound techniques in adolescent and adult patients. These imaging modalities appear to be more suitable for monitoring long-term, progressive muscle changes, effectively capturing atrophy, fatty infiltration, and fibrosis, which are more pronounced in advanced disease stages. MRI measurements from both upper and lower limb muscles significantly differed across SMA types and according to the walking ability of patients, with some variability depending on the proximal/distal level and type of muscles assessed [<xref ref-type="bibr" rid="CR115">115</xref>]. In adult patients, FF in the tight muscles of patients with SMA types II and III significantly increased over time despite the lack of evident worsening in muscle strength and motor function scores. Exploratory DTI parameters such as fractional anisotropy (FA) and mean diffusivity (MD) were decreased and increased, respectively, compared with healthy controls and correlated with muscle strength and motor function [<xref ref-type="bibr" rid="CR134">134</xref>, <xref ref-type="bibr" rid="CR135">135</xref>]. FF and DTI measures were also decreased in the upper muscles in SMA patients vs. healthy controls [<xref ref-type="bibr" rid="CR136">136</xref>]. Other studies confirmed that MRI could assist in monitoring the slow disease progression in adults, emphasizing large variability in muscle involvement from proximal to distal regions across and within SMA types [<xref ref-type="bibr" rid="CR113">113</xref>, <xref ref-type="bibr" rid="CR137">137</xref>]. Treatment with nusinersen did not affect FF values, despite parallel stabilization or improvement in motor function scores [<xref ref-type="bibr" rid="CR138">138</xref>, <xref ref-type="bibr" rid="CR139">139</xref>]. However, while FF remained unchanged, nusinersen reduced baseline FA values in two siblings with SMA type IIIb after 10&#160;months, with either stabilization or further decline at 24 months, implying that muscle atrophy may occur independently of FF [<xref ref-type="bibr" rid="CR138">138</xref>]. Like MRI, muscle ultrasound can help assess the severity of muscle atrophy and structural changes in adult SMA, indicating its potential role as a disease severity marker [<xref ref-type="bibr" rid="CR140">140</xref>]. More and larger studies are needed to further elucidate the role of MRI and ultrasound as reliable SMA biomarkers for adolescents and adults in clinical practice.</p></sec><sec id="Sec18"><title>Neurofilaments in adult patients</title><p id="Par41">Differently from newborns and children, NF levels in adolescents and adults are generally comparable to those of healthy controls [<xref ref-type="bibr" rid="CR141">141</xref>&#8211;<xref ref-type="bibr" rid="CR146">146</xref>]. When measured before and after nusinersen treatment, the levels of plasma and/or CSF NFs (either NF-L or PNF-H) did not show meaningful variations despite improvements in clinical outcomes [<xref ref-type="bibr" rid="CR141">141</xref>&#8211;<xref ref-type="bibr" rid="CR143">143</xref>, <xref ref-type="bibr" rid="CR145">145</xref>&#8211;<xref ref-type="bibr" rid="CR147">147</xref>]. Even if NF-L levels were recently found to be decreased during nusinersen treatment, this reduction did not consistently correspond to clinical improvements, and its clinical significance remains uncertain [<xref ref-type="bibr" rid="CR148">148</xref>]. Given the current evidence, NFs are unlikely to represent a relevant biomarker in this patient setting.</p><p id="Par42">Given the variability in age, disease duration, and individual disease burden, personalized interpretation of these biomarkers is critical for optimizing patient care.</p><p id="Par43">Table <xref rid="Tab3" ref-type="table">3</xref> reports the main studies evaluating the role of biomarkers in adolescents and/or adults with SMA [<xref ref-type="bibr" rid="CR103">103</xref>, <xref ref-type="bibr" rid="CR125">125</xref>, <xref ref-type="bibr" rid="CR126">126</xref>, <xref ref-type="bibr" rid="CR128">128</xref>, <xref ref-type="bibr" rid="CR129">129</xref>, <xref ref-type="bibr" rid="CR132">132</xref>, <xref ref-type="bibr" rid="CR134">134</xref>, <xref ref-type="bibr" rid="CR138">138</xref>].<table-wrap id="Tab3" position="float" orientation="portrait"><label>Table&#160;3</label><caption><p>Main studies assessing the role of biomarkers in patient cohorts predominantly consisting of adolescents and/or adults</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Study (first author, year)</th><th align="left" colspan="1" rowspan="1">Study design</th><th align="left" colspan="1" rowspan="1">Number of patients</th><th align="left" colspan="1" rowspan="1">Age</th><th align="left" colspan="1" rowspan="1">Biomarker(s)</th><th align="left" colspan="1" rowspan="1">Role</th><th align="left" colspan="1" rowspan="1">Main findings</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Sleutjes et al., 2020 [<xref ref-type="bibr" rid="CR103">103</xref>]</td><td align="left" colspan="1" rowspan="1">Cross-sectional study</td><td align="left" colspan="1" rowspan="1">24 patients types 2&#8211;4</td><td align="left" colspan="1" rowspan="1">39&#160;years (median) (range: 12&#8211;75)</td><td align="left" colspan="1" rowspan="1">CMAP, MUNE, D50</td><td align="left" colspan="1" rowspan="1">Monitoring</td><td align="left" colspan="1" rowspan="1">CMAP, MUNE, and D50 values correlated with motor function scores and SMA severity</td></tr><tr><td align="left" colspan="1" rowspan="1">Elsheikh et al., 2021 [<xref ref-type="bibr" rid="CR129">129</xref>]</td><td align="left" colspan="1" rowspan="1">Longitudinal study</td><td align="left" colspan="1" rowspan="1">13</td><td align="left" colspan="1" rowspan="1">36.6&#160;years (median) (range: 18&#8211;59)</td><td align="left" colspan="1" rowspan="1">CMAP, MUNE</td><td align="left" colspan="1" rowspan="1">Monitoring</td><td align="left" colspan="1" rowspan="1">CMAP and SMUP increased during nusinersen treatment in ambulatory patients showing stable muscle contraction and improved motor function scores</td></tr><tr><td align="left" colspan="1" rowspan="1">Elsheikh et al., 2021 [<xref ref-type="bibr" rid="CR128">128</xref>]</td><td align="left" colspan="1" rowspan="1">Longitudinal study</td><td align="left" colspan="1" rowspan="1">19</td><td align="left" colspan="1" rowspan="1">39.7&#160;years&#8201;&#177;&#8201;13.9 (mean&#8201;&#177;&#8201;SD) (range: 21.3&#8211;64.8)</td><td align="left" colspan="1" rowspan="1">CMAP, MUNE</td><td align="left" colspan="1" rowspan="1">Monitoring</td><td align="left" colspan="1" rowspan="1">CMAP and single motor unit potential sizes increased despite stable motor function scores in non-ambulatory patients treated with nusinersen</td></tr><tr><td align="left" colspan="1" rowspan="1">Schneider et al., 2021 [<xref ref-type="bibr" rid="CR125">125</xref>]</td><td align="left" colspan="1" rowspan="1">Longitudinal study</td><td align="left" colspan="1" rowspan="1">15 patients, 15 controls</td><td align="left" colspan="1" rowspan="1">36&#160;years (median) (interquartile range: 26&#8211;52)</td><td align="left" colspan="1" rowspan="1">MScanFit, CMAP</td><td align="left" colspan="1" rowspan="1">Monitoring</td><td align="left" colspan="1" rowspan="1">The number of motor units increased in distal muscles in ambulatory patients only during nusinersen treatment, despite unchanged motor function scores; CMAP was unchanged</td></tr><tr><td align="left" colspan="1" rowspan="1">Vacchiano et al., 2024 [<xref ref-type="bibr" rid="CR126">126</xref>]</td><td align="left" colspan="1" rowspan="1">MScanFit study</td><td align="left" colspan="1" rowspan="1">23 patients, 12 controls</td><td align="left" colspan="1" rowspan="1">24&#160;years (median) (range: 16&#8211;39)</td><td align="left" colspan="1" rowspan="1">MScanFit MUNE</td><td align="left" colspan="1" rowspan="1">Prognostic</td><td align="left" colspan="1" rowspan="1">CMAP and MUNE correlated with clinical severity; measures of collateral reinnervation (median amplitude and LSMUP) were lower in walkers compared to sitters</td></tr><tr><td align="left" colspan="1" rowspan="1">Querin et al., 2018 [<xref ref-type="bibr" rid="CR132">132</xref>]</td><td align="left" colspan="1" rowspan="1">Cross-sectional study</td><td align="left" colspan="1" rowspan="1">19 patients, 16 controls</td><td align="left" colspan="1" rowspan="1">43.32&#8201;&#177;&#8201;14.09&#160;years (mean&#8201;&#177;&#8201;SD)</td><td align="left" colspan="1" rowspan="1">MUNIX, MUSIX</td><td align="left" colspan="1" rowspan="1">Monitoring</td><td align="left" colspan="1" rowspan="1">MUNIX values were significantly decreased in SMA type III and IV; MUSIX was increased, suggesting active reinnervation</td></tr><tr><td align="left" colspan="1" rowspan="1">Otto et al., 2020 [<xref ref-type="bibr" rid="CR134">134</xref>]</td><td align="left" colspan="1" rowspan="1">Cross-sectional MRI study</td><td align="left" colspan="1" rowspan="1">31 patients, 20 controls</td><td align="left" colspan="1" rowspan="1">29.6&#160;years (median) (range: 7.6&#8211;73.9)</td><td align="left" colspan="1" rowspan="1">Quantitative MRI</td><td align="left" colspan="1" rowspan="1">Monitoring</td><td align="left" colspan="1" rowspan="1">Increased fat fraction and altered DTI metrics, which correlated with motor function scores and muscle strength, indicating muscle atrophy</td></tr><tr><td align="left" colspan="1" rowspan="1">Barp et al., [<xref ref-type="bibr" rid="CR138">138</xref>]</td><td align="left" colspan="1" rowspan="1">Case study</td><td align="left" colspan="1" rowspan="1">2</td><td align="left" colspan="1" rowspan="1">45 and 47&#160;years old</td><td align="left" colspan="1" rowspan="1">MRI</td><td align="left" colspan="1" rowspan="1">Monitoring</td><td align="left" colspan="1" rowspan="1">DTI showed improved muscle fiber organization during nusinersen treatment, despite stable motor scores</td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">CMAP</italic> Compound muscle action potential, <italic toggle="yes">DTI</italic> Diffusion tensor imaging, <italic toggle="yes">MUNE</italic> Motor unit number estimation, <italic toggle="yes">MUNIX</italic> Motor unit number index, <italic toggle="yes">MUSIX</italic> Motor unit size index, <italic toggle="yes">SD</italic> Standard deviation, <italic toggle="yes">SMA</italic> Spinal muscular atrophy</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec19"><title>Case study 5</title><p id="Par44">E. was a 25&#160;year-old patient diagnosed with SMA type III at 4 years of age due to progressive difficulty walking and muscle weakness. The patient had four copies of <italic toggle="yes">SMN2</italic> and had lost ambulation at age 16, now using a wheelchair and requiring non-invasive ventilation (NIV) at night. There were no swallowing difficulties, but the patient reported limited mouth opening with fatiguability during chewing and significant trunk fatiguability requiring assistance for daily activities. Neurophysiological studies at baseline reflected the chronic denervation expected in a long-standing, wheelchair-bound SMA patient: following ulnar nerve stimulation, CMAP amplitude was severely reduced at 1.2&#160;mV (normal&#8201;&gt;&#8201;4&#160;mV), and MUNE showed only 8 motor units (normal&#8201;&gt;&#8201;40), indicating extensive motor neuron loss. However, evidence of chronic collateral reinnervation was present with increased A50 (3.2&#160;mV) and LSMUP (6.8&#160;mV), demonstrating that surviving motor neurons had enlarged their territories over time. NF-L levels were 18&#160;pg/ml, within normal ranges for adults and therefore not contributory to clinical decision-making. Treatment was chosen after discussing delivery methods, clinical trial evidence in adults, and realistic expectations. At 14&#160;month follow-up, neurophysiological monitoring showed modest but meaningful improvements: CMAP increased to 1.9&#160;mV and MUNE improved to 11 motor units, suggesting some preservation or recovery of motor neuron function. Parameters reflecting reinnervation remained elevated, indicating ongoing compensatory mechanisms. Clinically, while Hammersmith Functional Motor Scale &#8211; Expanded (HFMSE) and Revised Upper Limb Module (RULM) scores remained stable (representing disease stabilization), the patient reported significant improvements in trunk fatiguability and endurance during daily activities, requiring less assistance for transfers and prolonged sitting. Respiratory function remained stable on NIV. This case demonstrates how, in chronic adult SMA, even modest neurophysiological improvements can translate into meaningful functional benefits, particularly in fatigue-related symptoms that are not captured by standard outcome measures, illustrating the complementary value of objective neurophysiological monitoring and patient-reported outcomes in this population.</p></sec></sec><sec id="Sec20"><title>Future directions</title><p id="Par45">Although we have examined the most informative biomarkers currently available for capturing the evolving complexity and phenotypic heterogeneity observed in SMA, several practical constraints limit their widespread implementation in routine clinical practice. Neurophysiological assessments demand specialized expertise and active patient cooperation, factors that may not always be readily available. Furthermore, advanced imaging modalities face significant accessibility challenges, as equipment availability during routine clinic visits remains inconsistent, while the associated costs present substantial burdens for healthcare systems and insurance providers alike.</p><p id="Par46">Emerging research directions encompass several promising biomarker categories that warrant continued investigation. Direct quantification of SMN protein levels and comprehensive <italic toggle="yes">SMN</italic> transcript analysis offer the potential to monitor therapeutic targets more precisely, thereby providing enhanced insights into treatment efficacy mechanisms [<xref ref-type="bibr" rid="CR149">149</xref>&#8211;<xref ref-type="bibr" rid="CR154">154</xref>]. Concurrently, neuroinflammatory biomarkers &#8211; particularly cytokines associated with microglial activation and astrocytic inflammatory responses &#8211; may yield valuable perspectives regarding disease progression trajectories and therapeutic responsiveness [<xref ref-type="bibr" rid="CR155">155</xref>, <xref ref-type="bibr" rid="CR156">156</xref>]. This approach appears especially relevant given the expanding recognition of neuroinflammatory processes within SMA pathophysiology.</p><p id="Par47">The field of microRNA research has undergone extensive examination [<xref ref-type="bibr" rid="CR53">53</xref>, <xref ref-type="bibr" rid="CR92">92</xref>, <xref ref-type="bibr" rid="CR105">105</xref>], although their clinical utility remains incompletely defined, and their translation into routine practice continues to face obstacles. Nevertheless, emerging evidence demonstrates altered expression patterns across various individual miRNAs and distinct miRNA classes, suggesting considerable potential for monitoring both disease progression and treatment responses. Chen and colleagues documented consistent miR34 downregulation throughout disease advancement [<xref ref-type="bibr" rid="CR157">157</xref>], whereas investigations by multiple research groups revealed elevated serum concentrations of miR-9, miR-132, and miR-206 in SMA patients relative to healthy control populations [<xref ref-type="bibr" rid="CR158">158</xref>, <xref ref-type="bibr" rid="CR159">159</xref>]. Cerebrospinal fluid analyses have further demonstrated increased levels of these miRNAs, alongside miR-218 and miR-23a, following nusinersen administration [<xref ref-type="bibr" rid="CR160">160</xref>]. Notably, lower baseline CSF concentrations of miR-206 and miR-133a-3p correlated with superior therapeutic responses to nusinersen treatment [<xref ref-type="bibr" rid="CR161">161</xref>]. To our knowledge, no data are available regarding the use of these biomarkers in patients treated with risdiplam.</p><p id="Par48">Contemporary high-throughput technological advances have substantially broadened our comprehension of molecular alterations characteristic of SMA [<xref ref-type="bibr" rid="CR162">162</xref>]. Comprehensive RNA sequencing investigations utilizing both cerebrospinal fluid and serum samples, complemented by single-cell RNA sequencing and spatial transcriptomics methodologies, have unveiled intricate gene expression modification patterns. These studies reveal that certain molecular markers demonstrate disease-specificity, others exhibit treatment-specific characteristics, while additional markers display treatment-dependent modifications, collectively establishing novel pathways for biomarker development [<xref ref-type="bibr" rid="CR163">163</xref>, <xref ref-type="bibr" rid="CR164">164</xref>]. Proteomic investigations have similarly demonstrated SMA-specific protein modification patterns. The comprehensive work by Panicucci and colleagues successfully identified severity-dependent treatment effects, establishing distinct molecular signatures within cerebrospinal fluid across different SMA subtypes [<xref ref-type="bibr" rid="CR165">165</xref>]. Additional proteomic research has documented altered concentrations of specific proteins in cerebrospinal fluid samples obtained from nusinersen-treated patients [<xref ref-type="bibr" rid="CR166">166</xref>]. Remarkably, only the investigation conducted by Pant et al. has systematically examined neuroinflammatory marker alterations in both plasma and cerebrospinal fluid specimens from pediatric patients receiving AVXS-101 therapy, potentially identifying novel treatment-specific pathways [<xref ref-type="bibr" rid="CR167">167</xref>].</p><p id="Par49">Metabolomic research has contributed essential insights regarding altered biochemical pathways characteristic of SMA pathophysiology. Lu and colleagues identified metabolic markers significantly associated with disease severity within cerebrospinal fluid samples, establishing their potential utility as prognostic indicators [<xref ref-type="bibr" rid="CR168">168</xref>]. Similarly, Saffari et al. characterized distinctive metabolic signatures present in plasma and urine specimens from SMA patients, successfully differentiating between early-onset and late-onset disease variants [<xref ref-type="bibr" rid="CR169">169</xref>]. Limited investigations have examined metabolic consequences of nusinersen therapy within cerebrospinal fluid samples, revealing longitudinal effects on amino acid metabolic pathways [<xref ref-type="bibr" rid="CR166">166</xref>, <xref ref-type="bibr" rid="CR170">170</xref>].</p><sec id="Sec21"><title>Biomarker integration</title><p id="Par50">Contemporary clinical practice increasingly recognizes that no single biomarker possesses sufficient capability to guide comprehensive personalized treatment strategies, acknowledging that individualized approaches require multifaceted assessment frameworks rather than uniform methodologies. Consequently, a combination of clinical observations and laboratory findings&#8212;incorporating neurophysiological assessments, neurofilament measurements, and potentially imaging studies in selected cases&#8212;appears most likely to inform evidence-based clinical decision-making. Individual biomarkers demonstrate insufficient capacity for comprehensively characterizing disease progression trajectories or accurately predicting treatment outcomes, particularly when considering the diverse age-stratified patient populations and heterogeneous SMA phenotypic presentations encountered in clinical practice.</p><p id="Par51">Therefore, prioritizing the integration of multiple biomarkers within carefully designed combination panels represents a fundamental requirement for developing multidimensional assessment frameworks. Such approaches could be systematically adapted according to individual patient characteristics and specific clinical needs. The strategic combination of genetic assessments with neurophysiological measurements, supplemented by neurofilament quantification and age-appropriate imaging studies, provides substantially enhanced understanding of disease severity and potential progression patterns, thereby supporting more informed therapeutic decision-making processes.</p><p id="Par52">Integrating these established biomarker approaches with novel molecular markers emerging from transcriptomic, proteomic, and metabolomic investigations within sophisticated multidimensional algorithms holds considerable promise for developing more robust, personalized, and sensitive disease-monitoring instruments. Machine learning methodologies and advanced analytical platforms prove invaluable not only for biomarker discovery and validation processes but also for facilitating the integration of multiple biomarkers to enhance patient stratification according to disease severity, progression potential, and treatment responsiveness [<xref ref-type="bibr" rid="CR165">165</xref>, <xref ref-type="bibr" rid="CR171">171</xref>, <xref ref-type="bibr" rid="CR172">172</xref>].</p></sec></sec><sec id="Sec22"><title>Conclusion</title><p id="Par53">This review illustrates how key biomarkers (<italic toggle="yes">SMN2</italic> copy number, neurophysiological measurements, NFs and imaging techniques) can offer critical insights into SMA progression and treatment outcomes at different stages of the disease (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref> and Table&#160;<xref rid="Tab4" ref-type="table">4</xref>), highlighting that no single biomarker can be universally applied across all patients. A multi-biomarker approach that integrates neurophysiological, imaging, and molecular data holds promise for more sensitive, individualized monitoring and decision-making. Continuing research into novel biomarkers, along with rigorous validation and standardized methodologies, is paramount. Ultimately, these efforts will refine clinical management, enhance therapeutic interventions, and improve outcomes across the spectrum of SMA phenotypes.<fig id="Fig1" position="float" orientation="portrait"><label>Fig.&#160;1</label><caption><p>Flowchart illustrating the role of key biomarkers in SMA patients stratified by age. Newborns identified through NBS undergo genetic testing to confirm SMA via detection of <italic toggle="yes">SMN1</italic> deletion and <italic toggle="yes">SMN2</italic> copy number. The latter biomarker may help inform prognosis. In this presymptomatic stage, neurophysiological assessments and NF level measurements may be of help to predict treatment response. Following treatment initiation, these biomarkers, along with clinical outcome measures, may be used to monitor therapeutic effectiveness. In symptomatic children, in whom genetic testing is already available and treatment discussion is under way, neurophysiological markers and NF levels may serve to both predict and monitor treatment response. For adolescents and adults, neurophysiological assessments and imaging techniques may have a role for monitoring treatment efficacy over time. *Truly presymptomatic as assessed by clinical evaluation and/or Hammersmith Neonatal Neurological Examination (HNNE) and its additional module [<xref ref-type="bibr" rid="CR173">173</xref>]. **Either in serum or CSF. ***MRI or ultrasound. <italic toggle="yes">CSF</italic> Cerebrospinal fluid, <italic toggle="yes">HNNE</italic> Hammersmith neonatal neurological examination, <italic toggle="yes">MRI</italic> Magnetic resonance imaging, <italic toggle="yes">NF</italic> Neurofilament, <italic toggle="yes">SMA</italic> Spinal muscular atrophy, <italic toggle="yes">SMN</italic> Survival motor neuron</p></caption><graphic id="MO1" position="float" orientation="portrait" xlink:href="415_2025_13314_Fig1_HTML.jpg"/></fig><table-wrap id="Tab4" position="float" orientation="portrait"><label>Table&#160;4</label><caption><p>The role and key characteristics of selected SMA biomarkers in age-stratified patient settings</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Biomarker</th><th align="left" colspan="1" rowspan="1">Age-stratified patient settings</th><th align="left" colspan="1" rowspan="1">Role</th><th align="left" colspan="1" rowspan="1">Key characteristics</th><th align="left" colspan="1" rowspan="1">Refs</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1"><italic toggle="yes">SMN1</italic> genetic testing</td><td align="left" colspan="1" rowspan="1">All (especially newborns through NBS)</td><td align="left" colspan="1" rowspan="1">Diagnostic</td><td align="left" colspan="1" rowspan="1">Gold standard for SMA diagnosis</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR55">55</xref>&#8211;<xref ref-type="bibr" rid="CR57">57</xref>, <xref ref-type="bibr" rid="CR80">80</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1"><italic toggle="yes">SMN2</italic> copy number</td><td align="left" colspan="1" rowspan="1">All (especially newborns through NBS)</td><td align="left" colspan="1" rowspan="1">Prognostic</td><td align="left" colspan="1" rowspan="1">Strongest genetic predictor of disease severity; higher copy numbers generally indicate milder phenotype</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR59">59</xref>, <xref ref-type="bibr" rid="CR60">60</xref>, <xref ref-type="bibr" rid="CR81">81</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">CMAP</td><td align="left" colspan="1" rowspan="1">All</td><td align="left" colspan="1" rowspan="1">Prognostic, predictive, monitoring</td><td align="left" colspan="1" rowspan="1">Reflects motor unit integrity; can detect early degeneration and treatment response</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR81">81</xref>, <xref ref-type="bibr" rid="CR94">94</xref>, <xref ref-type="bibr" rid="CR101">101</xref>, <xref ref-type="bibr" rid="CR103">103</xref>, <xref ref-type="bibr" rid="CR125">125</xref>, <xref ref-type="bibr" rid="CR128">128</xref>, <xref ref-type="bibr" rid="CR129">129</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">MUNE</td><td align="left" colspan="1" rowspan="1">Children, adolescents/adults</td><td align="left" colspan="1" rowspan="1">Prognostic, monitoring</td><td align="left" colspan="1" rowspan="1">More sensitive than CMAP for detecting motor unit loss or remodeling</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR94">94</xref>, <xref ref-type="bibr" rid="CR103">103</xref>, <xref ref-type="bibr" rid="CR126">126</xref>&#8211;<xref ref-type="bibr" rid="CR129">129</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">MUNIX/MUSIX</td><td align="left" colspan="1" rowspan="1">Children, adolescents/adults</td><td align="left" colspan="1" rowspan="1">Monitoring</td><td align="left" colspan="1" rowspan="1">Quantifies motor unit number and size; sensitive to chronic denervation and reinnervation</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR93">93</xref>, <xref ref-type="bibr" rid="CR132">132</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">NF-L/pNF-H</td><td align="left" colspan="1" rowspan="1">Newborns, children</td><td align="left" colspan="1" rowspan="1">Diagnostic, prognostic, predictive, monitoring</td><td align="left" colspan="1" rowspan="1">High levels reflect active neurodegeneration; sensitive in early disease phases</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR88">88</xref>&#8211;<xref ref-type="bibr" rid="CR90">90</xref>, <xref ref-type="bibr" rid="CR106">106</xref>, <xref ref-type="bibr" rid="CR107">107</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Muscle MRI</td><td align="left" colspan="1" rowspan="1">Children, adolescents/adults</td><td align="left" colspan="1" rowspan="1">Monitoring</td><td align="left" colspan="1" rowspan="1">Useful in tracking long-term muscle structural changes</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR117">117</xref>, <xref ref-type="bibr" rid="CR134">134</xref>, <xref ref-type="bibr" rid="CR138">138</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Muscle ultrasound</td><td align="left" colspan="1" rowspan="1">Children, adolescents/adults</td><td align="left" colspan="1" rowspan="1">Monitoring</td><td align="left" colspan="1" rowspan="1">Non-invasive assessment of muscle architecture that complements MRI measurements</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR114">114</xref>, <xref ref-type="bibr" rid="CR116">116</xref>, <xref ref-type="bibr" rid="CR140">140</xref>]</td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">CMAP</italic> Compound muscle action potential, <italic toggle="yes">MUNE</italic> Motor unit number estimation, <italic toggle="yes">MUNIX</italic> Motor unit number index, <italic toggle="yes">MUSIX</italic> motor unit size index, <italic toggle="yes">NF-L</italic> Neurofilament light chain, <italic toggle="yes">pNF-H</italic> Phosphorylated neurofilament heavy chain, <italic toggle="yes">SMA</italic> Spinal muscular atrophy, <italic toggle="yes">SMN</italic> Survival motor neuron</p></table-wrap-foot></table-wrap></p></sec></body><back><ack><title>Acknowledgements</title><p>Writing and editorial assistance was provided by Alessandra Rossi, PhD, Valentina Attanasio, and Aashni Shah (Polistudium SRL, Milan, Italy).</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>SC, LO, and VS conceived the idea for this review, conducted the literature search and data analysis, and drafted the manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>Medical writing support was funded by Biogen.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>Not applicable</p></notes><notes><title>Declarations</title><notes id="FPar1" notes-type="COI-statement"><title>Conflicts of interest</title><p id="Par54">SC served in SAB for Biogen, Novartis, Roche. LO reports no competing interests in relation to this paper. VS participated in SAB for Roche, Biogen, Novartis, and Sarepta. Her work has involved clinical trials and studies related to neuromuscular conditions. No competing interests related to this paper.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>D'Amico</surname><given-names>A</given-names></name><name name-style="western"><surname>Mercuri</surname><given-names>E</given-names></name><name name-style="western"><surname>Tiziano</surname><given-names>FD</given-names></name><name name-style="western"><surname>Bertini</surname><given-names>E</given-names></name></person-group><article-title>Spinal muscular atrophy</article-title><source>Orphanet J Rare Dis</source><year>2011</year><volume>6</volume><fpage>71</fpage><pub-id pub-id-type="doi">10.1186/1750-1172-6-71</pub-id><pub-id pub-id-type="pmid">22047105</pub-id><pub-id pub-id-type="pmcid">PMC3231874</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">D&#8217;Amico A, Mercuri E, Tiziano FD, Bertini E (2011) Spinal muscular atrophy. Orphanet J Rare Dis 6:71. 10.1186/1750-1172-6-71<pub-id pub-id-type="pmid">22047105</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1750-1172-6-71</pub-id><pub-id pub-id-type="pmcid">PMC3231874</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mercuri</surname><given-names>E</given-names></name><name name-style="western"><surname>Sumner</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Muntoni</surname><given-names>F</given-names></name><name name-style="western"><surname>Darras</surname><given-names>BT</given-names></name><name name-style="western"><surname>Finkel</surname><given-names>RS</given-names></name></person-group><article-title>Spinal muscular atrophy</article-title><source>Nat Rev Dis Primers</source><year>2022</year><volume>8</volume><fpage>52</fpage><pub-id pub-id-type="doi">10.1038/s41572-022-00380-8</pub-id><pub-id pub-id-type="pmid">35927425</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Mercuri E, Sumner CJ, Muntoni F, Darras BT, Finkel RS (2022) Spinal muscular atrophy. Nat Rev Dis Primers 8:52. 10.1038/s41572-022-00380-8<pub-id pub-id-type="pmid">35927425</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41572-022-00380-8</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lefebvre</surname><given-names>S</given-names></name><name name-style="western"><surname>B&#252;rglen</surname><given-names>L</given-names></name><name name-style="western"><surname>Reboullet</surname><given-names>S</given-names></name><name name-style="western"><surname>Clermont</surname><given-names>O</given-names></name><name name-style="western"><surname>Burlet</surname><given-names>P</given-names></name><name name-style="western"><surname>Viollet</surname><given-names>L</given-names></name><name name-style="western"><surname>Benichou</surname><given-names>B</given-names></name><name name-style="western"><surname>Cruaud</surname><given-names>C</given-names></name><name name-style="western"><surname>Millasseau</surname><given-names>P</given-names></name><name name-style="western"><surname>Zeviani</surname><given-names>M</given-names></name><name name-style="western"><surname>Le Paslier</surname><given-names>D</given-names></name><name name-style="western"><surname>Fr&#233;zal</surname><given-names>J</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>D</given-names></name><name name-style="western"><surname>Weissenbach</surname><given-names>J</given-names></name><name name-style="western"><surname>Munnich</surname><given-names>A</given-names></name><name name-style="western"><surname>Melki</surname><given-names>J</given-names></name></person-group><article-title>Identification and characterization of a spinal muscular atrophy-determining gene</article-title><source>Cell</source><year>1995</year><volume>80</volume><fpage>155</fpage><lpage>165</lpage><pub-id pub-id-type="doi">10.1016/0092-8674(95)90460-3</pub-id><pub-id pub-id-type="pmid">7813012</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Lefebvre S, B&#252;rglen L, Reboullet S, Clermont O, Burlet P, Viollet L, Benichou B, Cruaud C, Millasseau P, Zeviani M, Le Paslier D, Fr&#233;zal J, Cohen D, Weissenbach J, Munnich A, Melki J (1995) Identification and characterization of a spinal muscular atrophy-determining gene. Cell 80:155&#8211;165. 10.1016/0092-8674(95)90460-3<pub-id pub-id-type="pmid">7813012</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0092-8674(95)90460-3</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Audic</surname><given-names>F</given-names></name><name name-style="western"><surname>Barnerias</surname><given-names>C</given-names></name></person-group><article-title>Spinal muscular atrophy (SMA) type I (Werdnig-Hoffmann disease)</article-title><source>Arch Pediatr</source><year>2020</year><volume>27</volume><issue>7</issue><fpage>7S15</fpage><lpage>7S17</lpage><pub-id pub-id-type="doi">10.1016/S0929-693X(20)30271-2</pub-id><pub-id pub-id-type="pmid">33357591</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Audic F, Barnerias C (2020) Spinal muscular atrophy (SMA) type I (Werdnig-Hoffmann disease). Arch Pediatr 27(7):7S15-7S17. 10.1016/S0929-693X(20)30271-2<pub-id pub-id-type="pmid">33357591</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0929-693X(20)30271-2</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arnold</surname><given-names>WD</given-names></name><name name-style="western"><surname>Kassar</surname><given-names>D</given-names></name><name name-style="western"><surname>Kissel</surname><given-names>JT</given-names></name></person-group><article-title>Spinal muscular atrophy: diagnosis and management in a new therapeutic era</article-title><source>Muscle Nerve</source><year>2015</year><volume>51</volume><fpage>157</fpage><lpage>167</lpage><pub-id pub-id-type="doi">10.1002/mus.24497</pub-id><pub-id pub-id-type="pmid">25346245</pub-id><pub-id pub-id-type="pmcid">PMC4293319</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Arnold WD, Kassar D, Kissel JT (2015) Spinal muscular atrophy: diagnosis and management in a new therapeutic era. Muscle Nerve 51:157&#8211;167. 10.1002/mus.24497<pub-id pub-id-type="pmid">25346245</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mus.24497</pub-id><pub-id pub-id-type="pmcid">PMC4293319</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaufmann</surname><given-names>P</given-names></name></person-group><article-title>Observational study of spinal muscular atrophy type 2 and 3: functional outcomes over 1 year</article-title><source>Arch Neurol</source><year>2011</year><volume>68</volume><fpage>779</fpage><pub-id pub-id-type="doi">10.1001/archneurol.2010.373</pub-id><pub-id pub-id-type="pmid">21320981</pub-id><pub-id pub-id-type="pmcid">PMC3839315</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Kaufmann P (2011) Observational study of spinal muscular atrophy type 2 and 3: functional outcomes over 1 year. Arch Neurol 68:779. 10.1001/archneurol.2010.373<pub-id pub-id-type="pmid">21320981</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/archneurol.2010.373</pub-id><pub-id pub-id-type="pmcid">PMC3839315</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mercuri</surname><given-names>E</given-names></name><name name-style="western"><surname>Finkel</surname><given-names>RS</given-names></name><name name-style="western"><surname>Muntoni</surname><given-names>F</given-names></name><name name-style="western"><surname>Wirth</surname><given-names>B</given-names></name><name name-style="western"><surname>Montes</surname><given-names>J</given-names></name><name name-style="western"><surname>Main</surname><given-names>M</given-names></name><name name-style="western"><surname>Mazzone</surname><given-names>ES</given-names></name><name name-style="western"><surname>Vitale</surname><given-names>M</given-names></name><name name-style="western"><surname>Snyder</surname><given-names>B</given-names></name><name name-style="western"><surname>Quijano-Roy</surname><given-names>S</given-names></name><name name-style="western"><surname>Bertini</surname><given-names>E</given-names></name><name name-style="western"><surname>Davis</surname><given-names>RH</given-names></name><name name-style="western"><surname>Meyer</surname><given-names>OH</given-names></name><name name-style="western"><surname>Simonds</surname><given-names>AK</given-names></name><name name-style="western"><surname>Schroth</surname><given-names>MK</given-names></name><name name-style="western"><surname>Graham</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Kirschner</surname><given-names>J</given-names></name><name name-style="western"><surname>Iannaccone</surname><given-names>ST</given-names></name><name name-style="western"><surname>Crawford</surname><given-names>TO</given-names></name><name name-style="western"><surname>Woods</surname><given-names>S</given-names></name><etal/></person-group><article-title>Diagnosis and management of spinal muscular atrophy: Part 1: recommendations for diagnosis, rehabilitation, orthopedic and nutritional care</article-title><source>Neuromuscul Disord</source><year>2018</year><volume>28</volume><fpage>103</fpage><lpage>115</lpage><pub-id pub-id-type="doi">10.1016/j.nmd.2017.11.005</pub-id><pub-id pub-id-type="pmid">29290580</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Mercuri E, Finkel RS, Muntoni F, Wirth B, Montes J, Main M, Mazzone ES, Vitale M, Snyder B, Quijano-Roy S, Bertini E, Davis RH, Meyer OH, Simonds AK, Schroth MK, Graham RJ, Kirschner J, Iannaccone ST, Crawford TO, Woods S et al (2018) Diagnosis and management of spinal muscular atrophy: Part 1: recommendations for diagnosis, rehabilitation, orthopedic and nutritional care. Neuromuscul Disord 28:103&#8211;115. 10.1016/j.nmd.2017.11.005<pub-id pub-id-type="pmid">29290580</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.nmd.2017.11.005</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schmalbruch</surname><given-names>H</given-names></name><name name-style="western"><surname>Haase</surname><given-names>G</given-names></name></person-group><article-title>Spinal muscular atrophy: present state</article-title><source>Brain Pathol</source><year>2001</year><volume>11</volume><fpage>231</fpage><lpage>247</lpage><pub-id pub-id-type="doi">10.1111/j.1750-3639.2001.tb00395.x</pub-id><pub-id pub-id-type="pmid">11303798</pub-id><pub-id pub-id-type="pmcid">PMC8098133</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Schmalbruch H, Haase G (2001) Spinal muscular atrophy: present state. Brain Pathol 11:231&#8211;247. 10.1111/j.1750-3639.2001.tb00395.x<pub-id pub-id-type="pmid">11303798</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1750-3639.2001.tb00395.x</pub-id><pub-id pub-id-type="pmcid">PMC8098133</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smeriglio</surname><given-names>P</given-names></name><name name-style="western"><surname>Langard</surname><given-names>P</given-names></name><name name-style="western"><surname>Querin</surname><given-names>G</given-names></name><name name-style="western"><surname>Biferi</surname><given-names>MG</given-names></name></person-group><article-title>The identification of novel biomarkers is required to improve adult SMA patient stratification, diagnosis and treatment</article-title><source>J Pers Med</source><year>2020</year><volume>10</volume><fpage>75</fpage><pub-id pub-id-type="doi">10.3390/jpm10030075</pub-id><pub-id pub-id-type="pmid">32751151</pub-id><pub-id pub-id-type="pmcid">PMC7564782</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Smeriglio P, Langard P, Querin G, Biferi MG (2020) The identification of novel biomarkers is required to improve adult SMA patient stratification, diagnosis and treatment. J Pers Med 10:75. 10.3390/jpm10030075<pub-id pub-id-type="pmid">32751151</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/jpm10030075</pub-id><pub-id pub-id-type="pmcid">PMC7564782</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aslesh</surname><given-names>T</given-names></name><name name-style="western"><surname>Yokota</surname><given-names>T</given-names></name></person-group><article-title>Restoring SMN expression: an overview of the therapeutic developments for the treatment of spinal muscular atrophy</article-title><source>Cells</source><year>2022</year><volume>11</volume><fpage>417</fpage><pub-id pub-id-type="doi">10.3390/cells11030417</pub-id><pub-id pub-id-type="pmid">35159227</pub-id><pub-id pub-id-type="pmcid">PMC8834523</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Aslesh T, Yokota T (2022) Restoring SMN expression: an overview of the therapeutic developments for the treatment of spinal muscular atrophy. Cells 11:417. 10.3390/cells11030417<pub-id pub-id-type="pmid">35159227</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cells11030417</pub-id><pub-id pub-id-type="pmcid">PMC8834523</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lorson</surname><given-names>CL</given-names></name><name name-style="western"><surname>Hahnen</surname><given-names>E</given-names></name><name name-style="western"><surname>Androphy</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Wirth</surname><given-names>B</given-names></name></person-group><article-title>A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy</article-title><source>Proc Natl Acad Sci U S A</source><year>1999</year><volume>96</volume><fpage>6307</fpage><lpage>6311</lpage><pub-id pub-id-type="doi">10.1073/pnas.96.11.6307</pub-id><pub-id pub-id-type="pmid">10339583</pub-id><pub-id pub-id-type="pmcid">PMC26877</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Lorson CL, Hahnen E, Androphy EJ, Wirth B (1999) A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proc Natl Acad Sci U S A 96:6307&#8211;6311. 10.1073/pnas.96.11.6307<pub-id pub-id-type="pmid">10339583</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.96.11.6307</pub-id><pub-id pub-id-type="pmcid">PMC26877</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Monani</surname><given-names>UR</given-names></name></person-group><article-title>A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2</article-title><source>Hum Mol Genet</source><year>1999</year><volume>8</volume><fpage>1177</fpage><lpage>1183</lpage><pub-id pub-id-type="doi">10.1093/hmg/8.7.1177</pub-id><pub-id pub-id-type="pmid">10369862</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Monani UR (1999) A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2. Hum Mol Genet 8:1177&#8211;1183. 10.1093/hmg/8.7.1177<pub-id pub-id-type="pmid">10369862</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/hmg/8.7.1177</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Feldk&#246;tter</surname><given-names>M</given-names></name><name name-style="western"><surname>Schwarzer</surname><given-names>V</given-names></name><name name-style="western"><surname>Wirth</surname><given-names>R</given-names></name><name name-style="western"><surname>Wienker</surname><given-names>TF</given-names></name><name name-style="western"><surname>Wirth</surname><given-names>B</given-names></name></person-group><article-title>Quantitative analyses of SMN1 and SMN2 based on real-time lightcycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy</article-title><source>Am J Hum Genet</source><year>2002</year><volume>70</volume><fpage>358</fpage><lpage>368</lpage><pub-id pub-id-type="doi">10.1086/338627</pub-id><pub-id pub-id-type="pmid">11791208</pub-id><pub-id pub-id-type="pmcid">PMC419987</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Feldk&#246;tter M, Schwarzer V, Wirth R, Wienker TF, Wirth B (2002) Quantitative analyses of SMN1 and SMN2 based on real-time lightcycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy. Am J Hum Genet 70:358&#8211;368. 10.1086/338627<pub-id pub-id-type="pmid">11791208</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1086/338627</pub-id><pub-id pub-id-type="pmcid">PMC419987</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Butchbach</surname><given-names>MER</given-names></name></person-group><article-title>Copy number variations in the survival motor neuron genes: implications for spinal muscular atrophy and other neurodegenerative diseases</article-title><source>Front Mol Biosci</source><year>2016</year><volume>3</volume><fpage>7</fpage><pub-id pub-id-type="doi">10.3389/fmolb.2016.00007</pub-id><pub-id pub-id-type="pmid">27014701</pub-id><pub-id pub-id-type="pmcid">PMC4785180</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Butchbach MER (2016) Copy number variations in the survival motor neuron genes: implications for spinal muscular atrophy and other neurodegenerative diseases. Front Mol Biosci 3:7. 10.3389/fmolb.2016.00007<pub-id pub-id-type="pmid">27014701</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fmolb.2016.00007</pub-id><pub-id pub-id-type="pmcid">PMC4785180</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hoy</surname><given-names>SM</given-names></name></person-group><article-title>Nusinersen: first global approval</article-title><source>Drugs</source><year>2017</year><volume>77</volume><fpage>473</fpage><lpage>479</lpage><pub-id pub-id-type="doi">10.1007/s40265-017-0711-7</pub-id><pub-id pub-id-type="pmid">28229309</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Hoy SM (2017) Nusinersen: first global approval. Drugs 77:473&#8211;479. 10.1007/s40265-017-0711-7<pub-id pub-id-type="pmid">28229309</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40265-017-0711-7</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hoy</surname><given-names>SM</given-names></name></person-group><article-title>Onasemnogene abeparvovec: first global approval</article-title><source>Drugs</source><year>2019</year><volume>79</volume><fpage>1255</fpage><lpage>1262</lpage><pub-id pub-id-type="doi">10.1007/s40265-019-01162-5</pub-id><pub-id pub-id-type="pmid">31270752</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Hoy SM (2019) Onasemnogene abeparvovec: first global approval. Drugs 79:1255&#8211;1262. 10.1007/s40265-019-01162-5<pub-id pub-id-type="pmid">31270752</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40265-019-01162-5</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dhillon</surname><given-names>S</given-names></name></person-group><article-title>Risdiplam: first approval</article-title><source>Drugs</source><year>2020</year><volume>80</volume><fpage>1853</fpage><lpage>1858</lpage><pub-id pub-id-type="doi">10.1007/s40265-020-01410-z</pub-id><pub-id pub-id-type="pmid">33044711</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Dhillon S (2020) Risdiplam: first approval. Drugs 80:1853&#8211;1858. 10.1007/s40265-020-01410-z<pub-id pub-id-type="pmid">33044711</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40265-020-01410-z</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aartsma-Rus</surname><given-names>A</given-names></name></person-group><article-title>FDA approval of nusinersen for spinal muscular atrophy makes 2016 the year of splice modulating oligonucleotides</article-title><source>Nucleic Acid Ther</source><year>2017</year><volume>27</volume><fpage>67</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.1089/nat.2017.0665</pub-id><pub-id pub-id-type="pmid">28346110</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Aartsma-Rus A (2017) FDA approval of nusinersen for spinal muscular atrophy makes 2016 the year of splice modulating oligonucleotides. Nucleic Acid Ther 27:67&#8211;69. 10.1089/nat.2017.0665<pub-id pub-id-type="pmid">28346110</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1089/nat.2017.0665</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>TH</given-names></name></person-group><article-title>New and developing therapies in spinal muscular atrophy: from genotype to phenotype to treatment and where do we stand?</article-title><source>Int J Mol Sci</source><year>2020</year><volume>21</volume><fpage>3297</fpage><pub-id pub-id-type="doi">10.3390/ijms21093297</pub-id><pub-id pub-id-type="pmid">32392694</pub-id><pub-id pub-id-type="pmcid">PMC7246502</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Chen TH (2020) New and developing therapies in spinal muscular atrophy: from genotype to phenotype to treatment and where do we stand? Int J Mol Sci 21:3297. 10.3390/ijms21093297<pub-id pub-id-type="pmid">32392694</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms21093297</pub-id><pub-id pub-id-type="pmcid">PMC7246502</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haque</surname><given-names>US</given-names></name><name name-style="western"><surname>Yokota</surname><given-names>T</given-names></name></person-group><article-title>Recent progress in gene-targeting therapies for spinal muscular atrophy: promises and challenges</article-title><source>Genes</source><year>2024</year><volume>15</volume><issue>8</issue><fpage>999</fpage><pub-id pub-id-type="doi">10.3390/genes15080999</pub-id><pub-id pub-id-type="pmid">39202360</pub-id><pub-id pub-id-type="pmcid">PMC11353366</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Haque US, Yokota T (2024) Recent progress in gene-targeting therapies for spinal muscular atrophy: promises and challenges. Genes 15(8):999. 10.3390/genes15080999<pub-id pub-id-type="pmid">39202360</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/genes15080999</pub-id><pub-id pub-id-type="pmcid">PMC11353366</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cooper</surname><given-names>K</given-names></name><name name-style="western"><surname>Nalbant</surname><given-names>G</given-names></name><name name-style="western"><surname>Sutton</surname><given-names>A</given-names></name><name name-style="western"><surname>Harnan</surname><given-names>S</given-names></name><name name-style="western"><surname>Thokala</surname><given-names>P</given-names></name><name name-style="western"><surname>Chilcott</surname><given-names>J</given-names></name><name name-style="western"><surname>McNeill</surname><given-names>A</given-names></name><name name-style="western"><surname>Bessey</surname><given-names>A</given-names></name></person-group><article-title>Systematic review of presymptomatic treatment for spinal muscular atrophy</article-title><source>Int J Neonatal Screen</source><year>2024</year><volume>10</volume><fpage>56</fpage><pub-id pub-id-type="doi">10.3390/ijns10030056</pub-id><pub-id pub-id-type="pmid">39189228</pub-id><pub-id pub-id-type="pmcid">PMC11348213</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Cooper K, Nalbant G, Sutton A, Harnan S, Thokala P, Chilcott J, McNeill A, Bessey A (2024) Systematic review of presymptomatic treatment for spinal muscular atrophy. Int J Neonatal Screen 10:56. 10.3390/ijns10030056<pub-id pub-id-type="pmid">39189228</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijns10030056</pub-id><pub-id pub-id-type="pmcid">PMC11348213</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sumner</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Crawford</surname><given-names>TO</given-names></name></person-group><article-title>Early treatment is a lifeline for infants with SMA</article-title><source>Nat Med</source><year>2022</year><volume>28</volume><fpage>1348</fpage><lpage>1349</lpage><pub-id pub-id-type="doi">10.1038/s41591-022-01889-x</pub-id><pub-id pub-id-type="pmid">35840728</pub-id><pub-id pub-id-type="pmcid">PMC10228631</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Sumner CJ, Crawford TO (2022) Early treatment is a lifeline for infants with SMA. Nat Med 28:1348&#8211;1349. 10.1038/s41591-022-01889-x<pub-id pub-id-type="pmid">35840728</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-022-01889-x</pub-id><pub-id pub-id-type="pmcid">PMC10228631</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hagenacker</surname><given-names>T</given-names></name><name name-style="western"><surname>Maggi</surname><given-names>L</given-names></name><name name-style="western"><surname>Coratti</surname><given-names>G</given-names></name><name name-style="western"><surname>Youn</surname><given-names>B</given-names></name><name name-style="western"><surname>Raynaud</surname><given-names>S</given-names></name><name name-style="western"><surname>Paradis</surname><given-names>AD</given-names></name><name name-style="western"><surname>Mercuri</surname><given-names>E</given-names></name></person-group><article-title>Effectiveness of nusinersen in adolescents and adults with spinal muscular atrophy: systematic review and meta-analysis</article-title><source>Neurol Ther</source><year>2024</year><volume>13</volume><fpage>1483</fpage><lpage>1504</lpage><pub-id pub-id-type="doi">10.1007/s40120-024-00653-2</pub-id><pub-id pub-id-type="pmid">39222296</pub-id><pub-id pub-id-type="pmcid">PMC11393259</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Hagenacker T, Maggi L, Coratti G, Youn B, Raynaud S, Paradis AD, Mercuri E (2024) Effectiveness of nusinersen in adolescents and adults with spinal muscular atrophy: systematic review and meta-analysis. Neurol Ther 13:1483&#8211;1504. 10.1007/s40120-024-00653-2<pub-id pub-id-type="pmid">39222296</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40120-024-00653-2</pub-id><pub-id pub-id-type="pmcid">PMC11393259</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maggi</surname><given-names>L</given-names></name><name name-style="western"><surname>Bello</surname><given-names>L</given-names></name><name name-style="western"><surname>Bonanno</surname><given-names>S</given-names></name><name name-style="western"><surname>Govoni</surname><given-names>A</given-names></name><name name-style="western"><surname>Caponnetto</surname><given-names>C</given-names></name><name name-style="western"><surname>Passamano</surname><given-names>L</given-names></name><name name-style="western"><surname>Grandis</surname><given-names>M</given-names></name><name name-style="western"><surname>Trojsi</surname><given-names>F</given-names></name><name name-style="western"><surname>Cerri</surname><given-names>F</given-names></name><name name-style="western"><surname>Ferraro</surname><given-names>M</given-names></name><name name-style="western"><surname>Bozzoni</surname><given-names>V</given-names></name><name name-style="western"><surname>Caumo</surname><given-names>L</given-names></name><name name-style="western"><surname>Piras</surname><given-names>R</given-names></name><name name-style="western"><surname>Tanel</surname><given-names>R</given-names></name><name name-style="western"><surname>Saccani</surname><given-names>E</given-names></name><name name-style="western"><surname>Meneri</surname><given-names>M</given-names></name><name name-style="western"><surname>Vacchiano</surname><given-names>V</given-names></name><name name-style="western"><surname>Ricci</surname><given-names>G</given-names></name><name name-style="western"><surname>Soraru'</surname><given-names>G</given-names></name><name name-style="western"><surname>D'Errico</surname><given-names>E</given-names></name><etal/></person-group><article-title>Nusinersen safety and effects on motor function in adult spinal muscular atrophy type 2 and 3</article-title><source>J Neurol Neurosurg Psychiatry</source><year>2020</year><volume>91</volume><fpage>1166</fpage><lpage>1174</lpage><pub-id pub-id-type="doi">10.1136/jnnp-2020-323822</pub-id><pub-id pub-id-type="pmid">32917822</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Maggi L, Bello L, Bonanno S, Govoni A, Caponnetto C, Passamano L, Grandis M, Trojsi F, Cerri F, Ferraro M, Bozzoni V, Caumo L, Piras R, Tanel R, Saccani E, Meneri M, Vacchiano V, Ricci G, Soraru&#8217; G, D&#8217;Errico E et al (2020) Nusinersen safety and effects on motor function in adult spinal muscular atrophy type 2 and 3. J Neurol Neurosurg Psychiatry 91:1166&#8211;1174. 10.1136/jnnp-2020-323822<pub-id pub-id-type="pmid">32917822</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jnnp-2020-323822</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Erdos</surname><given-names>J</given-names></name><name name-style="western"><surname>Wild</surname><given-names>C</given-names></name></person-group><article-title>Mid- and long-term (at least 12 months) follow-up of patients with spinal muscular atrophy (SMA) treated with nusinersen, onasemnogene abeparvovec, risdiplam or combination therapies: a systematic review of real-world study data</article-title><source>Eur J Paediatr Neurol</source><year>2022</year><volume>39</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1016/j.ejpn.2022.04.006</pub-id><pub-id pub-id-type="pmid">35533607</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Erdos J, Wild C (2022) Mid- and long-term (at least 12 months) follow-up of patients with spinal muscular atrophy (SMA) treated with nusinersen, onasemnogene abeparvovec, risdiplam or combination therapies: a systematic review of real-world study data. Eur J Paediatr Neurol 39:1&#8211;10. 10.1016/j.ejpn.2022.04.006<pub-id pub-id-type="pmid">35533607</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejpn.2022.04.006</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gidaro</surname><given-names>T</given-names></name><name name-style="western"><surname>Servais</surname><given-names>L</given-names></name></person-group><article-title>Nusinersen treatment of spinal muscular atrophy: current knowledge and existing gaps</article-title><source>Dev Med Child Neurol</source><year>2019</year><volume>61</volume><fpage>19</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1111/dmcn.14027</pub-id><pub-id pub-id-type="pmid">30221755</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Gidaro T, Servais L (2019) Nusinersen treatment of spinal muscular atrophy: current knowledge and existing gaps. Dev Med Child Neurol 61:19&#8211;24. 10.1111/dmcn.14027<pub-id pub-id-type="pmid">30221755</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/dmcn.14027</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kirschner</surname><given-names>J</given-names></name><name name-style="western"><surname>Bernert</surname><given-names>G</given-names></name><name name-style="western"><surname>Butoianu</surname><given-names>N</given-names></name><name name-style="western"><surname>De Waele</surname><given-names>L</given-names></name><name name-style="western"><surname>Fattal-Valevski</surname><given-names>A</given-names></name><name name-style="western"><surname>Haberlova</surname><given-names>J</given-names></name><name name-style="western"><surname>Moreno</surname><given-names>T</given-names></name><name name-style="western"><surname>Klein</surname><given-names>A</given-names></name><name name-style="western"><surname>Kostera-Pruszczyk</surname><given-names>A</given-names></name><name name-style="western"><surname>Mercuri</surname><given-names>E</given-names></name><name name-style="western"><surname>Quijano-Roy</surname><given-names>S</given-names></name><name name-style="western"><surname>Sejersen</surname><given-names>T</given-names></name><name name-style="western"><surname>Tizzano</surname><given-names>EF</given-names></name><name name-style="western"><surname>Van Der Pol</surname><given-names>WL</given-names></name><name name-style="western"><surname>Wallace</surname><given-names>S</given-names></name><name name-style="western"><surname>Zafeiriou</surname><given-names>D</given-names></name><name name-style="western"><surname>Ziegler</surname><given-names>A</given-names></name><name name-style="western"><surname>Muntoni</surname><given-names>F</given-names></name><name name-style="western"><surname>Servais</surname><given-names>L</given-names></name></person-group><article-title>2024 update: European consensus statement on gene therapy for spinal muscular atrophy</article-title><source>Eur J Paediatr Neurol</source><year>2024</year><volume>51</volume><fpage>73</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1016/j.ejpn.2024.06.001</pub-id><pub-id pub-id-type="pmid">38878702</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Kirschner J, Bernert G, Butoianu N, De Waele L, Fattal-Valevski A, Haberlova J, Moreno T, Klein A, Kostera-Pruszczyk A, Mercuri E, Quijano-Roy S, Sejersen T, Tizzano EF, Van Der Pol WL, Wallace S, Zafeiriou D, Ziegler A, Muntoni F, Servais L (2024) 2024 update: European consensus statement on gene therapy for spinal muscular atrophy. Eur J Paediatr Neurol 51:73&#8211;78. 10.1016/j.ejpn.2024.06.001<pub-id pub-id-type="pmid">38878702</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejpn.2024.06.001</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Butterfield</surname><given-names>RJ</given-names></name></person-group><article-title>Spinal muscular atrophy treatments, newborn screening, and the creation of a neurogenetics urgency</article-title><source>Semin Pediatr Neurol</source><year>2021</year><volume>38</volume><fpage>100899</fpage><pub-id pub-id-type="doi">10.1016/j.spen.2021.100899</pub-id><pub-id pub-id-type="pmid">34183144</pub-id><pub-id pub-id-type="pmcid">PMC8243405</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Butterfield RJ (2021) Spinal muscular atrophy treatments, newborn screening, and the creation of a neurogenetics urgency. Semin Pediatr Neurol 38:100899. 10.1016/j.spen.2021.100899<pub-id pub-id-type="pmid">34183144</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.spen.2021.100899</pub-id><pub-id pub-id-type="pmcid">PMC8243405</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schroth</surname><given-names>M</given-names></name><name name-style="western"><surname>Deans</surname><given-names>J</given-names></name><name name-style="western"><surname>Arya</surname><given-names>K</given-names></name><name name-style="western"><surname>Castro</surname><given-names>DC</given-names></name><name name-style="western"><surname>De Vivo</surname><given-names>DC</given-names></name><name name-style="western"><surname>Gibbons</surname><given-names>MA</given-names></name><name name-style="western"><surname>Ionita</surname><given-names>C</given-names></name><name name-style="western"><surname>Kuntz</surname><given-names>NL</given-names></name><name name-style="western"><surname>Lakhotia</surname><given-names>A</given-names></name><name name-style="western"><surname>Neil Knierbein</surname><given-names>E</given-names></name><name name-style="western"><surname>Scoto</surname><given-names>M</given-names></name><name name-style="western"><surname>Sejersen</surname><given-names>T</given-names></name><name name-style="western"><surname>Servais</surname><given-names>L</given-names></name><name name-style="western"><surname>Tian</surname><given-names>C</given-names></name><name name-style="western"><surname>Waldrop</surname><given-names>MA</given-names></name><name name-style="western"><surname>V&#225;zquez-Costa</surname><given-names>JF</given-names></name></person-group><article-title>Spinal muscular atrophy update in best practices: recommendations for diagnosis considerations</article-title><source>Neurol Clin Pract</source><year>2024</year><volume>14</volume><fpage>e200310</fpage><pub-id pub-id-type="doi">10.1212/CPJ.0000000000200310</pub-id><pub-id pub-id-type="pmid">38915908</pub-id><pub-id pub-id-type="pmcid">PMC11195435</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Schroth M, Deans J, Arya K, Castro DC, De Vivo DC, Gibbons MA, Ionita C, Kuntz NL, Lakhotia A, Neil Knierbein E, Scoto M, Sejersen T, Servais L, Tian C, Waldrop MA, V&#225;zquez-Costa JF (2024) Spinal muscular atrophy update in best practices: recommendations for diagnosis considerations. Neurol Clin Pract 14:e200310. 10.1212/CPJ.0000000000200310<pub-id pub-id-type="pmid">38915908</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/CPJ.0000000000200310</pub-id><pub-id pub-id-type="pmcid">PMC11195435</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lemska</surname><given-names>A</given-names></name><name name-style="western"><surname>Ruminski</surname><given-names>P</given-names></name><name name-style="western"><surname>Szymarek</surname><given-names>J</given-names></name><name name-style="western"><surname>Studzinska</surname><given-names>S</given-names></name><name name-style="western"><surname>Mazurkiewicz-Beldzinska</surname><given-names>M</given-names></name></person-group><article-title>Efficacy of nusinersen treatment in type 1, 2, and 3 spinal muscular atrophy: real-world data from a single-center study</article-title><source>Neurol Int</source><year>2024</year><volume>16</volume><fpage>1266</fpage><lpage>1278</lpage><pub-id pub-id-type="doi">10.3390/neurolint16060096</pub-id><pub-id pub-id-type="pmid">39585055</pub-id><pub-id pub-id-type="pmcid">PMC11587074</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Lemska A, Ruminski P, Szymarek J, Studzinska S, Mazurkiewicz-Beldzinska M (2024) Efficacy of nusinersen treatment in type 1, 2, and 3 spinal muscular atrophy: real-world data from a single-center study. Neurol Int 16:1266&#8211;1278. 10.3390/neurolint16060096<pub-id pub-id-type="pmid">39585055</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/neurolint16060096</pub-id><pub-id pub-id-type="pmcid">PMC11587074</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reilly</surname><given-names>A</given-names></name><name name-style="western"><surname>Chehade</surname><given-names>L</given-names></name><name name-style="western"><surname>Kothary</surname><given-names>R</given-names></name></person-group><article-title>Curing SMA: are we there yet?</article-title><source>Gene Ther</source><year>2023</year><volume>30</volume><fpage>8</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1038/s41434-022-00349-y</pub-id><pub-id pub-id-type="pmid">35614235</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Reilly A, Chehade L, Kothary R (2023) Curing SMA: are we there yet? Gene Ther 30:8&#8211;17. 10.1038/s41434-022-00349-y<pub-id pub-id-type="pmid">35614235</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41434-022-00349-y</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Antonaci</surname><given-names>L</given-names></name><name name-style="western"><surname>Pera</surname><given-names>MC</given-names></name><name name-style="western"><surname>Mercuri</surname><given-names>E</given-names></name></person-group><article-title>New therapies for spinal muscular atrophy: where we stand and what is next</article-title><source>Eur J Pediatr</source><year>2023</year><volume>182</volume><fpage>2935</fpage><lpage>2942</lpage><pub-id pub-id-type="doi">10.1007/s00431-023-04883-8</pub-id><pub-id pub-id-type="pmid">37067602</pub-id><pub-id pub-id-type="pmcid">PMC10354145</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Antonaci L, Pera MC, Mercuri E (2023) New therapies for spinal muscular atrophy: where we stand and what is next. Eur J Pediatr 182:2935&#8211;2942. 10.1007/s00431-023-04883-8<pub-id pub-id-type="pmid">37067602</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00431-023-04883-8</pub-id><pub-id pub-id-type="pmcid">PMC10354145</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hagenacker</surname><given-names>T</given-names></name><name name-style="western"><surname>Wurster</surname><given-names>CD</given-names></name><name name-style="western"><surname>G&#252;nther</surname><given-names>R</given-names></name><name name-style="western"><surname>Schreiber-Katz</surname><given-names>O</given-names></name><name name-style="western"><surname>Osmanovic</surname><given-names>A</given-names></name><name name-style="western"><surname>Petri</surname><given-names>S</given-names></name><name name-style="western"><surname>Kizina</surname><given-names>K</given-names></name><name name-style="western"><surname>Zange</surname><given-names>J</given-names></name><name name-style="western"><surname>Koch</surname><given-names>JC</given-names></name><name name-style="western"><surname>Schilling</surname><given-names>M</given-names></name><name name-style="western"><surname>Steinbach</surname><given-names>R</given-names></name><name name-style="western"><surname>Fuss</surname><given-names>S</given-names></name><name name-style="western"><surname>Nobile</surname><given-names>T</given-names></name><name name-style="western"><surname>Wolf</surname><given-names>T</given-names></name><name name-style="western"><surname>Ludolph</surname><given-names>AC</given-names></name><name name-style="western"><surname>Otto</surname><given-names>M</given-names></name><name name-style="western"><surname>Dabbous</surname><given-names>O</given-names></name><name name-style="western"><surname>Meyer</surname><given-names>T</given-names></name></person-group><article-title>Nusinersen in adults with 5q spinal muscular atrophy: a non-interventional, multicentre, observational cohort study</article-title><source>Lancet Neurol</source><year>2020</year><volume>19</volume><fpage>317</fpage><lpage>325</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(20)30037-5</pub-id><pub-id pub-id-type="pmid">32199097</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Hagenacker T, Wurster CD, G&#252;nther R, Schreiber-Katz O, Osmanovic A, Petri S, Kizina K, Zange J, Koch JC, Schilling M, Steinbach R, Fuss S, Nobile T, Wolf T, Ludolph AC, Otto M, Dabbous O, Meyer T (2020) Nusinersen in adults with 5q spinal muscular atrophy: a non-interventional, multicentre, observational cohort study. Lancet Neurol 19:317&#8211;325. 10.1016/S1474-4422(20)30037-5<pub-id pub-id-type="pmid">32199097</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1474-4422(20)30037-5</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Duong</surname><given-names>T</given-names></name><name name-style="western"><surname>Wolford</surname><given-names>C</given-names></name><name name-style="western"><surname>McDermott</surname><given-names>MP</given-names></name><name name-style="western"><surname>Quigley</surname><given-names>J</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L</given-names></name><name name-style="western"><surname>McGraw</surname><given-names>S</given-names></name><name name-style="western"><surname>Martens</surname><given-names>WB</given-names></name><name name-style="western"><surname>Chung</surname><given-names>WK</given-names></name><name name-style="western"><surname>Ferguson</surname><given-names>ML</given-names></name><name name-style="western"><surname>Day</surname><given-names>JW</given-names></name><name name-style="western"><surname>Tawil</surname><given-names>R</given-names></name><name name-style="western"><surname>Pasternak</surname><given-names>A</given-names></name><name name-style="western"><surname>Sproule</surname><given-names>DM</given-names></name></person-group><article-title>Nusinersen treatment in adults with spinal muscular atrophy</article-title><source>Neurol Clin Pract</source><year>2021</year><volume>11</volume><fpage>e317</fpage><lpage>e327</lpage><pub-id pub-id-type="doi">10.1212/CPJ.0000000000001033</pub-id><pub-id pub-id-type="pmid">34476123</pub-id><pub-id pub-id-type="pmcid">PMC8382360</pub-id></element-citation><mixed-citation id="mc-CR34" publication-type="journal">Duong T, Wolford C, McDermott MP, Quigley J, Chen L, McGraw S, Martens WB, Chung WK, Ferguson ML, Day JW, Tawil R, Pasternak A, Sproule DM (2021) Nusinersen treatment in adults with spinal muscular atrophy. Neurol Clin Pract 11:e317&#8211;e327. 10.1212/CPJ.0000000000001033<pub-id pub-id-type="pmid">34476123</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/CPJ.0000000000001033</pub-id><pub-id pub-id-type="pmcid">PMC8382360</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Finkel</surname><given-names>RS</given-names></name><name name-style="western"><surname>Mercuri</surname><given-names>E</given-names></name><name name-style="western"><surname>Darras</surname><given-names>BT</given-names></name><name name-style="western"><surname>Connolly</surname><given-names>AM</given-names></name><name name-style="western"><surname>Kuntz</surname><given-names>NL</given-names></name><name name-style="western"><surname>Kirschner</surname><given-names>J</given-names></name><name name-style="western"><surname>Chiriboga</surname><given-names>CA</given-names></name><name name-style="western"><surname>Saito</surname><given-names>K</given-names></name><name name-style="western"><surname>Servais</surname><given-names>L</given-names></name><name name-style="western"><surname>Tizzano</surname><given-names>E</given-names></name><name name-style="western"><surname>Topaloglu</surname><given-names>H</given-names></name><name name-style="western"><surname>Tulinius</surname><given-names>M</given-names></name><name name-style="western"><surname>Montes</surname><given-names>J</given-names></name><name name-style="western"><surname>Glanzman</surname><given-names>AM</given-names></name><name name-style="western"><surname>Bishop</surname><given-names>K</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>ZJ</given-names></name><name name-style="western"><surname>Gheuens</surname><given-names>S</given-names></name><name name-style="western"><surname>Bennett</surname><given-names>CF</given-names></name><name name-style="western"><surname>Schneider</surname><given-names>E</given-names></name><name name-style="western"><surname>Farwell</surname><given-names>W</given-names></name><name name-style="western"><surname>De Vivo</surname><given-names>DC</given-names></name><collab>ENDEAR Study Group</collab></person-group><article-title>Nusinersen versus sham control in infantile-onset spinal muscular atrophy</article-title><source>N Engl J Med</source><year>2017</year><volume>377</volume><fpage>1723</fpage><lpage>1732</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1702752</pub-id><pub-id pub-id-type="pmid">29091570</pub-id></element-citation><mixed-citation id="mc-CR35" publication-type="journal">Finkel RS, Mercuri E, Darras BT, Connolly AM, Kuntz NL, Kirschner J, Chiriboga CA, Saito K, Servais L, Tizzano E, Topaloglu H, Tulinius M, Montes J, Glanzman AM, Bishop K, Zhong ZJ, Gheuens S, Bennett CF, Schneider E, Farwell W, De Vivo DC, ENDEAR Study Group (2017) Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med 377:1723&#8211;1732. 10.1056/NEJMoa1702752<pub-id pub-id-type="pmid">29091570</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1702752</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Crawford</surname><given-names>TO</given-names></name><name name-style="western"><surname>Swoboda</surname><given-names>KJ</given-names></name><name name-style="western"><surname>De Vivo</surname><given-names>DC</given-names></name><name name-style="western"><surname>Bertini</surname><given-names>E</given-names></name><name name-style="western"><surname>Hwu</surname><given-names>WL</given-names></name><name name-style="western"><surname>Finkel</surname><given-names>RS</given-names></name><name name-style="western"><surname>Kirschner</surname><given-names>J</given-names></name><name name-style="western"><surname>Kuntz</surname><given-names>NL</given-names></name><name name-style="western"><surname>Nazario</surname><given-names>AN</given-names></name><name name-style="western"><surname>Parsons</surname><given-names>JA</given-names></name><name name-style="western"><surname>Pechmann</surname><given-names>A</given-names></name><name name-style="western"><surname>Ryan</surname><given-names>MM</given-names></name><name name-style="western"><surname>Butterfield</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Topaloglu</surname><given-names>H</given-names></name><name name-style="western"><surname>Ben-Omran</surname><given-names>T</given-names></name><name name-style="western"><surname>Sansone</surname><given-names>VA</given-names></name><name name-style="western"><surname>Jong</surname><given-names>YJ</given-names></name><name name-style="western"><surname>Shu</surname><given-names>F</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>C</given-names></name><name name-style="western"><surname>Raynaud</surname><given-names>S</given-names></name><name name-style="western"><surname>Lago</surname><given-names>TR</given-names></name><name name-style="western"><surname>Paradis</surname><given-names>AD</given-names></name><name name-style="western"><surname>Foster</surname><given-names>R</given-names></name><name name-style="western"><surname>Chin</surname><given-names>R</given-names></name><name name-style="western"><surname>Berger</surname><given-names>Z</given-names></name><collab>NURTURE Study Group</collab></person-group><article-title>Continued benefit of nusinersen initiated in the presymptomatic stage of spinal muscular atrophy: 5-year update of the NURTURE study</article-title><source>Muscle Nerve</source><year>2023</year><volume>68</volume><fpage>157</fpage><lpage>170</lpage><pub-id pub-id-type="doi">10.1002/mus.27853</pub-id><pub-id pub-id-type="pmid">37409780</pub-id></element-citation><mixed-citation id="mc-CR36" publication-type="journal">Crawford TO, Swoboda KJ, De Vivo DC, Bertini E, Hwu WL, Finkel RS, Kirschner J, Kuntz NL, Nazario AN, Parsons JA, Pechmann A, Ryan MM, Butterfield RJ, Topaloglu H, Ben-Omran T, Sansone VA, Jong YJ, Shu F, Zhu C, Raynaud S, Lago TR, Paradis AD, Foster R, Chin R, Berger Z, NURTURE Study Group (2023) Continued benefit of nusinersen initiated in the presymptomatic stage of spinal muscular atrophy: 5-year update of the NURTURE study. Muscle Nerve 68:157&#8211;170. 10.1002/mus.27853<pub-id pub-id-type="pmid">37409780</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mus.27853</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Darras</surname><given-names>BT</given-names></name><name name-style="western"><surname>Masson</surname><given-names>R</given-names></name><name name-style="western"><surname>Mazurkiewicz-Be&#322;dzi&#324;ska</surname><given-names>M</given-names></name><name name-style="western"><surname>Rose</surname><given-names>K</given-names></name><name name-style="western"><surname>Xiong</surname><given-names>H</given-names></name><name name-style="western"><surname>Zanoteli</surname><given-names>E</given-names></name><name name-style="western"><surname>Baranello</surname><given-names>G</given-names></name><name name-style="western"><surname>Bruno</surname><given-names>C</given-names></name><name name-style="western"><surname>Vlodavets</surname><given-names>D</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>El-Khairi</surname><given-names>M</given-names></name><name name-style="western"><surname>Gerber</surname><given-names>M</given-names></name><name name-style="western"><surname>Gorni</surname><given-names>K</given-names></name><name name-style="western"><surname>Khwaja</surname><given-names>O</given-names></name><name name-style="western"><surname>Kletzl</surname><given-names>H</given-names></name><name name-style="western"><surname>Scalco</surname><given-names>RS</given-names></name><name name-style="western"><surname>Fontoura</surname><given-names>P</given-names></name><name name-style="western"><surname>Servais</surname><given-names>L</given-names></name><collab>FIREFISH Working Group</collab></person-group><article-title>Risdiplam-treated infants with type 1 spinal muscular atrophy versus historical controls</article-title><source>N Engl J Med</source><year>2021</year><volume>385</volume><fpage>427</fpage><lpage>435</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2102047</pub-id><pub-id pub-id-type="pmid">34320287</pub-id></element-citation><mixed-citation id="mc-CR37" publication-type="journal">Darras BT, Masson R, Mazurkiewicz-Be&#322;dzi&#324;ska M, Rose K, Xiong H, Zanoteli E, Baranello G, Bruno C, Vlodavets D, Wang Y, El-Khairi M, Gerber M, Gorni K, Khwaja O, Kletzl H, Scalco RS, Fontoura P, Servais L, FIREFISH Working Group (2021) Risdiplam-treated infants with type 1 spinal muscular atrophy versus historical controls. N Engl J Med 385:427&#8211;435. 10.1056/NEJMoa2102047<pub-id pub-id-type="pmid">34320287</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2102047</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mercuri</surname><given-names>E</given-names></name><name name-style="western"><surname>Deconinck</surname><given-names>N</given-names></name><name name-style="western"><surname>Mazzone</surname><given-names>ES</given-names></name><name name-style="western"><surname>Nascimento</surname><given-names>A</given-names></name><name name-style="western"><surname>Oskoui</surname><given-names>M</given-names></name><name name-style="western"><surname>Saito</surname><given-names>K</given-names></name><name name-style="western"><surname>Vuillerot</surname><given-names>C</given-names></name><name name-style="western"><surname>Baranello</surname><given-names>G</given-names></name><name name-style="western"><surname>Boespflug-Tanguy</surname><given-names>O</given-names></name><name name-style="western"><surname>Goemans</surname><given-names>N</given-names></name><name name-style="western"><surname>Kirschner</surname><given-names>J</given-names></name><name name-style="western"><surname>Kostera-Pruszczyk</surname><given-names>A</given-names></name><name name-style="western"><surname>Servais</surname><given-names>L</given-names></name><name name-style="western"><surname>Gerber</surname><given-names>M</given-names></name><name name-style="western"><surname>Gorni</surname><given-names>K</given-names></name><name name-style="western"><surname>Khwaja</surname><given-names>O</given-names></name><name name-style="western"><surname>Kletzl</surname><given-names>H</given-names></name><name name-style="western"><surname>Scalco</surname><given-names>RS</given-names></name><name name-style="western"><surname>Staunton</surname><given-names>H</given-names></name><name name-style="western"><surname>Yeung</surname><given-names>WY</given-names></name><name name-style="western"><surname>Martin</surname><given-names>C</given-names></name><name name-style="western"><surname>Fontoura</surname><given-names>P</given-names></name><name name-style="western"><surname>Day</surname><given-names>JW</given-names></name><collab>SUNFISH Study Group</collab></person-group><article-title>Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo- controlled trial</article-title><source>Lancet Neurol</source><year>2022</year><volume>21</volume><fpage>42</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(21)00367-7</pub-id><pub-id pub-id-type="pmid">34942136</pub-id></element-citation><mixed-citation id="mc-CR38" publication-type="journal">Mercuri E, Deconinck N, Mazzone ES, Nascimento A, Oskoui M, Saito K, Vuillerot C, Baranello G, Boespflug-Tanguy O, Goemans N, Kirschner J, Kostera-Pruszczyk A, Servais L, Gerber M, Gorni K, Khwaja O, Kletzl H, Scalco RS, Staunton H, Yeung WY, Martin C, Fontoura P, Day JW, SUNFISH Study Group (2022) Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo- controlled trial. Lancet Neurol 21:42&#8211;52. 10.1016/S1474-4422(21)00367-7<pub-id pub-id-type="pmid">34942136</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1474-4422(21)00367-7</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mendell</surname><given-names>JR</given-names></name><name name-style="western"><surname>Al-Zaidy</surname><given-names>SA</given-names></name><name name-style="western"><surname>Lehman</surname><given-names>KJ</given-names></name><name name-style="western"><surname>McColly</surname><given-names>M</given-names></name><name name-style="western"><surname>Lowes</surname><given-names>LP</given-names></name><name name-style="western"><surname>Alfano</surname><given-names>LN</given-names></name><name name-style="western"><surname>Reash</surname><given-names>NF</given-names></name><name name-style="western"><surname>Iammarino</surname><given-names>MA</given-names></name><name name-style="western"><surname>Church</surname><given-names>KR</given-names></name><name name-style="western"><surname>Kleyn</surname><given-names>A</given-names></name><name name-style="western"><surname>Meriggioli</surname><given-names>MN</given-names></name><name name-style="western"><surname>Shell</surname><given-names>R</given-names></name></person-group><article-title>Five-year extension results of the phase 1 START trial of onasemnogene abeparvovec in spinal muscular atrophy</article-title><source>JAMA Neurol</source><year>2021</year><volume>78</volume><fpage>834</fpage><lpage>841</lpage><pub-id pub-id-type="doi">10.1001/jamaneurol.2021.1272</pub-id><pub-id pub-id-type="pmid">33999158</pub-id><pub-id pub-id-type="pmcid">PMC8129901</pub-id></element-citation><mixed-citation id="mc-CR39" publication-type="journal">Mendell JR, Al-Zaidy SA, Lehman KJ, McColly M, Lowes LP, Alfano LN, Reash NF, Iammarino MA, Church KR, Kleyn A, Meriggioli MN, Shell R (2021) Five-year extension results of the phase 1 START trial of onasemnogene abeparvovec in spinal muscular atrophy. JAMA Neurol 78:834&#8211;841. 10.1001/jamaneurol.2021.1272<pub-id pub-id-type="pmid">33999158</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaneurol.2021.1272</pub-id><pub-id pub-id-type="pmcid">PMC8129901</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Day</surname><given-names>JW</given-names></name><name name-style="western"><surname>Finkel</surname><given-names>RS</given-names></name><name name-style="western"><surname>Chiriboga</surname><given-names>CA</given-names></name><name name-style="western"><surname>Connolly</surname><given-names>AM</given-names></name><name name-style="western"><surname>Crawford</surname><given-names>TO</given-names></name><name name-style="western"><surname>Darras</surname><given-names>BT</given-names></name><name name-style="western"><surname>Iannaccone</surname><given-names>ST</given-names></name><name name-style="western"><surname>Kuntz</surname><given-names>NL</given-names></name><name name-style="western"><surname>Pe&#241;a</surname><given-names>LDM</given-names></name><name name-style="western"><surname>Shieh</surname><given-names>PB</given-names></name><name name-style="western"><surname>Smith</surname><given-names>EC</given-names></name><name name-style="western"><surname>Kwon</surname><given-names>JM</given-names></name><name name-style="western"><surname>Zaidman</surname><given-names>CM</given-names></name><name name-style="western"><surname>Schultz</surname><given-names>M</given-names></name><name name-style="western"><surname>Feltner</surname><given-names>DE</given-names></name><name name-style="western"><surname>Tauscher-Wisniewski</surname><given-names>S</given-names></name><name name-style="western"><surname>Ouyang</surname><given-names>H</given-names></name><name name-style="western"><surname>Chand</surname><given-names>DH</given-names></name><name name-style="western"><surname>Sproule</surname><given-names>DM</given-names></name><name name-style="western"><surname>Macek</surname><given-names>TA</given-names></name><name name-style="western"><surname>Mendell</surname><given-names>JR</given-names></name></person-group><article-title>Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial</article-title><source>Lancet Neurol</source><year>2021</year><volume>20</volume><fpage>284</fpage><lpage>293</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(21)00001-6</pub-id><pub-id pub-id-type="pmid">33743238</pub-id></element-citation><mixed-citation id="mc-CR40" publication-type="journal">Day JW, Finkel RS, Chiriboga CA, Connolly AM, Crawford TO, Darras BT, Iannaccone ST, Kuntz NL, Pe&#241;a LDM, Shieh PB, Smith EC, Kwon JM, Zaidman CM, Schultz M, Feltner DE, Tauscher-Wisniewski S, Ouyang H, Chand DH, Sproule DM, Macek TA, Mendell JR (2021) Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial. Lancet Neurol 20:284&#8211;293. 10.1016/S1474-4422(21)00001-6<pub-id pub-id-type="pmid">33743238</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1474-4422(21)00001-6</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Strauss</surname><given-names>KA</given-names></name><name name-style="western"><surname>Farrar</surname><given-names>MA</given-names></name><name name-style="western"><surname>Muntoni</surname><given-names>F</given-names></name><name name-style="western"><surname>Saito</surname><given-names>K</given-names></name><name name-style="western"><surname>Mendell</surname><given-names>JR</given-names></name><name name-style="western"><surname>Servais</surname><given-names>L</given-names></name><name name-style="western"><surname>McMillan</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Finkel</surname><given-names>RS</given-names></name><name name-style="western"><surname>Swoboda</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Kwon</surname><given-names>JM</given-names></name><name name-style="western"><surname>Zaidman</surname><given-names>CM</given-names></name><name name-style="western"><surname>Chiriboga</surname><given-names>CA</given-names></name><name name-style="western"><surname>Iannaccone</surname><given-names>ST</given-names></name><name name-style="western"><surname>Krueger</surname><given-names>JM</given-names></name><name name-style="western"><surname>Parsons</surname><given-names>JA</given-names></name><name name-style="western"><surname>Shieh</surname><given-names>PB</given-names></name><name name-style="western"><surname>Kavanagh</surname><given-names>S</given-names></name><name name-style="western"><surname>Wigderson</surname><given-names>M</given-names></name><name name-style="western"><surname>Tauscher-Wisniewski</surname><given-names>S</given-names></name><name name-style="western"><surname>McGill</surname><given-names>BE</given-names></name><name name-style="western"><surname>Macek</surname><given-names>TA</given-names></name></person-group><article-title>Onasemnogene abeparvovec for presymptomatic infants with three copies of <italic toggle="yes">SMN2</italic> at risk for spinal muscular atrophy: the phase III SPR1NT trial</article-title><source>Nat Med</source><year>2022</year><volume>28</volume><fpage>1390</fpage><lpage>1397</lpage><pub-id pub-id-type="doi">10.1038/s41591-022-01867-3</pub-id><pub-id pub-id-type="pmid">35715567</pub-id><pub-id pub-id-type="pmcid">PMC9205287</pub-id></element-citation><mixed-citation id="mc-CR41" publication-type="journal">Strauss KA, Farrar MA, Muntoni F, Saito K, Mendell JR, Servais L, McMillan HJ, Finkel RS, Swoboda KJ, Kwon JM, Zaidman CM, Chiriboga CA, Iannaccone ST, Krueger JM, Parsons JA, Shieh PB, Kavanagh S, Wigderson M, Tauscher-Wisniewski S, McGill BE, Macek TA (2022) Onasemnogene abeparvovec for presymptomatic infants with three copies of <italic toggle="yes">SMN2</italic> at risk for spinal muscular atrophy: the phase III SPR1NT trial. Nat Med 28:1390&#8211;1397. 10.1038/s41591-022-01867-3<pub-id pub-id-type="pmid">35715567</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-022-01867-3</pub-id><pub-id pub-id-type="pmcid">PMC9205287</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Strauss</surname><given-names>KA</given-names></name><name name-style="western"><surname>Farrar</surname><given-names>MA</given-names></name><name name-style="western"><surname>Muntoni</surname><given-names>F</given-names></name><name name-style="western"><surname>Saito</surname><given-names>K</given-names></name><name name-style="western"><surname>Mendell</surname><given-names>JR</given-names></name><name name-style="western"><surname>Servais</surname><given-names>L</given-names></name><name name-style="western"><surname>McMillan</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Finkel</surname><given-names>RS</given-names></name><name name-style="western"><surname>Swoboda</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Kwon</surname><given-names>JM</given-names></name><name name-style="western"><surname>Zaidman</surname><given-names>CM</given-names></name><name name-style="western"><surname>Chiriboga</surname><given-names>CA</given-names></name><name name-style="western"><surname>Iannaccone</surname><given-names>ST</given-names></name><name name-style="western"><surname>Krueger</surname><given-names>JM</given-names></name><name name-style="western"><surname>Parsons</surname><given-names>JA</given-names></name><name name-style="western"><surname>Shieh</surname><given-names>PB</given-names></name><name name-style="western"><surname>Kavanagh</surname><given-names>S</given-names></name><name name-style="western"><surname>Tauscher-Wisniewski</surname><given-names>S</given-names></name><name name-style="western"><surname>McGill</surname><given-names>BE</given-names></name><name name-style="western"><surname>Macek</surname><given-names>TA</given-names></name></person-group><article-title>Onasemnogene abeparvovec for presymptomatic infants with two copies of <italic toggle="yes">SMN2</italic> at risk for spinal muscular atrophy type 1: the phase III SPR1NT trial</article-title><source>Nat Med</source><year>2022</year><volume>28</volume><fpage>1381</fpage><lpage>1389</lpage><pub-id pub-id-type="doi">10.1038/s41591-022-01866-4</pub-id><pub-id pub-id-type="pmid">35715566</pub-id><pub-id pub-id-type="pmcid">PMC9205281</pub-id></element-citation><mixed-citation id="mc-CR42" publication-type="journal">Strauss KA, Farrar MA, Muntoni F, Saito K, Mendell JR, Servais L, McMillan HJ, Finkel RS, Swoboda KJ, Kwon JM, Zaidman CM, Chiriboga CA, Iannaccone ST, Krueger JM, Parsons JA, Shieh PB, Kavanagh S, Tauscher-Wisniewski S, McGill BE, Macek TA (2022) Onasemnogene abeparvovec for presymptomatic infants with two copies of <italic toggle="yes">SMN2</italic> at risk for spinal muscular atrophy type 1: the phase III SPR1NT trial. Nat Med 28:1381&#8211;1389. 10.1038/s41591-022-01866-4<pub-id pub-id-type="pmid">35715566</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-022-01866-4</pub-id><pub-id pub-id-type="pmcid">PMC9205281</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sitas</surname><given-names>B</given-names></name><name name-style="western"><surname>Hancevic</surname><given-names>M</given-names></name><name name-style="western"><surname>Bilic</surname><given-names>K</given-names></name><name name-style="western"><surname>Bilic</surname><given-names>H</given-names></name><name name-style="western"><surname>Bilic</surname><given-names>E</given-names></name></person-group><article-title>Risdiplam real world data - looking beyond motor neurons and motor function measures</article-title><source>J Neuromuscul Dis</source><year>2024</year><volume>11</volume><fpage>75</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.3233/JND-230197</pub-id><pub-id pub-id-type="pmid">38073396</pub-id><pub-id pub-id-type="pmcid">PMC10789321</pub-id></element-citation><mixed-citation id="mc-CR43" publication-type="journal">Sitas B, Hancevic M, Bilic K, Bilic H, Bilic E (2024) Risdiplam real world data - looking beyond motor neurons and motor function measures. J Neuromuscul Dis 11:75&#8211;84. 10.3233/JND-230197<pub-id pub-id-type="pmid">38073396</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JND-230197</pub-id><pub-id pub-id-type="pmcid">PMC10789321</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bitetti</surname><given-names>I</given-names></name><name name-style="western"><surname>Lanzara</surname><given-names>V</given-names></name><name name-style="western"><surname>Margiotta</surname><given-names>G</given-names></name><name name-style="western"><surname>Varone</surname><given-names>A</given-names></name></person-group><article-title>Onasemnogene abeparvovec gene replacement therapy for the treatment of spinal muscular atrophy: a real-world observational study</article-title><source>Gene Ther</source><year>2023</year><volume>30</volume><fpage>592</fpage><lpage>597</lpage><pub-id pub-id-type="doi">10.1038/s41434-022-00341-6</pub-id><pub-id pub-id-type="pmid">35606491</pub-id><pub-id pub-id-type="pmcid">PMC10457192</pub-id></element-citation><mixed-citation id="mc-CR44" publication-type="journal">Bitetti I, Lanzara V, Margiotta G, Varone A (2023) Onasemnogene abeparvovec gene replacement therapy for the treatment of spinal muscular atrophy: a real-world observational study. Gene Ther 30:592&#8211;597. 10.1038/s41434-022-00341-6<pub-id pub-id-type="pmid">35606491</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41434-022-00341-6</pub-id><pub-id pub-id-type="pmcid">PMC10457192</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pane</surname><given-names>M</given-names></name><name name-style="western"><surname>Berti</surname><given-names>B</given-names></name><name name-style="western"><surname>Capasso</surname><given-names>A</given-names></name><name name-style="western"><surname>Coratti</surname><given-names>G</given-names></name><name name-style="western"><surname>Varone</surname><given-names>A</given-names></name><name name-style="western"><surname>D'Amico</surname><given-names>A</given-names></name><name name-style="western"><surname>Messina</surname><given-names>S</given-names></name><name name-style="western"><surname>Masson</surname><given-names>R</given-names></name><name name-style="western"><surname>Sansone</surname><given-names>VA</given-names></name><name name-style="western"><surname>Donati</surname><given-names>MA</given-names></name><name name-style="western"><surname>Agosto</surname><given-names>C</given-names></name><name name-style="western"><surname>Bruno</surname><given-names>C</given-names></name><name name-style="western"><surname>Ricci</surname><given-names>F</given-names></name><name name-style="western"><surname>Pini</surname><given-names>A</given-names></name><name name-style="western"><surname>Gagliardi</surname><given-names>D</given-names></name><name name-style="western"><surname>Filosto</surname><given-names>M</given-names></name><name name-style="western"><surname>Corti</surname><given-names>S</given-names></name><name name-style="western"><surname>Leone</surname><given-names>D</given-names></name><name name-style="western"><surname>Palermo</surname><given-names>C</given-names></name><name name-style="western"><surname>Onesimo</surname><given-names>R</given-names></name><name name-style="western"><surname>De Sanctis</surname><given-names>R</given-names></name><name name-style="western"><surname>Ricci</surname><given-names>M</given-names></name><name name-style="western"><surname>Bitetti</surname><given-names>I</given-names></name><name name-style="western"><surname>Sframeli</surname><given-names>M</given-names></name><name name-style="western"><surname>Dosi</surname><given-names>C</given-names></name><name name-style="western"><surname>Albamonte</surname><given-names>E</given-names></name><name name-style="western"><surname>Ticci</surname><given-names>C</given-names></name><name name-style="western"><surname>Brolatti</surname><given-names>N</given-names></name><name name-style="western"><surname>Bertini</surname><given-names>E</given-names></name><name name-style="western"><surname>Finkel</surname><given-names>R</given-names></name><name name-style="western"><surname>Mercuri</surname><given-names>E</given-names></name><collab>ITASMAc Group</collab></person-group><article-title>Onasemnogene abeparvovec in spinal muscular atrophy: predictors of efficacy and safety in na&#239;ve patients with spinal muscular atrophy and following switch from other therapies</article-title><source>EClinicalMedicine</source><year>2023</year><volume>59</volume><fpage>101997</fpage><pub-id pub-id-type="doi">10.1016/j.eclinm.2023.101997</pub-id><pub-id pub-id-type="pmid">37197706</pub-id><pub-id pub-id-type="pmcid">PMC10184045</pub-id></element-citation><mixed-citation id="mc-CR45" publication-type="journal">Pane M, Berti B, Capasso A, Coratti G, Varone A, D&#8217;Amico A, Messina S, Masson R, Sansone VA, Donati MA, Agosto C, Bruno C, Ricci F, Pini A, Gagliardi D, Filosto M, Corti S, Leone D, Palermo C, Onesimo R, De Sanctis R, Ricci M, Bitetti I, Sframeli M, Dosi C, Albamonte E, Ticci C, Brolatti N, Bertini E, Finkel R, Mercuri E, ITASMAc Group (2023) Onasemnogene abeparvovec in spinal muscular atrophy: predictors of efficacy and safety in na&#239;ve patients with spinal muscular atrophy and following switch from other therapies. EClinicalMedicine 59:101997. 10.1016/j.eclinm.2023.101997<pub-id pub-id-type="pmid">37197706</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.eclinm.2023.101997</pub-id><pub-id pub-id-type="pmcid">PMC10184045</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bjelica</surname><given-names>B</given-names></name><name name-style="western"><surname>Wohnrade</surname><given-names>C</given-names></name><name name-style="western"><surname>Cespedes</surname><given-names>I</given-names></name><name name-style="western"><surname>Osmanovic</surname><given-names>A</given-names></name><name name-style="western"><surname>Schreiber-Katz</surname><given-names>O</given-names></name><name name-style="western"><surname>Petri</surname><given-names>S</given-names></name></person-group><article-title>Risdiplam therapy in adults with 5q-SMA: observational study on motor function and treatment satisfaction</article-title><source>BMC Neurol</source><year>2024</year><volume>24</volume><fpage>67</fpage><pub-id pub-id-type="doi">10.1186/s12883-024-03562-x</pub-id><pub-id pub-id-type="pmid">38368338</pub-id><pub-id pub-id-type="pmcid">PMC10873992</pub-id></element-citation><mixed-citation id="mc-CR46" publication-type="journal">Bjelica B, Wohnrade C, Cespedes I, Osmanovic A, Schreiber-Katz O, Petri S (2024) Risdiplam therapy in adults with 5q-SMA: observational study on motor function and treatment satisfaction. BMC Neurol 24:67. 10.1186/s12883-024-03562-x<pub-id pub-id-type="pmid">38368338</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12883-024-03562-x</pub-id><pub-id pub-id-type="pmcid">PMC10873992</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hagenacker</surname><given-names>T</given-names></name><name name-style="western"><surname>Paradis</surname><given-names>AD</given-names></name><name name-style="western"><surname>Lawson-Michod</surname><given-names>KA</given-names></name><name name-style="western"><surname>Youn</surname><given-names>B</given-names></name></person-group><article-title>Systematic review and meta-analysis of long-term nusinersen effectiveness in adolescents and adults with spinal muscular atrophy</article-title><source>Adv Ther</source><year>2025</year><pub-id pub-id-type="doi">10.1007/s12325-025-03260-1</pub-id><pub-id pub-id-type="pmid">40576875</pub-id><pub-id pub-id-type="pmcid">PMC12394302</pub-id></element-citation><mixed-citation id="mc-CR47" publication-type="journal">Hagenacker T, Paradis AD, Lawson-Michod KA, Youn B (2025) Systematic review and meta-analysis of long-term nusinersen effectiveness in adolescents and adults with spinal muscular atrophy. Adv Ther. 10.1007/s12325-025-03260-1<pub-id pub-id-type="pmid">40576875</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12325-025-03260-1</pub-id><pub-id pub-id-type="pmcid">PMC12394302</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coratti</surname><given-names>G</given-names></name><name name-style="western"><surname>Cutrona</surname><given-names>C</given-names></name><name name-style="western"><surname>Pera</surname><given-names>MC</given-names></name><name name-style="western"><surname>Bovis</surname><given-names>F</given-names></name><name name-style="western"><surname>Ponzano</surname><given-names>M</given-names></name><name name-style="western"><surname>Chieppa</surname><given-names>F</given-names></name><name name-style="western"><surname>Antonaci</surname><given-names>L</given-names></name><name name-style="western"><surname>Sansone</surname><given-names>V</given-names></name><name name-style="western"><surname>Finkel</surname><given-names>R</given-names></name><name name-style="western"><surname>Pane</surname><given-names>M</given-names></name><name name-style="western"><surname>Mercuri</surname><given-names>E</given-names></name></person-group><article-title>Motor function in type 2 and 3 SMA patients treated with Nusinersen: a critical review and meta-analysis</article-title><source>Orphanet J Rare Dis</source><year>2021</year><volume>16</volume><fpage>430</fpage><pub-id pub-id-type="doi">10.1186/s13023-021-02065-z</pub-id><pub-id pub-id-type="pmid">34645478</pub-id><pub-id pub-id-type="pmcid">PMC8515709</pub-id></element-citation><mixed-citation id="mc-CR48" publication-type="journal">Coratti G, Cutrona C, Pera MC, Bovis F, Ponzano M, Chieppa F, Antonaci L, Sansone V, Finkel R, Pane M, Mercuri E (2021) Motor function in type 2 and 3 SMA patients treated with Nusinersen: a critical review and meta-analysis. Orphanet J Rare Dis 16:430. 10.1186/s13023-021-02065-z<pub-id pub-id-type="pmid">34645478</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13023-021-02065-z</pub-id><pub-id pub-id-type="pmcid">PMC8515709</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Trucco</surname><given-names>F</given-names></name><name name-style="western"><surname>Ridout</surname><given-names>D</given-names></name><name name-style="western"><surname>Weststrate</surname><given-names>H</given-names></name><name name-style="western"><surname>Scoto</surname><given-names>M</given-names></name><name name-style="western"><surname>Rohwer</surname><given-names>A</given-names></name><name name-style="western"><surname>Coratti</surname><given-names>G</given-names></name><name name-style="western"><surname>Main</surname><given-names>ML</given-names></name><name name-style="western"><surname>Mayhew</surname><given-names>AG</given-names></name><name name-style="western"><surname>Montes</surname><given-names>J</given-names></name><name name-style="western"><surname>De Sanctis</surname><given-names>R</given-names></name><name name-style="western"><surname>Pane</surname><given-names>M</given-names></name><name name-style="western"><surname>Pera</surname><given-names>MC</given-names></name><name name-style="western"><surname>Sansone</surname><given-names>VA</given-names></name><name name-style="western"><surname>Albamonte</surname><given-names>E</given-names></name><name name-style="western"><surname>D'Amico</surname><given-names>A</given-names></name><name name-style="western"><surname>Bruno</surname><given-names>C</given-names></name><name name-style="western"><surname>Messina</surname><given-names>SS</given-names></name><name name-style="western"><surname>Childs</surname><given-names>AM</given-names></name><name name-style="western"><surname>Willis</surname><given-names>T</given-names></name><name name-style="western"><surname>Ong</surname><given-names>MT</given-names></name><name name-style="western"><surname>Servais</surname><given-names>L</given-names></name><name name-style="western"><surname>Majumdar</surname><given-names>A</given-names></name><name name-style="western"><surname>Hughes</surname><given-names>I</given-names></name><name name-style="western"><surname>Marini-Bettolo</surname><given-names>C</given-names></name><name name-style="western"><surname>Parasuraman</surname><given-names>D</given-names></name><name name-style="western"><surname>Gowda</surname><given-names>VL</given-names></name><name name-style="western"><surname>Baranello</surname><given-names>G</given-names></name><name name-style="western"><surname>Bertini</surname><given-names>ES</given-names></name><name name-style="western"><surname>De Vivo</surname><given-names>DC</given-names></name><name name-style="western"><surname>Darras</surname><given-names>BT</given-names></name><name name-style="western"><surname>Day</surname><given-names>JW</given-names></name><name name-style="western"><surname>Mayer</surname><given-names>O</given-names></name><name name-style="western"><surname>Zolkipli-Cunningham</surname><given-names>Z</given-names></name><name name-style="western"><surname>Finkel</surname><given-names>RS</given-names></name><name name-style="western"><surname>Mercuri</surname><given-names>E</given-names></name><name name-style="western"><surname>Muntoni</surname><given-names>F</given-names></name><collab>For iSMAc</collab></person-group><article-title>Therapeutic role of nusinersen on respiratory progression in pediatric patients with spinal muscular atrophy type 2 and nonambulant type 3</article-title><source>Neurol Clin Pract</source><year>2024</year><volume>14</volume><fpage>e200298</fpage><pub-id pub-id-type="doi">10.1212/CPJ.0000000000200298</pub-id><pub-id pub-id-type="pmid">38932995</pub-id><pub-id pub-id-type="pmcid">PMC11196214</pub-id></element-citation><mixed-citation id="mc-CR49" publication-type="journal">Trucco F, Ridout D, Weststrate H, Scoto M, Rohwer A, Coratti G, Main ML, Mayhew AG, Montes J, De Sanctis R, Pane M, Pera MC, Sansone VA, Albamonte E, D&#8217;Amico A, Bruno C, Messina SS, Childs AM, Willis T, Ong MT, Servais L, Majumdar A, Hughes I, Marini-Bettolo C, Parasuraman D, Gowda VL, Baranello G, Bertini ES, De Vivo DC, Darras BT, Day JW, Mayer O, Zolkipli-Cunningham Z, Finkel RS, Mercuri E, Muntoni F, For iSMAc (2024) Therapeutic role of nusinersen on respiratory progression in pediatric patients with spinal muscular atrophy type 2 and nonambulant type 3. Neurol Clin Pract 14:e200298. 10.1212/CPJ.0000000000200298<pub-id pub-id-type="pmid">38932995</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/CPJ.0000000000200298</pub-id><pub-id pub-id-type="pmcid">PMC11196214</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chacko</surname><given-names>A</given-names></name><name name-style="western"><surname>Sly</surname><given-names>PD</given-names></name><name name-style="western"><surname>Ware</surname><given-names>RS</given-names></name><name name-style="western"><surname>Dyer</surname><given-names>B</given-names></name><name name-style="western"><surname>Deegan</surname><given-names>S</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>N</given-names></name><name name-style="western"><surname>Gauld</surname><given-names>LM</given-names></name></person-group><article-title>Differential respiratory function response in paediatric spinal muscular atrophy types 2 and 3 treated with nusinersen over 3 years</article-title><source>Sleep Med</source><year>2025</year><volume>129</volume><fpage>354</fpage><lpage>362</lpage><pub-id pub-id-type="doi">10.1016/j.sleep.2025.02.034</pub-id><pub-id pub-id-type="pmid">40107088</pub-id></element-citation><mixed-citation id="mc-CR50" publication-type="journal">Chacko A, Sly PD, Ware RS, Dyer B, Deegan S, Thomas N, Gauld LM (2025) Differential respiratory function response in paediatric spinal muscular atrophy types 2 and 3 treated with nusinersen over 3 years. Sleep Med 129:354&#8211;362. 10.1016/j.sleep.2025.02.034<pub-id pub-id-type="pmid">40107088</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.sleep.2025.02.034</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Salmin</surname><given-names>F</given-names></name><name name-style="western"><surname>Albamonte</surname><given-names>E</given-names></name><name name-style="western"><surname>Morettini</surname><given-names>V</given-names></name><name name-style="western"><surname>Gagliano</surname><given-names>N</given-names></name><name name-style="western"><surname>Mercuri</surname><given-names>E</given-names></name><name name-style="western"><surname>Sansone</surname><given-names>VA</given-names></name></person-group><article-title>Resolution of skin necrosis after nusinersen treatment in an infant with spinal muscular atrophy</article-title><source>Muscle Nerve</source><year>2019</year><volume>59</volume><fpage>E42</fpage><lpage>E44</lpage><pub-id pub-id-type="doi">10.1002/mus.26457</pub-id><pub-id pub-id-type="pmid">30811610</pub-id></element-citation><mixed-citation id="mc-CR51" publication-type="journal">Salmin F, Albamonte E, Morettini V, Gagliano N, Mercuri E, Sansone VA (2019) Resolution of skin necrosis after nusinersen treatment in an infant with spinal muscular atrophy. Muscle Nerve 59:E42&#8211;E44. 10.1002/mus.26457<pub-id pub-id-type="pmid">30811610</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mus.26457</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xing</surname><given-names>X</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X</given-names></name><name name-style="western"><surname>Li</surname><given-names>X</given-names></name><name name-style="western"><surname>Li</surname><given-names>M</given-names></name><name name-style="western"><surname>Wu</surname><given-names>X</given-names></name><name name-style="western"><surname>Huang</surname><given-names>X</given-names></name><name name-style="western"><surname>Xu</surname><given-names>A</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name></person-group><article-title>Insights into spinal muscular atrophy from molecular biomarkers</article-title><source>Neural Regen Res</source><year>2025</year><volume>20</volume><fpage>1849</fpage><lpage>1863</lpage><pub-id pub-id-type="doi">10.4103/NRR.NRR-D-24-00067</pub-id><pub-id pub-id-type="pmid">38934395</pub-id><pub-id pub-id-type="pmcid">PMC11691461</pub-id></element-citation><mixed-citation id="mc-CR52" publication-type="journal">Xing X, Liu X, Li X, Li M, Wu X, Huang X, Xu A, Liu Y, Zhang J (2025) Insights into spinal muscular atrophy from molecular biomarkers. Neural Regen Res 20:1849&#8211;1863. 10.4103/NRR.NRR-D-24-00067<pub-id pub-id-type="pmid">38934395</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4103/NRR.NRR-D-24-00067</pub-id><pub-id pub-id-type="pmcid">PMC11691461</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR53"><label>53.</label><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pino</surname><given-names>MG</given-names></name><name name-style="western"><surname>Rich</surname><given-names>KA</given-names></name><name name-style="western"><surname>Kolb</surname><given-names>SJ</given-names></name></person-group><article-title>Update on biomarkers in spinal muscular atrophy</article-title><source>Biomark Insights</source><year>2021</year><volume>16</volume><fpage>11772719211035643</fpage><pub-id pub-id-type="doi">10.1177/11772719211035643</pub-id><pub-id pub-id-type="pmid">34421296</pub-id><pub-id pub-id-type="pmcid">PMC8371741</pub-id></element-citation><mixed-citation id="mc-CR53" publication-type="journal">Pino MG, Rich KA, Kolb SJ (2021) Update on biomarkers in spinal muscular atrophy. Biomark Insights 16:11772719211035644. 10.1177/11772719211035643<pub-id pub-id-type="pmid">34421296</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/11772719211035643</pub-id><pub-id pub-id-type="pmcid">PMC8371741</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR54"><label>54.</label><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Glascock</surname><given-names>J</given-names></name><name name-style="western"><surname>Darras</surname><given-names>BT</given-names></name><name name-style="western"><surname>Crawford</surname><given-names>TO</given-names></name><name name-style="western"><surname>Sumner</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Kolb</surname><given-names>SJ</given-names></name><name name-style="western"><surname>DiDonato</surname><given-names>C</given-names></name><name name-style="western"><surname>Elsheikh</surname><given-names>B</given-names></name><name name-style="western"><surname>Howell</surname><given-names>K</given-names></name><name name-style="western"><surname>Farwell</surname><given-names>W</given-names></name><name name-style="western"><surname>Valente</surname><given-names>M</given-names></name><name name-style="western"><surname>Petrillo</surname><given-names>M</given-names></name><name name-style="western"><surname>Tingey</surname><given-names>J</given-names></name><name name-style="western"><surname>Jarecki</surname><given-names>J</given-names></name></person-group><article-title>Identifying biomarkers of spinal muscular atrophy for further development</article-title><source>J Neuromuscul Dis</source><year>2023</year><volume>10</volume><fpage>937</fpage><lpage>954</lpage><pub-id pub-id-type="doi">10.3233/JND-230054</pub-id><pub-id pub-id-type="pmid">37458045</pub-id><pub-id pub-id-type="pmcid">PMC10578234</pub-id></element-citation><mixed-citation id="mc-CR54" publication-type="journal">Glascock J, Darras BT, Crawford TO, Sumner CJ, Kolb SJ, DiDonato C, Elsheikh B, Howell K, Farwell W, Valente M, Petrillo M, Tingey J, Jarecki J (2023) Identifying biomarkers of spinal muscular atrophy for further development. J Neuromuscul Dis 10:937&#8211;954. 10.3233/JND-230054<pub-id pub-id-type="pmid">37458045</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JND-230054</pub-id><pub-id pub-id-type="pmcid">PMC10578234</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR55"><label>55.</label><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vill</surname><given-names>K</given-names></name><name name-style="western"><surname>K&#246;lbel</surname><given-names>H</given-names></name><name name-style="western"><surname>Schwartz</surname><given-names>O</given-names></name><name name-style="western"><surname>Blaschek</surname><given-names>A</given-names></name><name name-style="western"><surname>Olgem&#246;ller</surname><given-names>B</given-names></name><name name-style="western"><surname>Harms</surname><given-names>E</given-names></name><name name-style="western"><surname>Burggraf</surname><given-names>S</given-names></name><name name-style="western"><surname>R&#246;schinger</surname><given-names>W</given-names></name><name name-style="western"><surname>Durner</surname><given-names>J</given-names></name><name name-style="western"><surname>Gl&#228;ser</surname><given-names>D</given-names></name><name name-style="western"><surname>Nennstiel</surname><given-names>U</given-names></name><name name-style="western"><surname>Wirth</surname><given-names>B</given-names></name><name name-style="western"><surname>Schara</surname><given-names>U</given-names></name><name name-style="western"><surname>Jensen</surname><given-names>B</given-names></name><name name-style="western"><surname>Becker</surname><given-names>M</given-names></name><name name-style="western"><surname>Hohenfellner</surname><given-names>K</given-names></name><name name-style="western"><surname>M&#252;ller-Felber</surname><given-names>W</given-names></name></person-group><article-title>One year of newborn screening for SMA - results of a German pilot project</article-title><source>J Neuromuscul Dis</source><year>2019</year><volume>6</volume><fpage>503</fpage><lpage>515</lpage><pub-id pub-id-type="doi">10.3233/JND-190428</pub-id><pub-id pub-id-type="pmid">31594245</pub-id><pub-id pub-id-type="pmcid">PMC6918901</pub-id></element-citation><mixed-citation id="mc-CR55" publication-type="journal">Vill K, K&#246;lbel H, Schwartz O, Blaschek A, Olgem&#246;ller B, Harms E, Burggraf S, R&#246;schinger W, Durner J, Gl&#228;ser D, Nennstiel U, Wirth B, Schara U, Jensen B, Becker M, Hohenfellner K, M&#252;ller-Felber W (2019) One year of newborn screening for SMA - results of a German pilot project. J Neuromuscul Dis 6:503&#8211;515. 10.3233/JND-190428<pub-id pub-id-type="pmid">31594245</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JND-190428</pub-id><pub-id pub-id-type="pmcid">PMC6918901</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR56"><label>56.</label><citation-alternatives><element-citation id="ec-CR56" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>X</given-names></name><name name-style="western"><surname>Sanchis-Juan</surname><given-names>A</given-names></name><name name-style="western"><surname>French</surname><given-names>CE</given-names></name><name name-style="western"><surname>Connell</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Delon</surname><given-names>I</given-names></name><name name-style="western"><surname>Kingsbury</surname><given-names>Z</given-names></name><name name-style="western"><surname>Chawla</surname><given-names>A</given-names></name><name name-style="western"><surname>Halpern</surname><given-names>AL</given-names></name><name name-style="western"><surname>Taft</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Bentley</surname><given-names>DR</given-names></name><name name-style="western"><surname>Butchbach</surname><given-names>MER</given-names></name><name name-style="western"><surname>Raymond</surname><given-names>FL</given-names></name><name name-style="western"><surname>Eberle</surname><given-names>MA</given-names></name></person-group><article-title>Spinal muscular atrophy diagnosis and carrier screening from genome sequencing data</article-title><source>Genet Med</source><year>2020</year><volume>22</volume><fpage>945</fpage><lpage>953</lpage><pub-id pub-id-type="doi">10.1038/s41436-020-0754-0</pub-id><pub-id pub-id-type="pmid">32066871</pub-id><pub-id pub-id-type="pmcid">PMC7200598</pub-id></element-citation><mixed-citation id="mc-CR56" publication-type="journal">Chen X, Sanchis-Juan A, French CE, Connell AJ, Delon I, Kingsbury Z, Chawla A, Halpern AL, Taft RJ, Bentley DR, Butchbach MER, Raymond FL, Eberle MA (2020) Spinal muscular atrophy diagnosis and carrier screening from genome sequencing data. Genet Med 22:945&#8211;953. 10.1038/s41436-020-0754-0<pub-id pub-id-type="pmid">32066871</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41436-020-0754-0</pub-id><pub-id pub-id-type="pmcid">PMC7200598</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR57"><label>57.</label><citation-alternatives><element-citation id="ec-CR57" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Berzal-Serrano</surname><given-names>A</given-names></name><name name-style="western"><surname>Garc&#237;a-Boh&#243;rquez</surname><given-names>B</given-names></name><name name-style="western"><surname>Aller</surname><given-names>E</given-names></name><name name-style="western"><surname>Jaijo</surname><given-names>T</given-names></name><name name-style="western"><surname>Pitarch-Castellano</surname><given-names>I</given-names></name><name name-style="western"><surname>Rausell</surname><given-names>D</given-names></name><name name-style="western"><surname>Garc&#237;a-Garc&#237;a</surname><given-names>G</given-names></name><name name-style="western"><surname>Mill&#225;n</surname><given-names>JM</given-names></name></person-group><article-title>Outcomes of a pilot newborn screening program for spinal muscular atrophy in the valencian community</article-title><source>Int J Neonatal Screen</source><year>2025</year><volume>11</volume><fpage>7</fpage><pub-id pub-id-type="doi">10.3390/ijns11010007</pub-id><pub-id pub-id-type="pmid">39846593</pub-id><pub-id pub-id-type="pmcid">PMC11755645</pub-id></element-citation><mixed-citation id="mc-CR57" publication-type="journal">Berzal-Serrano A, Garc&#237;a-Boh&#243;rquez B, Aller E, Jaijo T, Pitarch-Castellano I, Rausell D, Garc&#237;a-Garc&#237;a G, Mill&#225;n JM (2025) Outcomes of a pilot newborn screening program for spinal muscular atrophy in the valencian community. Int J Neonatal Screen 11:7. 10.3390/ijns11010007<pub-id pub-id-type="pmid">39846593</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijns11010007</pub-id><pub-id pub-id-type="pmcid">PMC11755645</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR58"><label>58.</label><citation-alternatives><element-citation id="ec-CR58" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dangouloff</surname><given-names>T</given-names></name><name name-style="western"><surname>Servais</surname><given-names>L</given-names></name></person-group><article-title>Clinical evidence supporting early treatment of patients with spinal muscular atrophy: current perspectives</article-title><source>Ther Clin Risk Manag</source><year>2019</year><volume>15</volume><fpage>1153</fpage><lpage>1161</lpage><pub-id pub-id-type="doi">10.2147/TCRM.S172291</pub-id><pub-id pub-id-type="pmid">31632042</pub-id><pub-id pub-id-type="pmcid">PMC6778729</pub-id></element-citation><mixed-citation id="mc-CR58" publication-type="journal">Dangouloff T, Servais L (2019) Clinical evidence supporting early treatment of patients with spinal muscular atrophy: current perspectives. Ther Clin Risk Manag 15:1153&#8211;1161. 10.2147/TCRM.S172291<pub-id pub-id-type="pmid">31632042</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/TCRM.S172291</pub-id><pub-id pub-id-type="pmcid">PMC6778729</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR59"><label>59.</label><citation-alternatives><element-citation id="ec-CR59" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prior</surname><given-names>TW</given-names></name><name name-style="western"><surname>Krainer</surname><given-names>AR</given-names></name><name name-style="western"><surname>Hua</surname><given-names>Y</given-names></name><name name-style="western"><surname>Swoboda</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Snyder</surname><given-names>PC</given-names></name><name name-style="western"><surname>Bridgeman</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Burghes</surname><given-names>AHM</given-names></name><name name-style="western"><surname>Kissel</surname><given-names>JT</given-names></name></person-group><article-title>A positive modifier of spinal muscular atrophy in the SMN2 gene</article-title><source>Am J Hum Genet</source><year>2009</year><volume>85</volume><fpage>408</fpage><lpage>413</lpage><pub-id pub-id-type="doi">10.1016/j.ajhg.2009.08.002</pub-id><pub-id pub-id-type="pmid">19716110</pub-id><pub-id pub-id-type="pmcid">PMC2771537</pub-id></element-citation><mixed-citation id="mc-CR59" publication-type="journal">Prior TW, Krainer AR, Hua Y, Swoboda KJ, Snyder PC, Bridgeman SJ, Burghes AHM, Kissel JT (2009) A positive modifier of spinal muscular atrophy in the SMN2 gene. Am J Hum Genet 85:408&#8211;413. 10.1016/j.ajhg.2009.08.002<pub-id pub-id-type="pmid">19716110</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ajhg.2009.08.002</pub-id><pub-id pub-id-type="pmcid">PMC2771537</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR60"><label>60.</label><citation-alternatives><element-citation id="ec-CR60" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mailman</surname><given-names>MD</given-names></name><name name-style="western"><surname>Heinz</surname><given-names>JW</given-names></name><name name-style="western"><surname>Papp</surname><given-names>AC</given-names></name><name name-style="western"><surname>Snyder</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Sedra</surname><given-names>MS</given-names></name><name name-style="western"><surname>Wirth</surname><given-names>B</given-names></name><name name-style="western"><surname>Burghes</surname><given-names>AHM</given-names></name><name name-style="western"><surname>Prior</surname><given-names>TW</given-names></name></person-group><article-title>Molecular analysis of spinal muscular atrophy and modification of the phenotype by SMN2</article-title><source>Genet Med</source><year>2002</year><volume>4</volume><fpage>20</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1097/00125817-200201000-00004</pub-id><pub-id pub-id-type="pmid">11839954</pub-id></element-citation><mixed-citation id="mc-CR60" publication-type="journal">Mailman MD, Heinz JW, Papp AC, Snyder PJ, Sedra MS, Wirth B, Burghes AHM, Prior TW (2002) Molecular analysis of spinal muscular atrophy and modification of the phenotype by SMN2. Genet Med 4:20&#8211;26. 10.1097/00125817-200201000-00004<pub-id pub-id-type="pmid">11839954</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00125817-200201000-00004</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR61"><label>61.</label><citation-alternatives><element-citation id="ec-CR61" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Calucho</surname><given-names>M</given-names></name><name name-style="western"><surname>Bernal</surname><given-names>S</given-names></name><name name-style="western"><surname>Al&#237;as</surname><given-names>L</given-names></name><name name-style="western"><surname>March</surname><given-names>F</given-names></name><name name-style="western"><surname>Vencesl&#225;</surname><given-names>A</given-names></name><name name-style="western"><surname>Rodr&#237;guez-&#193;lvarez</surname><given-names>FJ</given-names></name><name name-style="western"><surname>Aller</surname><given-names>E</given-names></name><name name-style="western"><surname>Fern&#225;ndez</surname><given-names>RM</given-names></name><name name-style="western"><surname>Borrego</surname><given-names>S</given-names></name><name name-style="western"><surname>Mill&#225;n</surname><given-names>JM</given-names></name><name name-style="western"><surname>Hern&#225;ndez-Chico</surname><given-names>C</given-names></name><name name-style="western"><surname>Cusc&#243;</surname><given-names>I</given-names></name><name name-style="western"><surname>Fuentes-Prior</surname><given-names>P</given-names></name><name name-style="western"><surname>Tizzano</surname><given-names>EF</given-names></name></person-group><article-title>Correlation between SMA type and SMN2 copy number revisited: an analysis of 625 unrelated Spanish patients and a compilation of 2834 reported cases</article-title><source>Neuromuscul Disord</source><year>2018</year><volume>28</volume><fpage>208</fpage><lpage>215</lpage><pub-id pub-id-type="doi">10.1016/j.nmd.2018.01.003</pub-id><pub-id pub-id-type="pmid">29433793</pub-id></element-citation><mixed-citation id="mc-CR61" publication-type="journal">Calucho M, Bernal S, Al&#237;as L, March F, Vencesl&#225; A, Rodr&#237;guez-&#193;lvarez FJ, Aller E, Fern&#225;ndez RM, Borrego S, Mill&#225;n JM, Hern&#225;ndez-Chico C, Cusc&#243; I, Fuentes-Prior P, Tizzano EF (2018) Correlation between SMA type and SMN2 copy number revisited: an analysis of 625 unrelated Spanish patients and a compilation of 2834 reported cases. Neuromuscul Disord 28:208&#8211;215. 10.1016/j.nmd.2018.01.003<pub-id pub-id-type="pmid">29433793</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.nmd.2018.01.003</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR62"><label>62.</label><citation-alternatives><element-citation id="ec-CR62" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Elsheikh</surname><given-names>B</given-names></name><name name-style="western"><surname>Prior</surname><given-names>T</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><name name-style="western"><surname>Miller</surname><given-names>R</given-names></name><name name-style="western"><surname>Kolb</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Moore</surname><given-names>D</given-names></name><name name-style="western"><surname>Bradley</surname><given-names>W</given-names></name><name name-style="western"><surname>Barohn</surname><given-names>R</given-names></name><name name-style="western"><surname>Bryan</surname><given-names>W</given-names></name><name name-style="western"><surname>Gelinas</surname><given-names>D</given-names></name><name name-style="western"><surname>Iannaccone</surname><given-names>S</given-names></name><name name-style="western"><surname>Leshner</surname><given-names>R</given-names></name><name name-style="western"><surname>Mendell</surname><given-names>JR</given-names></name><name name-style="western"><surname>Mendoza</surname><given-names>M</given-names></name><name name-style="western"><surname>Russman</surname><given-names>B</given-names></name><name name-style="western"><surname>Smith</surname><given-names>S</given-names></name><name name-style="western"><surname>King</surname><given-names>W</given-names></name><name name-style="western"><surname>Kissel</surname><given-names>JT</given-names></name></person-group><article-title>An analysis of disease severity based on SMN2 copy number in adults with spinal muscular atrophy</article-title><source>Muscle Nerve</source><year>2009</year><volume>40</volume><fpage>652</fpage><lpage>656</lpage><pub-id pub-id-type="doi">10.1002/mus.21350</pub-id><pub-id pub-id-type="pmid">19760790</pub-id></element-citation><mixed-citation id="mc-CR62" publication-type="journal">Elsheikh B, Prior T, Zhang X, Miller R, Kolb SJ, Moore D, Bradley W, Barohn R, Bryan W, Gelinas D, Iannaccone S, Leshner R, Mendell JR, Mendoza M, Russman B, Smith S, King W, Kissel JT (2009) An analysis of disease severity based on SMN2 copy number in adults with spinal muscular atrophy. Muscle Nerve 40:652&#8211;656. 10.1002/mus.21350<pub-id pub-id-type="pmid">19760790</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mus.21350</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR63"><label>63.</label><citation-alternatives><element-citation id="ec-CR63" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wirth</surname><given-names>B</given-names></name><name name-style="western"><surname>Karakaya</surname><given-names>M</given-names></name><name name-style="western"><surname>Kye</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Mendoza-Ferreira</surname><given-names>N</given-names></name></person-group><article-title>Twenty-five years of spinal muscular atrophy research: from phenotype to genotype to therapy, and what comes next</article-title><source>Annu Rev Genomics Hum Genet</source><year>2020</year><volume>21</volume><fpage>231</fpage><lpage>261</lpage><pub-id pub-id-type="doi">10.1146/annurev-genom-102319-103602</pub-id><pub-id pub-id-type="pmid">32004094</pub-id></element-citation><mixed-citation id="mc-CR63" publication-type="journal">Wirth B, Karakaya M, Kye MJ, Mendoza-Ferreira N (2020) Twenty-five years of spinal muscular atrophy research: from phenotype to genotype to therapy, and what comes next. Annu Rev Genomics Hum Genet 21:231&#8211;261. 10.1146/annurev-genom-102319-103602<pub-id pub-id-type="pmid">32004094</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1146/annurev-genom-102319-103602</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR64"><label>64.</label><citation-alternatives><element-citation id="ec-CR64" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wirth</surname><given-names>B</given-names></name><name name-style="western"><surname>Brichta</surname><given-names>L</given-names></name><name name-style="western"><surname>Schrank</surname><given-names>B</given-names></name><name name-style="western"><surname>Lochm&#252;ller</surname><given-names>H</given-names></name><name name-style="western"><surname>Blick</surname><given-names>S</given-names></name><name name-style="western"><surname>Baasner</surname><given-names>A</given-names></name><name name-style="western"><surname>Heller</surname><given-names>R</given-names></name></person-group><article-title>Mildly affected patients with spinal muscular atrophy are partially protected by an increased SMN2 copy number</article-title><source>Hum Genet</source><year>2006</year><volume>119</volume><fpage>422</fpage><lpage>428</lpage><pub-id pub-id-type="doi">10.1007/s00439-006-0156-7</pub-id><pub-id pub-id-type="pmid">16508748</pub-id></element-citation><mixed-citation id="mc-CR64" publication-type="journal">Wirth B, Brichta L, Schrank B, Lochm&#252;ller H, Blick S, Baasner A, Heller R (2006) Mildly affected patients with spinal muscular atrophy are partially protected by an increased SMN2 copy number. Hum Genet 119:422&#8211;428. 10.1007/s00439-006-0156-7<pub-id pub-id-type="pmid">16508748</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00439-006-0156-7</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR65"><label>65.</label><citation-alternatives><element-citation id="ec-CR65" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wadman</surname><given-names>RI</given-names></name><name name-style="western"><surname>Stam</surname><given-names>M</given-names></name><name name-style="western"><surname>Gijzen</surname><given-names>M</given-names></name><name name-style="western"><surname>Lemmink</surname><given-names>HH</given-names></name><name name-style="western"><surname>Snoeck</surname><given-names>IN</given-names></name><name name-style="western"><surname>Wijngaarde</surname><given-names>CA</given-names></name><name name-style="western"><surname>Braun</surname><given-names>KPJ</given-names></name><name name-style="western"><surname>Schoenmakers</surname><given-names>MAGC</given-names></name><name name-style="western"><surname>Van Den Berg</surname><given-names>LH</given-names></name><name name-style="western"><surname>Dooijes</surname><given-names>D</given-names></name><name name-style="western"><surname>Van Der Pol</surname><given-names>WL</given-names></name></person-group><article-title>Association of motor milestones, SMN2 copy and outcome in spinal muscular atrophy types 0&#8211;4</article-title><source>J Neurol Neurosurg Psychiatry</source><year>2017</year><volume>88</volume><fpage>365</fpage><lpage>367</lpage><pub-id pub-id-type="doi">10.1136/jnnp-2016-314292</pub-id><pub-id pub-id-type="pmid">28108522</pub-id></element-citation><mixed-citation id="mc-CR65" publication-type="journal">Wadman RI, Stam M, Gijzen M, Lemmink HH, Snoeck IN, Wijngaarde CA, Braun KPJ, Schoenmakers MAGC, Van Den Berg LH, Dooijes D, Van Der Pol WL (2017) Association of motor milestones, SMN2 copy and outcome in spinal muscular atrophy types 0&#8211;4. J Neurol Neurosurg Psychiatry 88:365&#8211;367. 10.1136/jnnp-2016-314292<pub-id pub-id-type="pmid">28108522</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jnnp-2016-314292</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR66"><label>66.</label><citation-alternatives><element-citation id="ec-CR66" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>WJ</given-names></name><name name-style="western"><surname>He</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>QJ</given-names></name><name name-style="western"><surname>Lin</surname><given-names>QF</given-names></name><name name-style="western"><surname>Chen</surname><given-names>YF</given-names></name><name name-style="western"><surname>Lin</surname><given-names>XZ</given-names></name><name name-style="western"><surname>Lin</surname><given-names>MT</given-names></name><name name-style="western"><surname>Murong</surname><given-names>SX</given-names></name><name name-style="western"><surname>Wang</surname><given-names>N</given-names></name></person-group><article-title>Modification of phenotype by SMN2 copy numbers in two Chinese families with SMN1 deletion in two continuous generations</article-title><source>Clin Chim Acta</source><year>2012</year><volume>413</volume><fpage>1855</fpage><lpage>1860</lpage><pub-id pub-id-type="doi">10.1016/j.cca.2012.07.020</pub-id><pub-id pub-id-type="pmid">22884440</pub-id></element-citation><mixed-citation id="mc-CR66" publication-type="journal">Chen WJ, He J, Zhang QJ, Lin QF, Chen YF, Lin XZ, Lin MT, Murong SX, Wang N (2012) Modification of phenotype by SMN2 copy numbers in two Chinese families with SMN1 deletion in two continuous generations. Clin Chim Acta 413:1855&#8211;1860. 10.1016/j.cca.2012.07.020<pub-id pub-id-type="pmid">22884440</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cca.2012.07.020</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR67"><label>67.</label><citation-alternatives><element-citation id="ec-CR67" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dosi</surname><given-names>C</given-names></name><name name-style="western"><surname>Masson</surname><given-names>R</given-names></name></person-group><article-title>The impact of three SMN2 gene copies on clinical characteristics and effect of disease-modifying treatment in patients with spinal muscular atrophy: a systematic literature review</article-title><source>Front Neurol</source><year>2024</year><volume>15</volume><fpage>1308296</fpage><pub-id pub-id-type="doi">10.3389/fneur.2024.1308296</pub-id><pub-id pub-id-type="pmid">38487326</pub-id><pub-id pub-id-type="pmcid">PMC10937544</pub-id></element-citation><mixed-citation id="mc-CR67" publication-type="journal">Dosi C, Masson R (2024) The impact of three SMN2 gene copies on clinical characteristics and effect of disease-modifying treatment in patients with spinal muscular atrophy: a systematic literature review. Front Neurol 15:1308296. 10.3389/fneur.2024.1308296<pub-id pub-id-type="pmid">38487326</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fneur.2024.1308296</pub-id><pub-id pub-id-type="pmcid">PMC10937544</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR68"><label>68.</label><citation-alternatives><element-citation id="ec-CR68" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ricci</surname><given-names>M</given-names></name><name name-style="western"><surname>Cicala</surname><given-names>G</given-names></name><name name-style="western"><surname>Capasso</surname><given-names>A</given-names></name><name name-style="western"><surname>Coratti</surname><given-names>G</given-names></name><name name-style="western"><surname>Fiori</surname><given-names>S</given-names></name><name name-style="western"><surname>Cutrona</surname><given-names>C</given-names></name><name name-style="western"><surname>D'Amico</surname><given-names>A</given-names></name><name name-style="western"><surname>Sansone</surname><given-names>VA</given-names></name><name name-style="western"><surname>Bruno</surname><given-names>C</given-names></name><name name-style="western"><surname>Messina</surname><given-names>S</given-names></name><name name-style="western"><surname>Mongini</surname><given-names>T</given-names></name><name name-style="western"><surname>Coccia</surname><given-names>M</given-names></name><name name-style="western"><surname>Siciliano</surname><given-names>G</given-names></name><name name-style="western"><surname>Pegoraro</surname><given-names>E</given-names></name><name name-style="western"><surname>Masson</surname><given-names>R</given-names></name><name name-style="western"><surname>Filosto</surname><given-names>M</given-names></name><name name-style="western"><surname>Comi</surname><given-names>GP</given-names></name><name name-style="western"><surname>Corti</surname><given-names>S</given-names></name><name name-style="western"><surname>Ronchi</surname><given-names>D</given-names></name><name name-style="western"><surname>Maggi</surname><given-names>L</given-names></name><etal/></person-group><article-title>Clinical phenotype of pediatric and adult patients with spinal muscular atrophy with four SMN2 copies: are they really all stable?</article-title><source>Ann Neurol</source><year>2023</year><volume>94</volume><fpage>1126</fpage><lpage>1135</lpage><pub-id pub-id-type="doi">10.1002/ana.26788</pub-id><pub-id pub-id-type="pmid">37695206</pub-id></element-citation><mixed-citation id="mc-CR68" publication-type="journal">Ricci M, Cicala G, Capasso A, Coratti G, Fiori S, Cutrona C, D&#8217;Amico A, Sansone VA, Bruno C, Messina S, Mongini T, Coccia M, Siciliano G, Pegoraro E, Masson R, Filosto M, Comi GP, Corti S, Ronchi D, Maggi L et al (2023) Clinical phenotype of pediatric and adult patients with spinal muscular atrophy with four SMN2 copies: are they really all stable? Ann Neurol 94:1126&#8211;1135. 10.1002/ana.26788<pub-id pub-id-type="pmid">37695206</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ana.26788</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR69"><label>69.</label><citation-alternatives><element-citation id="ec-CR69" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cusc&#243;</surname><given-names>I</given-names></name><name name-style="western"><surname>Barcel&#243;</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Rojas-Garc&#237;a</surname><given-names>R</given-names></name><name name-style="western"><surname>Illa</surname><given-names>I</given-names></name><name name-style="western"><surname>G&#225;mez</surname><given-names>J</given-names></name><name name-style="western"><surname>Cervera</surname><given-names>C</given-names></name><name name-style="western"><surname>Pou</surname><given-names>A</given-names></name><name name-style="western"><surname>Izquierdo</surname><given-names>G</given-names></name><name name-style="western"><surname>Baiget</surname><given-names>M</given-names></name><name name-style="western"><surname>Tizzano</surname><given-names>EF</given-names></name></person-group><article-title>SMN2 copy number predicts acute or chronic spinal muscular atrophy but does not account for intrafamilial variability in siblings</article-title><source>J Neurol</source><year>2006</year><volume>253</volume><fpage>21</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1007/s00415-005-0912-y</pub-id><pub-id pub-id-type="pmid">15981080</pub-id></element-citation><mixed-citation id="mc-CR69" publication-type="journal">Cusc&#243; I, Barcel&#243; MJ, Rojas-Garc&#237;a R, Illa I, G&#225;mez J, Cervera C, Pou A, Izquierdo G, Baiget M, Tizzano EF (2006) SMN2 copy number predicts acute or chronic spinal muscular atrophy but does not account for intrafamilial variability in siblings. J Neurol 253:21&#8211;25. 10.1007/s00415-005-0912-y<pub-id pub-id-type="pmid">15981080</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00415-005-0912-y</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR70"><label>70.</label><citation-alternatives><element-citation id="ec-CR70" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maretina</surname><given-names>MA</given-names></name><name name-style="western"><surname>Zheleznyakova</surname><given-names>GY</given-names></name><name name-style="western"><surname>Lanko</surname><given-names>KM</given-names></name><name name-style="western"><surname>Egorova</surname><given-names>AA</given-names></name><name name-style="western"><surname>Baranov</surname><given-names>VS</given-names></name><name name-style="western"><surname>Kiselev</surname><given-names>AV</given-names></name></person-group><article-title>Molecular factors involved in spinal muscular atrophy pathways as possible disease-modifying candidates</article-title><source>Curr Genomics</source><year>2018</year><volume>19</volume><fpage>339</fpage><lpage>355</lpage><pub-id pub-id-type="doi">10.2174/1389202919666180101154916</pub-id><pub-id pub-id-type="pmid">30065610</pub-id><pub-id pub-id-type="pmcid">PMC6030859</pub-id></element-citation><mixed-citation id="mc-CR70" publication-type="journal">Maretina MA, Zheleznyakova GY, Lanko KM, Egorova AA, Baranov VS, Kiselev AV (2018) Molecular factors involved in spinal muscular atrophy pathways as possible disease-modifying candidates. Curr Genomics 19:339&#8211;355. 10.2174/1389202919666180101154916<pub-id pub-id-type="pmid">30065610</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/1389202919666180101154916</pub-id><pub-id pub-id-type="pmcid">PMC6030859</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR71"><label>71.</label><citation-alternatives><element-citation id="ec-CR71" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blasco-P&#233;rez</surname><given-names>L</given-names></name><name name-style="western"><surname>Paramonov</surname><given-names>I</given-names></name><name name-style="western"><surname>Leno</surname><given-names>J</given-names></name><name name-style="western"><surname>Bernal</surname><given-names>S</given-names></name><name name-style="western"><surname>Alias</surname><given-names>L</given-names></name><name name-style="western"><surname>Fuentes-Prior</surname><given-names>P</given-names></name><name name-style="western"><surname>Cusc&#243;</surname><given-names>I</given-names></name><name name-style="western"><surname>Tizzano</surname><given-names>EF</given-names></name></person-group><article-title>Beyond copy number: a new, rapid, and versatile method for sequencing the entire SMN2 gene in SMA patients</article-title><source>Hum Mutat</source><year>2021</year><volume>42</volume><fpage>787</fpage><lpage>795</lpage><pub-id pub-id-type="doi">10.1002/humu.24200</pub-id><pub-id pub-id-type="pmid">33739559</pub-id><pub-id pub-id-type="pmcid">PMC8252042</pub-id></element-citation><mixed-citation id="mc-CR71" publication-type="journal">Blasco-P&#233;rez L, Paramonov I, Leno J, Bernal S, Alias L, Fuentes-Prior P, Cusc&#243; I, Tizzano EF (2021) Beyond copy number: a new, rapid, and versatile method for sequencing the entire SMN2 gene in SMA patients. Hum Mutat 42:787&#8211;795. 10.1002/humu.24200<pub-id pub-id-type="pmid">33739559</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/humu.24200</pub-id><pub-id pub-id-type="pmcid">PMC8252042</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR72"><label>72.</label><citation-alternatives><element-citation id="ec-CR72" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ruhno</surname><given-names>C</given-names></name><name name-style="western"><surname>McGovern</surname><given-names>VL</given-names></name><name name-style="western"><surname>Avenarius</surname><given-names>MR</given-names></name><name name-style="western"><surname>Snyder</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Prior</surname><given-names>TW</given-names></name><name name-style="western"><surname>Nery</surname><given-names>FC</given-names></name><name name-style="western"><surname>Muhtaseb</surname><given-names>A</given-names></name><name name-style="western"><surname>Roggenbuck</surname><given-names>JS</given-names></name><name name-style="western"><surname>Kissel</surname><given-names>JT</given-names></name><name name-style="western"><surname>Sansone</surname><given-names>VA</given-names></name><name name-style="western"><surname>Siranosian</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Johnstone</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Nwe</surname><given-names>PH</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>RZ</given-names></name><name name-style="western"><surname>Swoboda</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Burghes</surname><given-names>AHM</given-names></name></person-group><article-title>Complete sequencing of the <italic toggle="yes">SMN2</italic> gene in SMA patients detects SMN gene deletion junctions and variants in <italic toggle="yes">SMN2</italic> that modify the SMA phenotype</article-title><source>Hum Genet</source><year>2019</year><volume>138</volume><fpage>241</fpage><lpage>256</lpage><pub-id pub-id-type="doi">10.1007/s00439-019-01983-0</pub-id><pub-id pub-id-type="pmid">30788592</pub-id><pub-id pub-id-type="pmcid">PMC6503527</pub-id></element-citation><mixed-citation id="mc-CR72" publication-type="journal">Ruhno C, McGovern VL, Avenarius MR, Snyder PJ, Prior TW, Nery FC, Muhtaseb A, Roggenbuck JS, Kissel JT, Sansone VA, Siranosian JJ, Johnstone AJ, Nwe PH, Zhang RZ, Swoboda KJ, Burghes AHM (2019) Complete sequencing of the <italic toggle="yes">SMN2</italic> gene in SMA patients detects SMN gene deletion junctions and variants in <italic toggle="yes">SMN2</italic> that modify the SMA phenotype. Hum Genet 138:241&#8211;256. 10.1007/s00439-019-01983-0<pub-id pub-id-type="pmid">30788592</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00439-019-01983-0</pub-id><pub-id pub-id-type="pmcid">PMC6503527</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR73"><label>73.</label><citation-alternatives><element-citation id="ec-CR73" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oprea</surname><given-names>GE</given-names></name><name name-style="western"><surname>Kr&#246;ber</surname><given-names>S</given-names></name><name name-style="western"><surname>McWhorter</surname><given-names>ML</given-names></name><name name-style="western"><surname>Rossoll</surname><given-names>W</given-names></name><name name-style="western"><surname>M&#252;ller</surname><given-names>S</given-names></name><name name-style="western"><surname>Krawczak</surname><given-names>M</given-names></name><name name-style="western"><surname>Bassell</surname><given-names>GJ</given-names></name><name name-style="western"><surname>Beattie</surname><given-names>CE</given-names></name><name name-style="western"><surname>Wirth</surname><given-names>B</given-names></name></person-group><article-title>Plastin 3 is a protective modifier of autosomal recessive spinal muscular atrophy</article-title><source>Science</source><year>2008</year><volume>320</volume><fpage>524</fpage><lpage>527</lpage><pub-id pub-id-type="doi">10.1126/science.1155085</pub-id><pub-id pub-id-type="pmid">18440926</pub-id><pub-id pub-id-type="pmcid">PMC4908855</pub-id></element-citation><mixed-citation id="mc-CR73" publication-type="journal">Oprea GE, Kr&#246;ber S, McWhorter ML, Rossoll W, M&#252;ller S, Krawczak M, Bassell GJ, Beattie CE, Wirth B (2008) Plastin 3 is a protective modifier of autosomal recessive spinal muscular atrophy. Science 320:524&#8211;527. 10.1126/science.1155085<pub-id pub-id-type="pmid">18440926</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.1155085</pub-id><pub-id pub-id-type="pmcid">PMC4908855</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR74"><label>74.</label><citation-alternatives><element-citation id="ec-CR74" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bernal</surname><given-names>S</given-names></name><name name-style="western"><surname>Also-Rallo</surname><given-names>E</given-names></name><name name-style="western"><surname>Mart&#237;nez-Hern&#225;ndez</surname><given-names>R</given-names></name><name name-style="western"><surname>Al&#237;as</surname><given-names>L</given-names></name><name name-style="western"><surname>Rodr&#237;guez-Alvarez</surname><given-names>FJ</given-names></name><name name-style="western"><surname>Mill&#225;n</surname><given-names>JM</given-names></name><name name-style="western"><surname>Hern&#225;ndez-Chico</surname><given-names>C</given-names></name><name name-style="western"><surname>Baiget</surname><given-names>M</given-names></name><name name-style="western"><surname>Tizzano</surname><given-names>EF</given-names></name></person-group><article-title>Plastin 3 expression in discordant spinal muscular atrophy (SMA) siblings</article-title><source>Neuromuscul Disord</source><year>2011</year><volume>21</volume><fpage>413</fpage><lpage>419</lpage><pub-id pub-id-type="doi">10.1016/j.nmd.2011.03.009</pub-id><pub-id pub-id-type="pmid">21546251</pub-id></element-citation><mixed-citation id="mc-CR74" publication-type="journal">Bernal S, Also-Rallo E, Mart&#237;nez-Hern&#225;ndez R, Al&#237;as L, Rodr&#237;guez-Alvarez FJ, Mill&#225;n JM, Hern&#225;ndez-Chico C, Baiget M, Tizzano EF (2011) Plastin 3 expression in discordant spinal muscular atrophy (SMA) siblings. Neuromuscul Disord 21:413&#8211;419. 10.1016/j.nmd.2011.03.009<pub-id pub-id-type="pmid">21546251</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.nmd.2011.03.009</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR75"><label>75.</label><citation-alternatives><element-citation id="ec-CR75" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Riessland</surname><given-names>M</given-names></name><name name-style="western"><surname>Kaczmarek</surname><given-names>A</given-names></name><name name-style="western"><surname>Schneider</surname><given-names>S</given-names></name><name name-style="western"><surname>Swoboda</surname><given-names>KJ</given-names></name><name name-style="western"><surname>L&#246;hr</surname><given-names>H</given-names></name><name name-style="western"><surname>Bradler</surname><given-names>C</given-names></name><name name-style="western"><surname>Grysko</surname><given-names>V</given-names></name><name name-style="western"><surname>Dimitriadi</surname><given-names>M</given-names></name><name name-style="western"><surname>Hosseinibarkooie</surname><given-names>S</given-names></name><name name-style="western"><surname>Torres-Benito</surname><given-names>L</given-names></name><name name-style="western"><surname>Peters</surname><given-names>M</given-names></name><name name-style="western"><surname>Upadhyay</surname><given-names>A</given-names></name><name name-style="western"><surname>Biglari</surname><given-names>N</given-names></name><name name-style="western"><surname>Kr&#246;ber</surname><given-names>S</given-names></name><name name-style="western"><surname>H&#246;lker</surname><given-names>I</given-names></name><name name-style="western"><surname>Garbes</surname><given-names>L</given-names></name><name name-style="western"><surname>Gilissen</surname><given-names>C</given-names></name><name name-style="western"><surname>Hoischen</surname><given-names>A</given-names></name><name name-style="western"><surname>N&#252;rnberg</surname><given-names>G</given-names></name><name name-style="western"><surname>N&#252;rnberg</surname><given-names>P</given-names></name><name name-style="western"><surname>Walter</surname><given-names>M</given-names></name><name name-style="western"><surname>Rigo</surname><given-names>F</given-names></name><name name-style="western"><surname>Bennett</surname><given-names>CF</given-names></name><name name-style="western"><surname>Kye</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Hart</surname><given-names>AC</given-names></name><name name-style="western"><surname>Hammerschmidt</surname><given-names>M</given-names></name><name name-style="western"><surname>Kloppenburg</surname><given-names>P</given-names></name><name name-style="western"><surname>Wirth</surname><given-names>B</given-names></name></person-group><article-title>Neurocalcin delta suppression protects against spinal muscular atrophy in humans and across species by restoring impaired endocytosis</article-title><source>Am J Hum Genet</source><year>2017</year><volume>100</volume><fpage>297</fpage><lpage>315</lpage><pub-id pub-id-type="doi">10.1016/j.ajhg.2017.01.005</pub-id><pub-id pub-id-type="pmid">28132687</pub-id><pub-id pub-id-type="pmcid">PMC5294679</pub-id></element-citation><mixed-citation id="mc-CR75" publication-type="journal">Riessland M, Kaczmarek A, Schneider S, Swoboda KJ, L&#246;hr H, Bradler C, Grysko V, Dimitriadi M, Hosseinibarkooie S, Torres-Benito L, Peters M, Upadhyay A, Biglari N, Kr&#246;ber S, H&#246;lker I, Garbes L, Gilissen C, Hoischen A, N&#252;rnberg G, N&#252;rnberg P, Walter M, Rigo F, Bennett CF, Kye MJ, Hart AC, Hammerschmidt M, Kloppenburg P, Wirth B (2017) Neurocalcin delta suppression protects against spinal muscular atrophy in humans and across species by restoring impaired endocytosis. Am J Hum Genet 100:297&#8211;315. 10.1016/j.ajhg.2017.01.005<pub-id pub-id-type="pmid">28132687</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ajhg.2017.01.005</pub-id><pub-id pub-id-type="pmcid">PMC5294679</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR76"><label>76.</label><citation-alternatives><element-citation id="ec-CR76" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Swoboda</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Prior</surname><given-names>TW</given-names></name><name name-style="western"><surname>Scott</surname><given-names>CB</given-names></name><name name-style="western"><surname>McNaught</surname><given-names>TP</given-names></name><name name-style="western"><surname>Wride</surname><given-names>MC</given-names></name><name name-style="western"><surname>Reyna</surname><given-names>SP</given-names></name><name name-style="western"><surname>Bromberg</surname><given-names>MB</given-names></name></person-group><article-title>Natural history of denervation in SMA: relation to age, SMN2 copy number, and function</article-title><source>Ann Neurol</source><year>2005</year><volume>57</volume><fpage>704</fpage><lpage>712</lpage><pub-id pub-id-type="doi">10.1002/ana.20473</pub-id><pub-id pub-id-type="pmid">15852397</pub-id><pub-id pub-id-type="pmcid">PMC4334582</pub-id></element-citation><mixed-citation id="mc-CR76" publication-type="journal">Swoboda KJ, Prior TW, Scott CB, McNaught TP, Wride MC, Reyna SP, Bromberg MB (2005) Natural history of denervation in SMA: relation to age, SMN2 copy number, and function. Ann Neurol 57:704&#8211;712. 10.1002/ana.20473<pub-id pub-id-type="pmid">15852397</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ana.20473</pub-id><pub-id pub-id-type="pmcid">PMC4334582</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR77"><label>77.</label><citation-alternatives><element-citation id="ec-CR77" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lewelt</surname><given-names>A</given-names></name><name name-style="western"><surname>Krosschell</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Scott</surname><given-names>C</given-names></name><name name-style="western"><surname>Sakonju</surname><given-names>A</given-names></name><name name-style="western"><surname>Kissel</surname><given-names>JT</given-names></name><name name-style="western"><surname>Crawford</surname><given-names>TO</given-names></name><name name-style="western"><surname>Acsadi</surname><given-names>G</given-names></name><name name-style="western"><surname>D'Anjou</surname><given-names>G</given-names></name><name name-style="western"><surname>Elsheikh</surname><given-names>B</given-names></name><name name-style="western"><surname>Reyna</surname><given-names>SP</given-names></name><name name-style="western"><surname>Schroth</surname><given-names>MK</given-names></name><name name-style="western"><surname>Maczulski</surname><given-names>JA</given-names></name><name name-style="western"><surname>Stoddard</surname><given-names>GJ</given-names></name><name name-style="western"><surname>Elovic</surname><given-names>E</given-names></name><name name-style="western"><surname>Swoboda</surname><given-names>KJ</given-names></name></person-group><article-title>Compound muscle action potential and motor function in children with spinal muscular atrophy</article-title><source>Muscle Nerve</source><year>2010</year><volume>42</volume><fpage>703</fpage><lpage>708</lpage><pub-id pub-id-type="doi">10.1002/mus.21838</pub-id><pub-id pub-id-type="pmid">20737553</pub-id><pub-id pub-id-type="pmcid">PMC2964439</pub-id></element-citation><mixed-citation id="mc-CR77" publication-type="journal">Lewelt A, Krosschell KJ, Scott C, Sakonju A, Kissel JT, Crawford TO, Acsadi G, D&#8217;Anjou G, Elsheikh B, Reyna SP, Schroth MK, Maczulski JA, Stoddard GJ, Elovic E, Swoboda KJ (2010) Compound muscle action potential and motor function in children with spinal muscular atrophy. Muscle Nerve 42:703&#8211;708. 10.1002/mus.21838<pub-id pub-id-type="pmid">20737553</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mus.21838</pub-id><pub-id pub-id-type="pmcid">PMC2964439</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR78"><label>78.</label><citation-alternatives><element-citation id="ec-CR78" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kolb</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Coffey</surname><given-names>CS</given-names></name><name name-style="western"><surname>Yankey</surname><given-names>JW</given-names></name><name name-style="western"><surname>Krosschell</surname><given-names>K</given-names></name><name name-style="western"><surname>Arnold</surname><given-names>WD</given-names></name><name name-style="western"><surname>Rutkove</surname><given-names>SB</given-names></name><name name-style="western"><surname>Swoboda</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Reyna</surname><given-names>SP</given-names></name><name name-style="western"><surname>Sakonju</surname><given-names>A</given-names></name><name name-style="western"><surname>Darras</surname><given-names>BT</given-names></name><name name-style="western"><surname>Shell</surname><given-names>R</given-names></name><name name-style="western"><surname>Kuntz</surname><given-names>N</given-names></name><name name-style="western"><surname>Castro</surname><given-names>D</given-names></name><name name-style="western"><surname>Parsons</surname><given-names>J</given-names></name><name name-style="western"><surname>Connolly</surname><given-names>AM</given-names></name><name name-style="western"><surname>Chiriboga</surname><given-names>CA</given-names></name><name name-style="western"><surname>McDonald</surname><given-names>C</given-names></name><name name-style="western"><surname>Burnette</surname><given-names>WB</given-names></name><name name-style="western"><surname>Werner</surname><given-names>K</given-names></name><name name-style="western"><surname>Thangarajh</surname><given-names>M</given-names></name><name name-style="western"><surname>Shieh</surname><given-names>PB</given-names></name><name name-style="western"><surname>Finanger</surname><given-names>E</given-names></name><name name-style="western"><surname>Cudkowicz</surname><given-names>ME</given-names></name><name name-style="western"><surname>McGovern</surname><given-names>MM</given-names></name><name name-style="western"><surname>McNeil</surname><given-names>DE</given-names></name><name name-style="western"><surname>Finkel</surname><given-names>R</given-names></name><name name-style="western"><surname>Iannaccone</surname><given-names>ST</given-names></name><name name-style="western"><surname>Kaye</surname><given-names>E</given-names></name><name name-style="western"><surname>Kingsley</surname><given-names>A</given-names></name><name name-style="western"><surname>Renusch</surname><given-names>SR</given-names></name><name name-style="western"><surname>McGovern</surname><given-names>VL</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>Zaworski</surname><given-names>PG</given-names></name><name name-style="western"><surname>Prior</surname><given-names>TW</given-names></name><name name-style="western"><surname>Burghes</surname><given-names>AHM</given-names></name><name name-style="western"><surname>Bartlett</surname><given-names>A</given-names></name><name name-style="western"><surname>Kissel</surname><given-names>JT</given-names></name><collab>NeuroNEXT Clinical Trial Network on behalf of the NN101 SMA Biomarker Investigators</collab></person-group><article-title>Natural history of infantile-onset spinal muscular atrophy</article-title><source>Ann Neurol</source><year>2017</year><volume>82</volume><fpage>883</fpage><lpage>891</lpage><pub-id pub-id-type="doi">10.1002/ana.25101</pub-id><pub-id pub-id-type="pmid">29149772</pub-id><pub-id pub-id-type="pmcid">PMC5776712</pub-id></element-citation><mixed-citation id="mc-CR78" publication-type="journal">Kolb SJ, Coffey CS, Yankey JW, Krosschell K, Arnold WD, Rutkove SB, Swoboda KJ, Reyna SP, Sakonju A, Darras BT, Shell R, Kuntz N, Castro D, Parsons J, Connolly AM, Chiriboga CA, McDonald C, Burnette WB, Werner K, Thangarajh M, Shieh PB, Finanger E, Cudkowicz ME, McGovern MM, McNeil DE, Finkel R, Iannaccone ST, Kaye E, Kingsley A, Renusch SR, McGovern VL, Wang X, Zaworski PG, Prior TW, Burghes AHM, Bartlett A, Kissel JT, NeuroNEXT Clinical Trial Network on behalf of the NN101 SMA Biomarker Investigators (2017) Natural history of infantile-onset spinal muscular atrophy. Ann Neurol 82:883&#8211;891. 10.1002/ana.25101<pub-id pub-id-type="pmid">29149772</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ana.25101</pub-id><pub-id pub-id-type="pmcid">PMC5776712</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR79"><label>79.</label><citation-alternatives><element-citation id="ec-CR79" publication-type="journal"><person-group person-group-type="author"><collab>The NeuroNEXT Clinical Trial Network</collab><collab>NN101 SMA Biomarker Investigators</collab><name name-style="western"><surname>Krosschell</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Bosch</surname><given-names>M</given-names></name><name name-style="western"><surname>Nelson</surname><given-names>L</given-names></name><name name-style="western"><surname>Duong</surname><given-names>T</given-names></name><name name-style="western"><surname>Lowes</surname><given-names>LP</given-names></name><name name-style="western"><surname>Alfano</surname><given-names>LN</given-names></name><name name-style="western"><surname>Benjamin</surname><given-names>D</given-names></name><name name-style="western"><surname>Carry</surname><given-names>TB</given-names></name><name name-style="western"><surname>Devine</surname><given-names>G</given-names></name><name name-style="western"><surname>Kelley</surname><given-names>C</given-names></name><name name-style="western"><surname>Gadekan</surname><given-names>R</given-names></name><name name-style="western"><surname>Malkus</surname><given-names>EC</given-names></name><name name-style="western"><surname>Pasternak</surname><given-names>A</given-names></name><name name-style="western"><surname>Provance-Orr</surname><given-names>S</given-names></name><name name-style="western"><surname>Roemeiser-Logan</surname><given-names>L</given-names></name><name name-style="western"><surname>Nicorici</surname><given-names>A</given-names></name><name name-style="western"><surname>Trussell</surname><given-names>D</given-names></name><name name-style="western"><surname>Young</surname><given-names>SD</given-names></name><name name-style="western"><surname>Fetterman</surname><given-names>JR</given-names></name><etal/></person-group><article-title>Motor function test reliability during the NeuroNEXT spinal muscular atrophy infant biomarker study</article-title><source>J Neuromuscul Dis</source><year>2018</year><volume>5</volume><fpage>509</fpage><lpage>521</lpage><pub-id pub-id-type="doi">10.3233/JND-180327</pub-id><pub-id pub-id-type="pmid">30223401</pub-id><pub-id pub-id-type="pmcid">PMC8112280</pub-id></element-citation><mixed-citation id="mc-CR79" publication-type="journal">The NeuroNEXT Clinical Trial Network, NN101 SMA Biomarker Investigators, Krosschell KJ, Bosch M, Nelson L, Duong T, Lowes LP, Alfano LN, Benjamin D, Carry TB, Devine G, Kelley C, Gadekan R, Malkus EC, Pasternak A, Provance-Orr S, Roemeiser-Logan L, Nicorici A, Trussell D, Young SD, Fetterman JR et al (2018) Motor function test reliability during the NeuroNEXT spinal muscular atrophy infant biomarker study. J Neuromuscul Dis 5:509&#8211;521. 10.3233/JND-180327<pub-id pub-id-type="pmid">30223401</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JND-180327</pub-id><pub-id pub-id-type="pmcid">PMC8112280</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR80"><label>80.</label><citation-alternatives><element-citation id="ec-CR80" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kariyawasam</surname><given-names>D</given-names></name><name name-style="western"><surname>Russell</surname><given-names>JS</given-names></name><name name-style="western"><surname>Wiley</surname><given-names>V</given-names></name><name name-style="western"><surname>Alexander</surname><given-names>IE</given-names></name><name name-style="western"><surname>Farrar</surname><given-names>MA</given-names></name></person-group><article-title>The implementation of newborn screening for spinal muscular atrophy: the Australian experience</article-title><source>Genet Med</source><year>2020</year><volume>22</volume><fpage>557</fpage><lpage>565</lpage><pub-id pub-id-type="doi">10.1038/s41436-019-0673-0</pub-id><pub-id pub-id-type="pmid">31607747</pub-id></element-citation><mixed-citation id="mc-CR80" publication-type="journal">Kariyawasam D, Russell JS, Wiley V, Alexander IE, Farrar MA (2020) The implementation of newborn screening for spinal muscular atrophy: the Australian experience. Genet Med 22:557&#8211;565. 10.1038/s41436-019-0673-0<pub-id pub-id-type="pmid">31607747</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41436-019-0673-0</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR81"><label>81.</label><citation-alternatives><element-citation id="ec-CR81" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weng</surname><given-names>WC</given-names></name><name name-style="western"><surname>Hsu</surname><given-names>YK</given-names></name><name name-style="western"><surname>Chang</surname><given-names>FM</given-names></name><name name-style="western"><surname>Lin</surname><given-names>CY</given-names></name><name name-style="western"><surname>Hwu</surname><given-names>WL</given-names></name><name name-style="western"><surname>Lee</surname><given-names>WT</given-names></name><name name-style="western"><surname>Lee</surname><given-names>NC</given-names></name><name name-style="western"><surname>Chien</surname><given-names>YH</given-names></name></person-group><article-title>CMAP changes upon symptom onset and during treatment in spinal muscular atrophy patients: lessons learned from newborn screening</article-title><source>Genet Med</source><year>2021</year><volume>23</volume><fpage>415</fpage><lpage>420</lpage><pub-id pub-id-type="doi">10.1038/s41436-020-00987-w</pub-id><pub-id pub-id-type="pmid">33033402</pub-id></element-citation><mixed-citation id="mc-CR81" publication-type="journal">Weng WC, Hsu YK, Chang FM, Lin CY, Hwu WL, Lee WT, Lee NC, Chien YH (2021) CMAP changes upon symptom onset and during treatment in spinal muscular atrophy patients: lessons learned from newborn screening. Genet Med 23:415&#8211;420. 10.1038/s41436-020-00987-w<pub-id pub-id-type="pmid">33033402</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41436-020-00987-w</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR82"><label>82.</label><citation-alternatives><element-citation id="ec-CR82" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Petzold</surname><given-names>A</given-names></name></person-group><article-title>Neurofilament phosphoforms: surrogate markers for axonal injury, degeneration and loss</article-title><source>J Neurol Sci</source><year>2005</year><volume>233</volume><fpage>183</fpage><lpage>198</lpage><pub-id pub-id-type="doi">10.1016/j.jns.2005.03.015</pub-id><pub-id pub-id-type="pmid">15896809</pub-id></element-citation><mixed-citation id="mc-CR82" publication-type="journal">Petzold A (2005) Neurofilament phosphoforms: surrogate markers for axonal injury, degeneration and loss. J Neurol Sci 233:183&#8211;198. 10.1016/j.jns.2005.03.015<pub-id pub-id-type="pmid">15896809</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jns.2005.03.015</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR83"><label>83.</label><citation-alternatives><element-citation id="ec-CR83" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yuan</surname><given-names>A</given-names></name><name name-style="western"><surname>Rao</surname><given-names>MV</given-names></name><name name-style="western"><surname>Veeranna</surname><given-names>NRA</given-names></name></person-group><article-title>Neurofilaments and neurofilament proteins in health and disease</article-title><source>Cold Spring Harb Perspect Biol</source><year>2017</year><volume>9</volume><fpage>a018309</fpage><pub-id pub-id-type="doi">10.1101/cshperspect.a018309</pub-id><pub-id pub-id-type="pmid">28373358</pub-id><pub-id pub-id-type="pmcid">PMC5378049</pub-id></element-citation><mixed-citation id="mc-CR83" publication-type="journal">Yuan A, Rao MV, Veeranna NRA (2017) Neurofilaments and neurofilament proteins in health and disease. Cold Spring Harb Perspect Biol 9:a018309. 10.1101/cshperspect.a018309<pub-id pub-id-type="pmid">28373358</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1101/cshperspect.a018309</pub-id><pub-id pub-id-type="pmcid">PMC5378049</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR84"><label>84.</label><citation-alternatives><element-citation id="ec-CR84" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gentil</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Tibshirani</surname><given-names>M</given-names></name><name name-style="western"><surname>Durham</surname><given-names>HD</given-names></name></person-group><article-title>Neurofilament dynamics and involvement in neurological disorders</article-title><source>Cell Tissue Res</source><year>2015</year><volume>360</volume><fpage>609</fpage><lpage>620</lpage><pub-id pub-id-type="doi">10.1007/s00441-014-2082-7</pub-id><pub-id pub-id-type="pmid">25567110</pub-id></element-citation><mixed-citation id="mc-CR84" publication-type="journal">Gentil BJ, Tibshirani M, Durham HD (2015) Neurofilament dynamics and involvement in neurological disorders. Cell Tissue Res 360:609&#8211;620. 10.1007/s00441-014-2082-7<pub-id pub-id-type="pmid">25567110</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00441-014-2082-7</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR85"><label>85.</label><citation-alternatives><element-citation id="ec-CR85" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Q</given-names></name><name name-style="western"><surname>Xie</surname><given-names>F</given-names></name><name name-style="western"><surname>Siedlak</surname><given-names>SL</given-names></name><name name-style="western"><surname>Nunomura</surname><given-names>A</given-names></name><name name-style="western"><surname>Honda</surname><given-names>K</given-names></name><name name-style="western"><surname>Moreira</surname><given-names>PI</given-names></name><name name-style="western"><surname>Zhua</surname><given-names>X</given-names></name><name name-style="western"><surname>Smith</surname><given-names>MA</given-names></name><name name-style="western"><surname>Perry</surname><given-names>G</given-names></name></person-group><article-title>Neurofilament proteins in neurodegenerative diseases</article-title><source>Cell Mol Life Sci</source><year>2004</year><volume>61</volume><fpage>3057</fpage><lpage>3075</lpage><pub-id pub-id-type="doi">10.1007/s00018-004-4268-8</pub-id><pub-id pub-id-type="pmid">15583867</pub-id><pub-id pub-id-type="pmcid">PMC11924432</pub-id></element-citation><mixed-citation id="mc-CR85" publication-type="journal">Liu Q, Xie F, Siedlak SL, Nunomura A, Honda K, Moreira PI, Zhua X, Smith MA, Perry G (2004) Neurofilament proteins in neurodegenerative diseases. Cell Mol Life Sci 61:3057&#8211;3075. 10.1007/s00018-004-4268-8<pub-id pub-id-type="pmid">15583867</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00018-004-4268-8</pub-id><pub-id pub-id-type="pmcid">PMC11924432</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR86"><label>86.</label><citation-alternatives><element-citation id="ec-CR86" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Perrot</surname><given-names>R</given-names></name><name name-style="western"><surname>Berges</surname><given-names>R</given-names></name><name name-style="western"><surname>Bocquet</surname><given-names>A</given-names></name><name name-style="western"><surname>Eyer</surname><given-names>J</given-names></name></person-group><article-title>Review of the multiple aspects of neurofilament functions, and their possible contribution to neurodegeneration</article-title><source>Mol Neurobiol</source><year>2008</year><volume>38</volume><fpage>27</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1007/s12035-008-8033-0</pub-id><pub-id pub-id-type="pmid">18649148</pub-id></element-citation><mixed-citation id="mc-CR86" publication-type="journal">Perrot R, Berges R, Bocquet A, Eyer J (2008) Review of the multiple aspects of neurofilament functions, and their possible contribution to neurodegeneration. Mol Neurobiol 38:27&#8211;65. 10.1007/s12035-008-8033-0<pub-id pub-id-type="pmid">18649148</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12035-008-8033-0</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR87"><label>87.</label><citation-alternatives><element-citation id="ec-CR87" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Darras</surname><given-names>BT</given-names></name><name name-style="western"><surname>Crawford</surname><given-names>TO</given-names></name><name name-style="western"><surname>Finkel</surname><given-names>RS</given-names></name><name name-style="western"><surname>Mercuri</surname><given-names>E</given-names></name><name name-style="western"><surname>De Vivo</surname><given-names>DC</given-names></name><name name-style="western"><surname>Oskoui</surname><given-names>M</given-names></name><name name-style="western"><surname>Tizzano</surname><given-names>EF</given-names></name><name name-style="western"><surname>Ryan</surname><given-names>MM</given-names></name><name name-style="western"><surname>Muntoni</surname><given-names>F</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>G</given-names></name><name name-style="western"><surname>Staropoli</surname><given-names>J</given-names></name><name name-style="western"><surname>McCampbell</surname><given-names>A</given-names></name><name name-style="western"><surname>Petrillo</surname><given-names>M</given-names></name><name name-style="western"><surname>Stebbins</surname><given-names>C</given-names></name><name name-style="western"><surname>Fradette</surname><given-names>S</given-names></name><name name-style="western"><surname>Farwell</surname><given-names>W</given-names></name><name name-style="western"><surname>Sumner</surname><given-names>CJ</given-names></name></person-group><article-title>Neurofilament as a potential biomarker for spinal muscular atrophy</article-title><source>Ann Clin Transl Neurol</source><year>2019</year><volume>6</volume><fpage>932</fpage><lpage>944</lpage><pub-id pub-id-type="doi">10.1002/acn3.779</pub-id><pub-id pub-id-type="pmid">31139691</pub-id><pub-id pub-id-type="pmcid">PMC6530526</pub-id></element-citation><mixed-citation id="mc-CR87" publication-type="journal">Darras BT, Crawford TO, Finkel RS, Mercuri E, De Vivo DC, Oskoui M, Tizzano EF, Ryan MM, Muntoni F, Zhao G, Staropoli J, McCampbell A, Petrillo M, Stebbins C, Fradette S, Farwell W, Sumner CJ (2019) Neurofilament as a potential biomarker for spinal muscular atrophy. Ann Clin Transl Neurol 6:932&#8211;944. 10.1002/acn3.779<pub-id pub-id-type="pmid">31139691</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/acn3.779</pub-id><pub-id pub-id-type="pmcid">PMC6530526</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR88"><label>88.</label><citation-alternatives><element-citation id="ec-CR88" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alves</surname><given-names>CRR</given-names></name><name name-style="western"><surname>Petrillo</surname><given-names>M</given-names></name><name name-style="western"><surname>Spellman</surname><given-names>R</given-names></name><name name-style="western"><surname>Garner</surname><given-names>R</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>R</given-names></name><name name-style="western"><surname>Kiefer</surname><given-names>M</given-names></name><name name-style="western"><surname>Simeone</surname><given-names>S</given-names></name><name name-style="western"><surname>Sohn</surname><given-names>J</given-names></name><name name-style="western"><surname>Eichelberger</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Rodrigues</surname><given-names>E</given-names></name><name name-style="western"><surname>Arruda</surname><given-names>EA</given-names></name><name name-style="western"><surname>Townsend</surname><given-names>EL</given-names></name><name name-style="western"><surname>Farwell</surname><given-names>W</given-names></name><name name-style="western"><surname>Swoboda</surname><given-names>KJ</given-names></name></person-group><article-title>Implications of circulating neurofilaments for spinal muscular atrophy treatment early in life: a case series</article-title><source>Mol Ther Methods Clin Dev</source><year>2021</year><volume>23</volume><fpage>524</fpage><lpage>538</lpage><pub-id pub-id-type="doi">10.1016/j.omtm.2021.10.011</pub-id><pub-id pub-id-type="pmid">34853799</pub-id><pub-id pub-id-type="pmcid">PMC8605296</pub-id></element-citation><mixed-citation id="mc-CR88" publication-type="journal">Alves CRR, Petrillo M, Spellman R, Garner R, Zhang R, Kiefer M, Simeone S, Sohn J, Eichelberger EJ, Rodrigues E, Arruda EA, Townsend EL, Farwell W, Swoboda KJ (2021) Implications of circulating neurofilaments for spinal muscular atrophy treatment early in life: a case series. Mol Ther Methods Clin Dev 23:524&#8211;538. 10.1016/j.omtm.2021.10.011<pub-id pub-id-type="pmid">34853799</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.omtm.2021.10.011</pub-id><pub-id pub-id-type="pmcid">PMC8605296</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR89"><label>89.</label><citation-alternatives><element-citation id="ec-CR89" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Vivo</surname><given-names>DC</given-names></name><name name-style="western"><surname>Bertini</surname><given-names>E</given-names></name><name name-style="western"><surname>Swoboda</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Hwu</surname><given-names>WL</given-names></name><name name-style="western"><surname>Crawford</surname><given-names>TO</given-names></name><name name-style="western"><surname>Finkel</surname><given-names>RS</given-names></name><name name-style="western"><surname>Kirschner</surname><given-names>J</given-names></name><name name-style="western"><surname>Kuntz</surname><given-names>NL</given-names></name><name name-style="western"><surname>Parsons</surname><given-names>JA</given-names></name><name name-style="western"><surname>Ryan</surname><given-names>MM</given-names></name><name name-style="western"><surname>Butterfield</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Topaloglu</surname><given-names>H</given-names></name><name name-style="western"><surname>Ben-Omran</surname><given-names>T</given-names></name><name name-style="western"><surname>Sansone</surname><given-names>VA</given-names></name><name name-style="western"><surname>Jong</surname><given-names>YJ</given-names></name><name name-style="western"><surname>Shu</surname><given-names>F</given-names></name><name name-style="western"><surname>Staropoli</surname><given-names>JF</given-names></name><name name-style="western"><surname>Kerr</surname><given-names>D</given-names></name><name name-style="western"><surname>Sandrock</surname><given-names>AW</given-names></name><name name-style="western"><surname>Stebbins</surname><given-names>C</given-names></name><etal/></person-group><article-title>Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: interim efficacy and safety results from the Phase 2 NURTURE study</article-title><source>Neuromuscul Disord</source><year>2019</year><volume>29</volume><fpage>842</fpage><lpage>856</lpage><pub-id pub-id-type="doi">10.1016/j.nmd.2019.09.007</pub-id><pub-id pub-id-type="pmid">31704158</pub-id><pub-id pub-id-type="pmcid">PMC7127286</pub-id></element-citation><mixed-citation id="mc-CR89" publication-type="journal">De Vivo DC, Bertini E, Swoboda KJ, Hwu WL, Crawford TO, Finkel RS, Kirschner J, Kuntz NL, Parsons JA, Ryan MM, Butterfield RJ, Topaloglu H, Ben-Omran T, Sansone VA, Jong YJ, Shu F, Staropoli JF, Kerr D, Sandrock AW, Stebbins C et al (2019) Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: interim efficacy and safety results from the Phase 2 NURTURE study. Neuromuscul Disord 29:842&#8211;856. 10.1016/j.nmd.2019.09.007<pub-id pub-id-type="pmid">31704158</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.nmd.2019.09.007</pub-id><pub-id pub-id-type="pmcid">PMC7127286</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR90"><label>90.</label><citation-alternatives><element-citation id="ec-CR90" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nitz</surname><given-names>E</given-names></name><name name-style="western"><surname>Smitka</surname><given-names>M</given-names></name><name name-style="western"><surname>Schallner</surname><given-names>J</given-names></name><name name-style="western"><surname>Akg&#252;n</surname><given-names>K</given-names></name><name name-style="western"><surname>Ziemssen</surname><given-names>T</given-names></name><name name-style="western"><surname>Von Der Hagen</surname><given-names>M</given-names></name><name name-style="western"><surname>T&#252;ngler</surname><given-names>V</given-names></name></person-group><article-title>Serum neurofilament light chain in pediatric spinal muscular atrophy patients and healthy children</article-title><source>Ann Clin Transl Neurol</source><year>2021</year><volume>8</volume><fpage>2013</fpage><lpage>2024</lpage><pub-id pub-id-type="doi">10.1002/acn3.51449</pub-id><pub-id pub-id-type="pmid">34482646</pub-id><pub-id pub-id-type="pmcid">PMC8528467</pub-id></element-citation><mixed-citation id="mc-CR90" publication-type="journal">Nitz E, Smitka M, Schallner J, Akg&#252;n K, Ziemssen T, Von Der Hagen M, T&#252;ngler V (2021) Serum neurofilament light chain in pediatric spinal muscular atrophy patients and healthy children. Ann Clin Transl Neurol 8:2013&#8211;2024. 10.1002/acn3.51449<pub-id pub-id-type="pmid">34482646</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/acn3.51449</pub-id><pub-id pub-id-type="pmcid">PMC8528467</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR91"><label>91.</label><citation-alternatives><element-citation id="ec-CR91" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Flotats-Bastardas</surname><given-names>M</given-names></name><name name-style="western"><surname>Bitzan</surname><given-names>L</given-names></name><name name-style="western"><surname>Grell</surname><given-names>C</given-names></name><name name-style="western"><surname>Martakis</surname><given-names>K</given-names></name><name name-style="western"><surname>Winter</surname><given-names>B</given-names></name><name name-style="western"><surname>Zemlin</surname><given-names>M</given-names></name><name name-style="western"><surname>Wurster</surname><given-names>CD</given-names></name><name name-style="western"><surname>Uzelac</surname><given-names>Z</given-names></name><name name-style="western"><surname>Wei&#223;</surname><given-names>C</given-names></name><name name-style="western"><surname>Hahn</surname><given-names>A</given-names></name></person-group><article-title>Paradoxical increase of neurofilaments in SMA patients treated with onasemnogene abeparvovec-xioi</article-title><source>Front Neurol</source><year>2023</year><volume>14</volume><fpage>1269406</fpage><pub-id pub-id-type="doi">10.3389/fneur.2023.1269406</pub-id><pub-id pub-id-type="pmid">38162454</pub-id><pub-id pub-id-type="pmcid">PMC10756901</pub-id></element-citation><mixed-citation id="mc-CR91" publication-type="journal">Flotats-Bastardas M, Bitzan L, Grell C, Martakis K, Winter B, Zemlin M, Wurster CD, Uzelac Z, Wei&#223; C, Hahn A (2023) Paradoxical increase of neurofilaments in SMA patients treated with onasemnogene abeparvovec-xioi. Front Neurol 14:1269406. 10.3389/fneur.2023.1269406<pub-id pub-id-type="pmid">38162454</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fneur.2023.1269406</pub-id><pub-id pub-id-type="pmcid">PMC10756901</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR92"><label>92.</label><citation-alternatives><element-citation id="ec-CR92" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maretina</surname><given-names>M</given-names></name><name name-style="western"><surname>Koroleva</surname><given-names>V</given-names></name><name name-style="western"><surname>Shchugareva</surname><given-names>L</given-names></name><name name-style="western"><surname>Glotov</surname><given-names>A</given-names></name><name name-style="western"><surname>Kiselev</surname><given-names>A</given-names></name></person-group><article-title>The relevance of spinal muscular atrophy biomarkers in the treatment era</article-title><source>Biomedicines</source><year>2024</year><pub-id pub-id-type="doi">10.3390/biomedicines12112486</pub-id><pub-id pub-id-type="pmid">39595052</pub-id><pub-id pub-id-type="pmcid">PMC11591959</pub-id></element-citation><mixed-citation id="mc-CR92" publication-type="journal">Maretina M, Koroleva V, Shchugareva L, Glotov A, Kiselev A (2024) The relevance of spinal muscular atrophy biomarkers in the treatment era. Biomedicines. 10.3390/biomedicines12112486<pub-id pub-id-type="pmid">39595052</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/biomedicines12112486</pub-id><pub-id pub-id-type="pmcid">PMC11591959</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR93"><label>93.</label><citation-alternatives><element-citation id="ec-CR93" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Verma</surname><given-names>S</given-names></name><name name-style="western"><surname>Forte</surname><given-names>J</given-names></name><name name-style="western"><surname>Ritchey</surname><given-names>M</given-names></name><name name-style="western"><surname>Shah</surname><given-names>D</given-names></name></person-group><article-title>Motor unit number index in children with later-onset spinal muscular atrophy</article-title><source>Muscle Nerve</source><year>2020</year><volume>62</volume><fpage>633</fpage><lpage>637</lpage><pub-id pub-id-type="doi">10.1002/mus.26909</pub-id><pub-id pub-id-type="pmid">32369629</pub-id></element-citation><mixed-citation id="mc-CR93" publication-type="journal">Verma S, Forte J, Ritchey M, Shah D (2020) Motor unit number index in children with later-onset spinal muscular atrophy. Muscle Nerve 62:633&#8211;637. 10.1002/mus.26909<pub-id pub-id-type="pmid">32369629</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mus.26909</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR94"><label>94.</label><citation-alternatives><element-citation id="ec-CR94" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kariyawasam</surname><given-names>D</given-names></name><name name-style="western"><surname>D'Silva</surname><given-names>A</given-names></name><name name-style="western"><surname>Howells</surname><given-names>J</given-names></name><name name-style="western"><surname>Herbert</surname><given-names>K</given-names></name><name name-style="western"><surname>Geelan-Small</surname><given-names>P</given-names></name><name name-style="western"><surname>Lin</surname><given-names>CSY</given-names></name><name name-style="western"><surname>Farrar</surname><given-names>MA</given-names></name></person-group><article-title>Motor unit changes in children with symptomatic spinal muscular atrophy treated with nusinersen</article-title><source>J Neurol Neurosurg Psychiatry</source><year>2021</year><volume>92</volume><fpage>78</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1136/jnnp-2020-324254</pub-id><pub-id pub-id-type="pmcid">PMC7803907</pub-id><pub-id pub-id-type="pmid">33106369</pub-id></element-citation><mixed-citation id="mc-CR94" publication-type="journal">Kariyawasam D, D&#8217;Silva A, Howells J, Herbert K, Geelan-Small P, Lin CSY, Farrar MA (2021) Motor unit changes in children with symptomatic spinal muscular atrophy treated with nusinersen. J Neurol Neurosurg Psychiatry 92:78&#8211;85. 10.1136/jnnp-2020-324254<pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jnnp-2020-324254</pub-id><pub-id pub-id-type="pmcid">PMC7803907</pub-id><pub-id pub-id-type="pmid">33106369</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR95"><label>95.</label><mixed-citation publication-type="other">Axente M (2021) Clinical and electrophysiological aspects in children with spinal muscular atrophy type 1, 2 and 3 before treatment. JNND 9. Available at: <ext-link ext-link-type="uri" xlink:href="https://www.jscholaronline.org/full-text/JNND/9_103/Clinical-and-Electrophysiological-Aspects.php">https://www.jscholaronline.org/full-text/JNND/9_103/Clinical-and-Electrophysiological-Aspects.php</ext-link> [Accessed 5 Feb 2025]. 10.17303/jnnd.2021.9.103</mixed-citation></ref><ref id="CR96"><label>96.</label><citation-alternatives><element-citation id="ec-CR96" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaufmann</surname><given-names>P</given-names></name><name name-style="western"><surname>McDermott</surname><given-names>MP</given-names></name><name name-style="western"><surname>Darras</surname><given-names>BT</given-names></name><name name-style="western"><surname>Finkel</surname><given-names>RS</given-names></name><name name-style="western"><surname>Sproule</surname><given-names>DM</given-names></name><name name-style="western"><surname>Kang</surname><given-names>PB</given-names></name><name name-style="western"><surname>Oskoui</surname><given-names>M</given-names></name><name name-style="western"><surname>Constantinescu</surname><given-names>A</given-names></name><name name-style="western"><surname>Gooch</surname><given-names>CL</given-names></name><name name-style="western"><surname>Foley</surname><given-names>AR</given-names></name><name name-style="western"><surname>Yang</surname><given-names>ML</given-names></name><name name-style="western"><surname>Tawil</surname><given-names>R</given-names></name><name name-style="western"><surname>Chung</surname><given-names>WK</given-names></name><name name-style="western"><surname>Martens</surname><given-names>WB</given-names></name><name name-style="western"><surname>Montes</surname><given-names>J</given-names></name><name name-style="western"><surname>Battista</surname><given-names>V</given-names></name><name name-style="western"><surname>O'Hagen</surname><given-names>J</given-names></name><name name-style="western"><surname>Dunaway</surname><given-names>S</given-names></name><name name-style="western"><surname>Flickinger</surname><given-names>J</given-names></name><name name-style="western"><surname>Quigley</surname><given-names>J</given-names></name><etal/></person-group><article-title>Prospective cohort study of spinal muscular atrophy types 2 and 3</article-title><source>Neurology</source><year>2012</year><volume>79</volume><fpage>1889</fpage><lpage>1897</lpage><pub-id pub-id-type="doi">10.1212/WNL.0b013e318271f7e4</pub-id><pub-id pub-id-type="pmid">23077013</pub-id><pub-id pub-id-type="pmcid">PMC3525313</pub-id></element-citation><mixed-citation id="mc-CR96" publication-type="journal">Kaufmann P, McDermott MP, Darras BT, Finkel RS, Sproule DM, Kang PB, Oskoui M, Constantinescu A, Gooch CL, Foley AR, Yang ML, Tawil R, Chung WK, Martens WB, Montes J, Battista V, O&#8217;Hagen J, Dunaway S, Flickinger J, Quigley J et al (2012) Prospective cohort study of spinal muscular atrophy types 2 and 3. Neurology 79:1889&#8211;1897. 10.1212/WNL.0b013e318271f7e4<pub-id pub-id-type="pmid">23077013</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0b013e318271f7e4</pub-id><pub-id pub-id-type="pmcid">PMC3525313</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR97"><label>97.</label><citation-alternatives><element-citation id="ec-CR97" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kang</surname><given-names>PB</given-names></name><name name-style="western"><surname>Gooch</surname><given-names>CL</given-names></name><name name-style="western"><surname>McDermott</surname><given-names>MP</given-names></name><name name-style="western"><surname>Darras</surname><given-names>BT</given-names></name><name name-style="western"><surname>Finkel</surname><given-names>RS</given-names></name><name name-style="western"><surname>Yang</surname><given-names>ML</given-names></name><name name-style="western"><surname>Sproule</surname><given-names>DM</given-names></name><name name-style="western"><surname>Chung</surname><given-names>WK</given-names></name><name name-style="western"><surname>Kaufmann</surname><given-names>P</given-names></name><name name-style="western"><surname>De Vivo</surname><given-names>DC</given-names></name><collab>Muscle Study Group and Pediatric Neuromuscular Clinical Research Network for Spinal Muscular Atrophy</collab></person-group><article-title>The motor neuron response to SMN1 deficiency in spinal muscular atrophy</article-title><source>Muscle Nerve</source><year>2014</year><volume>49</volume><fpage>636</fpage><lpage>644</lpage><pub-id pub-id-type="doi">10.1002/mus.23967</pub-id><pub-id pub-id-type="pmid">23893312</pub-id><pub-id pub-id-type="pmcid">PMC4090017</pub-id></element-citation><mixed-citation id="mc-CR97" publication-type="journal">Kang PB, Gooch CL, McDermott MP, Darras BT, Finkel RS, Yang ML, Sproule DM, Chung WK, Kaufmann P, De Vivo DC, Muscle Study Group and Pediatric Neuromuscular Clinical Research Network for Spinal Muscular Atrophy (2014) The motor neuron response to SMN1 deficiency in spinal muscular atrophy. Muscle Nerve 49:636&#8211;644. 10.1002/mus.23967<pub-id pub-id-type="pmid">23893312</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mus.23967</pub-id><pub-id pub-id-type="pmcid">PMC4090017</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR98"><label>98.</label><citation-alternatives><element-citation id="ec-CR98" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Feng</surname><given-names>L</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Q</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J</given-names></name><name name-style="western"><surname>Song</surname><given-names>X</given-names></name><name name-style="western"><surname>Han</surname><given-names>W</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>F</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>P</given-names></name><name name-style="western"><surname>Yao</surname><given-names>Z</given-names></name><name name-style="western"><surname>Xie</surname><given-names>L</given-names></name><name name-style="western"><surname>Li</surname><given-names>M</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>L</given-names></name><name name-style="western"><surname>Hong</surname><given-names>S</given-names></name></person-group><article-title>Motor function and compound muscle action potential amplitude in children with spinal muscular atrophy treated with nusinersen</article-title><source>Brain Dev</source><year>2025</year><volume>47</volume><fpage>104316</fpage><pub-id pub-id-type="doi">10.1016/j.braindev.2024.104316</pub-id><pub-id pub-id-type="pmid">39787994</pub-id></element-citation><mixed-citation id="mc-CR98" publication-type="journal">Peng Y, Feng L, Wu J, Zhou Q, Liu H, Chen J, Song X, Han W, Zhang F, Yuan P, Yao Z, Xie L, Li M, Jiang L, Hong S (2025) Motor function and compound muscle action potential amplitude in children with spinal muscular atrophy treated with nusinersen. Brain Dev 47:104316. 10.1016/j.braindev.2024.104316<pub-id pub-id-type="pmid">39787994</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.braindev.2024.104316</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR99"><label>99.</label><citation-alternatives><element-citation id="ec-CR99" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Richard</surname><given-names>M</given-names></name><name name-style="western"><surname>Barrois</surname><given-names>R</given-names></name><name name-style="western"><surname>Desguerre</surname><given-names>I</given-names></name><name name-style="western"><surname>Deladri&#232;re</surname><given-names>E</given-names></name><name name-style="western"><surname>Leloup-Germa</surname><given-names>V</given-names></name><name name-style="western"><surname>Barnerias</surname><given-names>C</given-names></name><name name-style="western"><surname>Gitiaux</surname><given-names>C</given-names></name></person-group><article-title>Correlations between clinical motor scores and CMAP in patients with type 2 spinal muscular amyotrophy treated with nusinersen</article-title><source>Arch Pediatr</source><year>2024</year><volume>31</volume><fpage>26</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1016/j.arcped.2023.08.011</pub-id><pub-id pub-id-type="pmid">37989659</pub-id></element-citation><mixed-citation id="mc-CR99" publication-type="journal">Richard M, Barrois R, Desguerre I, Deladri&#232;re E, Leloup-Germa V, Barnerias C, Gitiaux C (2024) Correlations between clinical motor scores and CMAP in patients with type 2 spinal muscular amyotrophy treated with nusinersen. Arch Pediatr 31:26&#8211;31. 10.1016/j.arcped.2023.08.011<pub-id pub-id-type="pmid">37989659</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.arcped.2023.08.011</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR100"><label>100.</label><citation-alternatives><element-citation id="ec-CR100" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Axente</surname><given-names>M</given-names></name><name name-style="western"><surname>Mirea</surname><given-names>A</given-names></name><name name-style="western"><surname>Sporea</surname><given-names>C</given-names></name><name name-style="western"><surname>P&#259;dure</surname><given-names>L</given-names></name><name name-style="western"><surname>Dr&#259;goi</surname><given-names>CM</given-names></name><name name-style="western"><surname>Nicolae</surname><given-names>AC</given-names></name><name name-style="western"><surname>Ion</surname><given-names>DA</given-names></name></person-group><article-title>Clinical and electrophysiological changes in pediatric spinal muscular atrophy after 2 years of nusinersen treatment</article-title><source>Pharmaceutics</source><year>2022</year><volume>14</volume><fpage>2074</fpage><pub-id pub-id-type="doi">10.3390/pharmaceutics14102074</pub-id><pub-id pub-id-type="pmid">36297509</pub-id><pub-id pub-id-type="pmcid">PMC9611420</pub-id></element-citation><mixed-citation id="mc-CR100" publication-type="journal">Axente M, Mirea A, Sporea C, P&#259;dure L, Dr&#259;goi CM, Nicolae AC, Ion DA (2022) Clinical and electrophysiological changes in pediatric spinal muscular atrophy after 2 years of nusinersen treatment. Pharmaceutics 14:2074. 10.3390/pharmaceutics14102074<pub-id pub-id-type="pmid">36297509</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/pharmaceutics14102074</pub-id><pub-id pub-id-type="pmcid">PMC9611420</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR101"><label>101.</label><citation-alternatives><element-citation id="ec-CR101" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barrois</surname><given-names>R</given-names></name><name name-style="western"><surname>Barnerias</surname><given-names>C</given-names></name><name name-style="western"><surname>Deladri&#232;re</surname><given-names>E</given-names></name><name name-style="western"><surname>Leloup-Germa</surname><given-names>V</given-names></name><name name-style="western"><surname>Tervil</surname><given-names>B</given-names></name><name name-style="western"><surname>Audic</surname><given-names>F</given-names></name><name name-style="western"><surname>Boulay</surname><given-names>C</given-names></name><name name-style="western"><surname>Cances</surname><given-names>C</given-names></name><name name-style="western"><surname>Cintas</surname><given-names>P</given-names></name><name name-style="western"><surname>Davion</surname><given-names>JB</given-names></name><name name-style="western"><surname>Espil-Taris</surname><given-names>C</given-names></name><name name-style="western"><surname>Manel</surname><given-names>V</given-names></name><name name-style="western"><surname>Pereon</surname><given-names>Y</given-names></name><name name-style="western"><surname>Piarroux</surname><given-names>J</given-names></name><name name-style="western"><surname>Quijano Roy</surname><given-names>S</given-names></name><name name-style="western"><surname>Vuillerot</surname><given-names>C</given-names></name><name name-style="western"><surname>Walther-Louvier</surname><given-names>U</given-names></name><name name-style="western"><surname>Desguerre</surname><given-names>I</given-names></name><name name-style="western"><surname>Gitiaux</surname><given-names>C</given-names></name></person-group><article-title>A new score combining compound muscle action potential (CMAP) amplitudes and motor score is predictive of motor outcome after AVXS-101 (onasemnogene abeparvovec) SMA therapy</article-title><source>Neuromuscul Disord</source><year>2023</year><volume>33</volume><fpage>309</fpage><lpage>314</lpage><pub-id pub-id-type="doi">10.1016/j.nmd.2023.02.004</pub-id><pub-id pub-id-type="pmid">36881951</pub-id></element-citation><mixed-citation id="mc-CR101" publication-type="journal">Barrois R, Barnerias C, Deladri&#232;re E, Leloup-Germa V, Tervil B, Audic F, Boulay C, Cances C, Cintas P, Davion JB, Espil-Taris C, Manel V, Pereon Y, Piarroux J, Quijano Roy S, Vuillerot C, Walther-Louvier U, Desguerre I, Gitiaux C (2023) A new score combining compound muscle action potential (CMAP) amplitudes and motor score is predictive of motor outcome after AVXS-101 (onasemnogene abeparvovec) SMA therapy. Neuromuscul Disord 33:309&#8211;314. 10.1016/j.nmd.2023.02.004<pub-id pub-id-type="pmid">36881951</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.nmd.2023.02.004</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR102"><label>102.</label><citation-alternatives><element-citation id="ec-CR102" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>D</given-names></name><name name-style="western"><surname>Sun</surname><given-names>N</given-names></name><name name-style="western"><surname>Xiang</surname><given-names>L</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>Yang</surname><given-names>L</given-names></name><name name-style="western"><surname>Huang</surname><given-names>S</given-names></name></person-group><article-title>Neurophysiological characteristics in type II and type III 5q spinal muscular atrophy patients: impact of nusinersen treatment</article-title><source>Drug Des Devel Ther</source><year>2024</year><volume>18</volume><fpage>953</fpage><lpage>965</lpage><pub-id pub-id-type="doi">10.2147/DDDT.S449066</pub-id><pub-id pub-id-type="pmid">38562520</pub-id><pub-id pub-id-type="pmcid">PMC10984209</pub-id></element-citation><mixed-citation id="mc-CR102" publication-type="journal">Li D, Sun N, Xiang L, Liu J, Wang X, Yang L, Huang S (2024) Neurophysiological characteristics in type II and type III 5q spinal muscular atrophy patients: impact of nusinersen treatment. Drug Des Devel Ther 18:953&#8211;965. 10.2147/DDDT.S449066<pub-id pub-id-type="pmid">38562520</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/DDDT.S449066</pub-id><pub-id pub-id-type="pmcid">PMC10984209</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR103"><label>103.</label><citation-alternatives><element-citation id="ec-CR103" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sleutjes</surname><given-names>BTHM</given-names></name><name name-style="western"><surname>Wijngaarde</surname><given-names>CA</given-names></name><name name-style="western"><surname>Wadman</surname><given-names>RI</given-names></name><name name-style="western"><surname>Otto</surname><given-names>LAM</given-names></name><name name-style="western"><surname>Asselman</surname><given-names>FL</given-names></name><name name-style="western"><surname>Cuppen</surname><given-names>I</given-names></name><name name-style="western"><surname>Van Den Berg</surname><given-names>LH</given-names></name><name name-style="western"><surname>Van Der Pol</surname><given-names>WL</given-names></name><name name-style="western"><surname>Goedee</surname><given-names>HS</given-names></name></person-group><article-title>Assessment of motor unit loss in patients with spinal muscular atrophy</article-title><source>Clin Neurophysiol</source><year>2020</year><volume>131</volume><fpage>1280</fpage><lpage>1286</lpage><pub-id pub-id-type="doi">10.1016/j.clinph.2020.01.018</pub-id><pub-id pub-id-type="pmid">32305855</pub-id></element-citation><mixed-citation id="mc-CR103" publication-type="journal">Sleutjes BTHM, Wijngaarde CA, Wadman RI, Otto LAM, Asselman FL, Cuppen I, Van Den Berg LH, Van Der Pol WL, Goedee HS (2020) Assessment of motor unit loss in patients with spinal muscular atrophy. Clin Neurophysiol 131:1280&#8211;1286. 10.1016/j.clinph.2020.01.018<pub-id pub-id-type="pmid">32305855</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.clinph.2020.01.018</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR104"><label>104.</label><citation-alternatives><element-citation id="ec-CR104" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gawel</surname><given-names>M</given-names></name><name name-style="western"><surname>Kostera-Pruszczyk</surname><given-names>A</given-names></name><name name-style="western"><surname>Lusakowska</surname><given-names>A</given-names></name><name name-style="western"><surname>Jedrzejowska</surname><given-names>M</given-names></name><name name-style="western"><surname>Ryniewicz</surname><given-names>B</given-names></name><name name-style="western"><surname>Lipowska</surname><given-names>M</given-names></name><name name-style="western"><surname>Gawel</surname><given-names>D</given-names></name><name name-style="western"><surname>Kaminska</surname><given-names>A</given-names></name></person-group><article-title>Motor unit loss estimation by the multipoint incremental MUNE method in children with spinal muscular atrophy - a preliminary study</article-title><source>Neuromuscul Disord</source><year>2015</year><volume>25</volume><fpage>216</fpage><lpage>221</lpage><pub-id pub-id-type="doi">10.1016/j.nmd.2014.11.012</pub-id><pub-id pub-id-type="pmid">25500012</pub-id></element-citation><mixed-citation id="mc-CR104" publication-type="journal">Gawel M, Kostera-Pruszczyk A, Lusakowska A, Jedrzejowska M, Ryniewicz B, Lipowska M, Gawel D, Kaminska A (2015) Motor unit loss estimation by the multipoint incremental MUNE method in children with spinal muscular atrophy - a preliminary study. Neuromuscul Disord 25:216&#8211;221. 10.1016/j.nmd.2014.11.012<pub-id pub-id-type="pmid">25500012</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.nmd.2014.11.012</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR105"><label>105.</label><citation-alternatives><element-citation id="ec-CR105" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lapp</surname><given-names>HS</given-names></name><name name-style="western"><surname>Freigang</surname><given-names>M</given-names></name><name name-style="western"><surname>Hagenacker</surname><given-names>T</given-names></name><name name-style="western"><surname>Weiler</surname><given-names>M</given-names></name><name name-style="western"><surname>Wurster</surname><given-names>CD</given-names></name><name name-style="western"><surname>G&#252;nther</surname><given-names>R</given-names></name></person-group><article-title>Biomarkers in 5q-associated spinal muscular atrophy-a narrative review</article-title><source>J Neurol</source><year>2023</year><volume>270</volume><fpage>4157</fpage><lpage>4178</lpage><pub-id pub-id-type="doi">10.1007/s00415-023-11787-y</pub-id><pub-id pub-id-type="pmid">37289324</pub-id><pub-id pub-id-type="pmcid">PMC10421827</pub-id></element-citation><mixed-citation id="mc-CR105" publication-type="journal">Lapp HS, Freigang M, Hagenacker T, Weiler M, Wurster CD, G&#252;nther R (2023) Biomarkers in 5q-associated spinal muscular atrophy-a narrative review. J Neurol 270:4157&#8211;4178. 10.1007/s00415-023-11787-y<pub-id pub-id-type="pmid">37289324</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00415-023-11787-y</pub-id><pub-id pub-id-type="pmcid">PMC10421827</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR106"><label>106.</label><citation-alternatives><element-citation id="ec-CR106" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Olsson</surname><given-names>B</given-names></name><name name-style="western"><surname>Alberg</surname><given-names>L</given-names></name><name name-style="western"><surname>Cullen</surname><given-names>NC</given-names></name><name name-style="western"><surname>Michael</surname><given-names>E</given-names></name><name name-style="western"><surname>Wahlgren</surname><given-names>L</given-names></name><name name-style="western"><surname>Kroksmark</surname><given-names>AK</given-names></name><name name-style="western"><surname>Rostasy</surname><given-names>K</given-names></name><name name-style="western"><surname>Blennow</surname><given-names>K</given-names></name><name name-style="western"><surname>Zetterberg</surname><given-names>H</given-names></name><name name-style="western"><surname>Tulinius</surname><given-names>M</given-names></name></person-group><article-title>NFL is a marker of treatment response in children with SMA treated with nusinersen</article-title><source>J Neurol</source><year>2019</year><volume>266</volume><fpage>2129</fpage><lpage>2136</lpage><pub-id pub-id-type="doi">10.1007/s00415-019-09389-8</pub-id><pub-id pub-id-type="pmid">31123861</pub-id><pub-id pub-id-type="pmcid">PMC6687695</pub-id></element-citation><mixed-citation id="mc-CR106" publication-type="journal">Olsson B, Alberg L, Cullen NC, Michael E, Wahlgren L, Kroksmark AK, Rostasy K, Blennow K, Zetterberg H, Tulinius M (2019) NFL is a marker of treatment response in children with SMA treated with nusinersen. J Neurol 266:2129&#8211;2136. 10.1007/s00415-019-09389-8<pub-id pub-id-type="pmid">31123861</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00415-019-09389-8</pub-id><pub-id pub-id-type="pmcid">PMC6687695</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR107"><label>107.</label><citation-alternatives><element-citation id="ec-CR107" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Seo</surname><given-names>G</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S</given-names></name><name name-style="western"><surname>Byun</surname><given-names>JC</given-names></name><name name-style="western"><surname>Kwon</surname><given-names>S</given-names></name><name name-style="western"><surname>Lee</surname><given-names>YJ</given-names></name></person-group><article-title>Evaluation of the neurofilament light chain as a biomarker in children with spinal muscular atrophy treated with nusinersen</article-title><source>Brain Dev</source><year>2023</year><volume>45</volume><fpage>554</fpage><lpage>563</lpage><pub-id pub-id-type="doi">10.1016/j.braindev.2023.07.005</pub-id><pub-id pub-id-type="pmid">37541812</pub-id></element-citation><mixed-citation id="mc-CR107" publication-type="journal">Seo G, Kim S, Byun JC, Kwon S, Lee YJ (2023) Evaluation of the neurofilament light chain as a biomarker in children with spinal muscular atrophy treated with nusinersen. Brain Dev 45:554&#8211;563. 10.1016/j.braindev.2023.07.005<pub-id pub-id-type="pmid">37541812</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.braindev.2023.07.005</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR108"><label>108.</label><citation-alternatives><element-citation id="ec-CR108" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bayoumy</surname><given-names>S</given-names></name><name name-style="western"><surname>Verberk</surname><given-names>IMW</given-names></name><name name-style="western"><surname>Vermunt</surname><given-names>L</given-names></name><name name-style="western"><surname>Willemse</surname><given-names>E</given-names></name><name name-style="western"><surname>Den Dulk</surname><given-names>B</given-names></name><name name-style="western"><surname>Van Der Ploeg</surname><given-names>AT</given-names></name><name name-style="western"><surname>Pajkrt</surname><given-names>D</given-names></name><name name-style="western"><surname>Nitz</surname><given-names>E</given-names></name><name name-style="western"><surname>Van Den Hout</surname><given-names>JMP</given-names></name><name name-style="western"><surname>Van Der Post</surname><given-names>J</given-names></name><name name-style="western"><surname>Wolf</surname><given-names>NI</given-names></name><name name-style="western"><surname>Beerepoot</surname><given-names>S</given-names></name><name name-style="western"><surname>Groen</surname><given-names>EJN</given-names></name><name name-style="western"><surname>T&#252;ngler</surname><given-names>V</given-names></name><name name-style="western"><surname>Teunissen</surname><given-names>CE</given-names></name></person-group><article-title>Neurofilament light protein as a biomarker for spinal muscular atrophy: a review and reference ranges</article-title><source>Clin Chem Lab Med</source><year>2024</year><volume>62</volume><fpage>1252</fpage><lpage>1265</lpage><pub-id pub-id-type="doi">10.1515/cclm-2023-1311</pub-id><pub-id pub-id-type="pmid">38215341</pub-id></element-citation><mixed-citation id="mc-CR108" publication-type="journal">Bayoumy S, Verberk IMW, Vermunt L, Willemse E, Den Dulk B, Van Der Ploeg AT, Pajkrt D, Nitz E, Van Den Hout JMP, Van Der Post J, Wolf NI, Beerepoot S, Groen EJN, T&#252;ngler V, Teunissen CE (2024) Neurofilament light protein as a biomarker for spinal muscular atrophy: a review and reference ranges. Clin Chem Lab Med 62:1252&#8211;1265. 10.1515/cclm-2023-1311<pub-id pub-id-type="pmid">38215341</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1515/cclm-2023-1311</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR109"><label>109.</label><citation-alternatives><element-citation id="ec-CR109" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tozawa</surname><given-names>T</given-names></name><name name-style="western"><surname>Kasai</surname><given-names>T</given-names></name><name name-style="western"><surname>Tatebe</surname><given-names>H</given-names></name><name name-style="western"><surname>Shiomi</surname><given-names>K</given-names></name><name name-style="western"><surname>Nishio</surname><given-names>H</given-names></name><name name-style="western"><surname>Tokuda</surname><given-names>T</given-names></name><name name-style="western"><surname>Chiyonobu</surname><given-names>T</given-names></name></person-group><article-title>Intrathecal nusinersen treatment after ventriculo-peritoneal shunt placement: a case report focusing on the neurofilament light chain in cerebrospinal fluid</article-title><source>Brain Dev</source><year>2020</year><volume>42</volume><fpage>311</fpage><lpage>314</lpage><pub-id pub-id-type="doi">10.1016/j.braindev.2019.12.006</pub-id><pub-id pub-id-type="pmid">31889567</pub-id></element-citation><mixed-citation id="mc-CR109" publication-type="journal">Tozawa T, Kasai T, Tatebe H, Shiomi K, Nishio H, Tokuda T, Chiyonobu T (2020) Intrathecal nusinersen treatment after ventriculo-peritoneal shunt placement: a case report focusing on the neurofilament light chain in cerebrospinal fluid. Brain Dev 42:311&#8211;314. 10.1016/j.braindev.2019.12.006<pub-id pub-id-type="pmid">31889567</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.braindev.2019.12.006</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR110"><label>110.</label><mixed-citation publication-type="other">European Medicines Agency (2022). Letter of support of neurofilament light in childhood neurological diseases. Available at: <ext-link ext-link-type="uri" xlink:href="https://www.ema.europa.eu/en/documents/other/letter-support-neurofilament-lightchildhood-neurological-diseases_en.pdf">https://www.ema.europa.eu/en/documents/other/letter-support-neurofilament-lightchildhood-neurological-diseases_en.pdf</ext-link></mixed-citation></ref><ref id="CR111"><label>111.</label><citation-alternatives><element-citation id="ec-CR111" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sproule</surname><given-names>DM</given-names></name><name name-style="western"><surname>Montgomery</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Punyanitya</surname><given-names>M</given-names></name><name name-style="western"><surname>Shen</surname><given-names>W</given-names></name><name name-style="western"><surname>Dashnaw</surname><given-names>S</given-names></name><name name-style="western"><surname>Montes</surname><given-names>J</given-names></name><name name-style="western"><surname>Dunaway</surname><given-names>S</given-names></name><name name-style="western"><surname>Finkel</surname><given-names>R</given-names></name><name name-style="western"><surname>Darras</surname><given-names>B</given-names></name><name name-style="western"><surname>De Vivo</surname><given-names>DC</given-names></name><name name-style="western"><surname>Kaufmann</surname><given-names>P</given-names></name></person-group><article-title>Thigh muscle volume measured by magnetic resonance imaging is stable over a 6-month interval in spinal muscular atrophy</article-title><source>J Child Neurol</source><year>2011</year><volume>26</volume><fpage>1252</fpage><lpage>1259</lpage><pub-id pub-id-type="doi">10.1177/0883073811405053</pub-id><pub-id pub-id-type="pmid">21572051</pub-id></element-citation><mixed-citation id="mc-CR111" publication-type="journal">Sproule DM, Montgomery MJ, Punyanitya M, Shen W, Dashnaw S, Montes J, Dunaway S, Finkel R, Darras B, De Vivo DC, Kaufmann P (2011) Thigh muscle volume measured by magnetic resonance imaging is stable over a 6-month interval in spinal muscular atrophy. J Child Neurol 26:1252&#8211;1259. 10.1177/0883073811405053<pub-id pub-id-type="pmid">21572051</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/0883073811405053</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR112"><label>112.</label><citation-alternatives><element-citation id="ec-CR112" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sproule</surname><given-names>DM</given-names></name><name name-style="western"><surname>Punyanitya</surname><given-names>M</given-names></name><name name-style="western"><surname>Shen</surname><given-names>W</given-names></name><name name-style="western"><surname>Dashnaw</surname><given-names>S</given-names></name><name name-style="western"><surname>Martens</surname><given-names>B</given-names></name><name name-style="western"><surname>Montgomery</surname><given-names>M</given-names></name><name name-style="western"><surname>Montes</surname><given-names>J</given-names></name><name name-style="western"><surname>Battista</surname><given-names>V</given-names></name><name name-style="western"><surname>Finkel</surname><given-names>R</given-names></name><name name-style="western"><surname>Darras</surname><given-names>B</given-names></name><name name-style="western"><surname>De Vivo</surname><given-names>DC</given-names></name><name name-style="western"><surname>Kaufmann</surname><given-names>P</given-names></name></person-group><article-title>Muscle volume estimation by magnetic resonance imaging in spinal muscular atrophy</article-title><source>J Child Neurol</source><year>2011</year><volume>26</volume><fpage>309</fpage><lpage>317</lpage><pub-id pub-id-type="doi">10.1177/0883073810380457</pub-id><pub-id pub-id-type="pmid">20929908</pub-id></element-citation><mixed-citation id="mc-CR112" publication-type="journal">Sproule DM, Punyanitya M, Shen W, Dashnaw S, Martens B, Montgomery M, Montes J, Battista V, Finkel R, Darras B, De Vivo DC, Kaufmann P (2011) Muscle volume estimation by magnetic resonance imaging in spinal muscular atrophy. J Child Neurol 26:309&#8211;317. 10.1177/0883073810380457<pub-id pub-id-type="pmid">20929908</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/0883073810380457</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR113"><label>113.</label><citation-alternatives><element-citation id="ec-CR113" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brogna</surname><given-names>C</given-names></name><name name-style="western"><surname>Cristiano</surname><given-names>L</given-names></name><name name-style="western"><surname>Verdolotti</surname><given-names>T</given-names></name><name name-style="western"><surname>Pichiecchio</surname><given-names>A</given-names></name><name name-style="western"><surname>Cinnante</surname><given-names>C</given-names></name><name name-style="western"><surname>Sansone</surname><given-names>V</given-names></name><name name-style="western"><surname>Sconfienza</surname><given-names>LM</given-names></name><name name-style="western"><surname>Berardinelli</surname><given-names>A</given-names></name><name name-style="western"><surname>Garibaldi</surname><given-names>M</given-names></name><name name-style="western"><surname>Antonini</surname><given-names>G</given-names></name><name name-style="western"><surname>Pane</surname><given-names>M</given-names></name><name name-style="western"><surname>Pera</surname><given-names>MC</given-names></name><name name-style="western"><surname>Antonaci</surname><given-names>L</given-names></name><name name-style="western"><surname>Ficociello</surname><given-names>L</given-names></name><name name-style="western"><surname>Albamonte</surname><given-names>E</given-names></name><name name-style="western"><surname>Tasca</surname><given-names>G</given-names></name><name name-style="western"><surname>Begliuomini</surname><given-names>C</given-names></name><name name-style="western"><surname>Tartaglione</surname><given-names>T</given-names></name><name name-style="western"><surname>Maggi</surname><given-names>L</given-names></name><name name-style="western"><surname>Govoni</surname><given-names>A</given-names></name><etal/></person-group><article-title>MRI patterns of muscle involvement in type 2 and 3 spinal muscular atrophy patients</article-title><source>J Neurol</source><year>2020</year><volume>267</volume><fpage>898</fpage><lpage>912</lpage><pub-id pub-id-type="doi">10.1007/s00415-019-09646-w</pub-id><pub-id pub-id-type="pmid">31776722</pub-id></element-citation><mixed-citation id="mc-CR113" publication-type="journal">Brogna C, Cristiano L, Verdolotti T, Pichiecchio A, Cinnante C, Sansone V, Sconfienza LM, Berardinelli A, Garibaldi M, Antonini G, Pane M, Pera MC, Antonaci L, Ficociello L, Albamonte E, Tasca G, Begliuomini C, Tartaglione T, Maggi L, Govoni A et al (2020) MRI patterns of muscle involvement in type 2 and 3 spinal muscular atrophy patients. J Neurol 267:898&#8211;912. 10.1007/s00415-019-09646-w<pub-id pub-id-type="pmid">31776722</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00415-019-09646-w</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR114"><label>114.</label><citation-alternatives><element-citation id="ec-CR114" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>JS</given-names></name><name name-style="western"><surname>Darras</surname><given-names>BT</given-names></name><name name-style="western"><surname>Rutkove</surname><given-names>SB</given-names></name></person-group><article-title>Assessing spinal muscular atrophy with quantitative ultrasound</article-title><source>Neurology</source><year>2010</year><volume>75</volume><fpage>526</fpage><lpage>531</lpage><pub-id pub-id-type="doi">10.1212/WNL.0b013e3181eccf8f</pub-id><pub-id pub-id-type="pmid">20697104</pub-id><pub-id pub-id-type="pmcid">PMC2918474</pub-id></element-citation><mixed-citation id="mc-CR114" publication-type="journal">Wu JS, Darras BT, Rutkove SB (2010) Assessing spinal muscular atrophy with quantitative ultrasound. Neurology 75:526&#8211;531. 10.1212/WNL.0b013e3181eccf8f<pub-id pub-id-type="pmid">20697104</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0b013e3181eccf8f</pub-id><pub-id pub-id-type="pmcid">PMC2918474</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR115"><label>115.</label><citation-alternatives><element-citation id="ec-CR115" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chabanon</surname><given-names>A</given-names></name><name name-style="western"><surname>Seferian</surname><given-names>AM</given-names></name><name name-style="western"><surname>Daron</surname><given-names>A</given-names></name><name name-style="western"><surname>P&#233;r&#233;on</surname><given-names>Y</given-names></name><name name-style="western"><surname>Cances</surname><given-names>C</given-names></name><name name-style="western"><surname>Vuillerot</surname><given-names>C</given-names></name><name name-style="western"><surname>De Waele</surname><given-names>L</given-names></name><name name-style="western"><surname>Cuisset</surname><given-names>JM</given-names></name><name name-style="western"><surname>Laugel</surname><given-names>V</given-names></name><name name-style="western"><surname>Schara</surname><given-names>U</given-names></name><name name-style="western"><surname>Gidaro</surname><given-names>T</given-names></name><name name-style="western"><surname>Gilabert</surname><given-names>S</given-names></name><name name-style="western"><surname>Hogrel</surname><given-names>JY</given-names></name><name name-style="western"><surname>Baudin</surname><given-names>PY</given-names></name><name name-style="western"><surname>Carlier</surname><given-names>P</given-names></name><name name-style="western"><surname>Fournier</surname><given-names>E</given-names></name><name name-style="western"><surname>Lowes</surname><given-names>LP</given-names></name><name name-style="western"><surname>Hellbach</surname><given-names>N</given-names></name><name name-style="western"><surname>Seabrook</surname><given-names>T</given-names></name><name name-style="western"><surname>Toledano</surname><given-names>E</given-names></name><etal/></person-group><article-title>Prospective and longitudinal natural history study of patients with type 2 and 3 spinal muscular atrophy: baseline data nathis-SMA study</article-title><source>PLoS ONE</source><year>2018</year><volume>13</volume><fpage>e0201004</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0201004</pub-id><pub-id pub-id-type="pmid">30048507</pub-id><pub-id pub-id-type="pmcid">PMC6062049</pub-id></element-citation><mixed-citation id="mc-CR115" publication-type="journal">Chabanon A, Seferian AM, Daron A, P&#233;r&#233;on Y, Cances C, Vuillerot C, De Waele L, Cuisset JM, Laugel V, Schara U, Gidaro T, Gilabert S, Hogrel JY, Baudin PY, Carlier P, Fournier E, Lowes LP, Hellbach N, Seabrook T, Toledano E et al (2018) Prospective and longitudinal natural history study of patients with type 2 and 3 spinal muscular atrophy: baseline data nathis-SMA study. PLoS ONE 13:e0201004. 10.1371/journal.pone.0201004<pub-id pub-id-type="pmid">30048507</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0201004</pub-id><pub-id pub-id-type="pmcid">PMC6062049</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR116"><label>116.</label><citation-alternatives><element-citation id="ec-CR116" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ng</surname><given-names>KW</given-names></name><name name-style="western"><surname>Connolly</surname><given-names>AM</given-names></name><name name-style="western"><surname>Zaidman</surname><given-names>CM</given-names></name></person-group><article-title>Quantitative muscle ultrasound measures rapid declines over time in children with SMA type 1</article-title><source>J Neurol Sci</source><year>2015</year><volume>358</volume><fpage>178</fpage><lpage>182</lpage><pub-id pub-id-type="doi">10.1016/j.jns.2015.08.1532</pub-id><pub-id pub-id-type="pmid">26432577</pub-id><pub-id pub-id-type="pmcid">PMC5931216</pub-id></element-citation><mixed-citation id="mc-CR116" publication-type="journal">Ng KW, Connolly AM, Zaidman CM (2015) Quantitative muscle ultrasound measures rapid declines over time in children with SMA type 1. J Neurol Sci 358:178&#8211;182. 10.1016/j.jns.2015.08.1532<pub-id pub-id-type="pmid">26432577</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jns.2015.08.1532</pub-id><pub-id pub-id-type="pmcid">PMC5931216</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR117"><label>117.</label><citation-alternatives><element-citation id="ec-CR117" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Otto</surname><given-names>LAM</given-names></name><name name-style="western"><surname>Froeling</surname><given-names>M</given-names></name><name name-style="western"><surname>Van Eijk</surname><given-names>RPA</given-names></name><name name-style="western"><surname>Wadman</surname><given-names>RI</given-names></name><name name-style="western"><surname>Cuppen</surname><given-names>I</given-names></name><name name-style="western"><surname>Van Der Woude</surname><given-names>DR</given-names></name><name name-style="western"><surname>Bartels</surname><given-names>B</given-names></name><name name-style="western"><surname>Asselman</surname><given-names>FL</given-names></name><name name-style="western"><surname>Hendrikse</surname><given-names>J</given-names></name><name name-style="western"><surname>Van Der Pol</surname><given-names>WL</given-names></name></person-group><article-title>Monitoring nusinersen treatment effects in children with spinal muscular atrophy with quantitative muscle MRI</article-title><source>J Neuromuscul Dis</source><year>2024</year><volume>11</volume><fpage>91</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.3233/JND-221671</pub-id><pub-id pub-id-type="pmid">38073395</pub-id><pub-id pub-id-type="pmcid">PMC10789331</pub-id></element-citation><mixed-citation id="mc-CR117" publication-type="journal">Otto LAM, Froeling M, Van Eijk RPA, Wadman RI, Cuppen I, Van Der Woude DR, Bartels B, Asselman FL, Hendrikse J, Van Der Pol WL (2024) Monitoring nusinersen treatment effects in children with spinal muscular atrophy with quantitative muscle MRI. J Neuromuscul Dis 11:91&#8211;101. 10.3233/JND-221671<pub-id pub-id-type="pmid">38073395</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JND-221671</pub-id><pub-id pub-id-type="pmcid">PMC10789331</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR118"><label>118.</label><citation-alternatives><element-citation id="ec-CR118" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lo</surname><given-names>SH</given-names></name><name name-style="western"><surname>Lawrence</surname><given-names>C</given-names></name><name name-style="western"><surname>Mart&#237;</surname><given-names>Y</given-names></name><name name-style="western"><surname>Caf&#233;</surname><given-names>A</given-names></name><name name-style="western"><surname>Lloyd</surname><given-names>AJ</given-names></name></person-group><article-title>Patient and caregiver treatment preferences in type 2 and non-ambulatory type 3 spinal muscular atrophy: a discrete choice experiment survey in five European countries</article-title><source>Pharmacoeconomics</source><year>2022</year><volume>40</volume><fpage>103</fpage><lpage>115</lpage><pub-id pub-id-type="doi">10.1007/s40273-021-01118-2</pub-id><pub-id pub-id-type="pmid">34897574</pub-id><pub-id pub-id-type="pmcid">PMC8994736</pub-id></element-citation><mixed-citation id="mc-CR118" publication-type="journal">Lo SH, Lawrence C, Mart&#237; Y, Caf&#233; A, Lloyd AJ (2022) Patient and caregiver treatment preferences in type 2 and non-ambulatory type 3 spinal muscular atrophy: a discrete choice experiment survey in five European countries. Pharmacoeconomics 40:103&#8211;115. 10.1007/s40273-021-01118-2<pub-id pub-id-type="pmid">34897574</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40273-021-01118-2</pub-id><pub-id pub-id-type="pmcid">PMC8994736</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR119"><label>119.</label><citation-alternatives><element-citation id="ec-CR119" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Monnette</surname><given-names>A</given-names></name><name name-style="western"><surname>Chen</surname><given-names>E</given-names></name><name name-style="western"><surname>Hong</surname><given-names>D</given-names></name><name name-style="western"><surname>Bazzano</surname><given-names>A</given-names></name><name name-style="western"><surname>Dixon</surname><given-names>S</given-names></name><name name-style="western"><surname>Arnold</surname><given-names>WD</given-names></name><name name-style="western"><surname>Shi</surname><given-names>L</given-names></name></person-group><article-title>Treatment preference among patients with spinal muscular atrophy (SMA): a discrete choice experiment</article-title><source>Orphanet J Rare Dis</source><year>2021</year><volume>16</volume><fpage>36</fpage><pub-id pub-id-type="doi">10.1186/s13023-020-01667-3</pub-id><pub-id pub-id-type="pmid">33472673</pub-id><pub-id pub-id-type="pmcid">PMC7819167</pub-id></element-citation><mixed-citation id="mc-CR119" publication-type="journal">Monnette A, Chen E, Hong D, Bazzano A, Dixon S, Arnold WD, Shi L (2021) Treatment preference among patients with spinal muscular atrophy (SMA): a discrete choice experiment. Orphanet J Rare Dis 16:36. 10.1186/s13023-020-01667-3<pub-id pub-id-type="pmid">33472673</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13023-020-01667-3</pub-id><pub-id pub-id-type="pmcid">PMC7819167</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR120"><label>120.</label><citation-alternatives><element-citation id="ec-CR120" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>CH</given-names></name><name name-style="western"><surname>Finkel</surname><given-names>RS</given-names></name><name name-style="western"><surname>Bertini</surname><given-names>ES</given-names></name><name name-style="western"><surname>Schroth</surname><given-names>M</given-names></name><name name-style="western"><surname>Simonds</surname><given-names>A</given-names></name><name name-style="western"><surname>Wong</surname><given-names>B</given-names></name><name name-style="western"><surname>Aloysius</surname><given-names>A</given-names></name><name name-style="western"><surname>Morrison</surname><given-names>L</given-names></name><name name-style="western"><surname>Main</surname><given-names>M</given-names></name><name name-style="western"><surname>Crawford</surname><given-names>TO</given-names></name><name name-style="western"><surname>Trela</surname><given-names>A</given-names></name><collab>Participants of the International Conference on SMA Standard of Care</collab></person-group><article-title>Consensus statement for standard of care in spinal muscular atrophy</article-title><source>J Child Neurol</source><year>2007</year><volume>22</volume><fpage>1027</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1177/0883073807305788</pub-id><pub-id pub-id-type="pmid">17761659</pub-id></element-citation><mixed-citation id="mc-CR120" publication-type="journal">Wang CH, Finkel RS, Bertini ES, Schroth M, Simonds A, Wong B, Aloysius A, Morrison L, Main M, Crawford TO, Trela A, Participants of the International Conference on SMA Standard of Care (2007) Consensus statement for standard of care in spinal muscular atrophy. J Child Neurol 22:1027&#8211;49. 10.1177/0883073807305788<pub-id pub-id-type="pmid">17761659</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/0883073807305788</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR121"><label>121.</label><citation-alternatives><element-citation id="ec-CR121" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Angeli</surname><given-names>M</given-names></name><name name-style="western"><surname>Alpantaki</surname><given-names>K</given-names></name><name name-style="western"><surname>Pandis</surname><given-names>N</given-names></name><name name-style="western"><surname>Koutserimpas</surname><given-names>C</given-names></name><name name-style="western"><surname>Hadjipavlou</surname><given-names>A</given-names></name></person-group><article-title>The effect of scoliosis surgery on pulmonary function in spinal muscular atrophy patients: review of the literature and a meta-analysis</article-title><source>Eur Spine J</source><year>2022</year><volume>31</volume><fpage>2279</fpage><lpage>2286</lpage><pub-id pub-id-type="doi">10.1007/s00586-022-07182-2</pub-id><pub-id pub-id-type="pmid">35662367</pub-id></element-citation><mixed-citation id="mc-CR121" publication-type="journal">Angeli M, Alpantaki K, Pandis N, Koutserimpas C, Hadjipavlou A (2022) The effect of scoliosis surgery on pulmonary function in spinal muscular atrophy patients: review of the literature and a meta-analysis. Eur Spine J 31:2279&#8211;2286. 10.1007/s00586-022-07182-2<pub-id pub-id-type="pmid">35662367</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00586-022-07182-2</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR122"><label>122.</label><citation-alternatives><element-citation id="ec-CR122" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Konigsberg</surname><given-names>MW</given-names></name><name name-style="western"><surname>Matsumoto</surname><given-names>H</given-names></name><name name-style="western"><surname>Ball</surname><given-names>JR</given-names></name><name name-style="western"><surname>Roye</surname><given-names>BD</given-names></name><name name-style="western"><surname>Vitale</surname><given-names>MG</given-names></name></person-group><article-title>Skip constructs in spinal muscular atrophy: outcomes of a novel approach for posterior spinal instrumentation and fusion</article-title><source>Spine Deform</source><year>2020</year><volume>8</volume><fpage>1093</fpage><lpage>1097</lpage><pub-id pub-id-type="doi">10.1007/s43390-020-00107-3</pub-id><pub-id pub-id-type="pmid">32253736</pub-id></element-citation><mixed-citation id="mc-CR122" publication-type="journal">Konigsberg MW, Matsumoto H, Ball JR, Roye BD, Vitale MG (2020) Skip constructs in spinal muscular atrophy: outcomes of a novel approach for posterior spinal instrumentation and fusion. Spine Deform 8:1093&#8211;1097. 10.1007/s43390-020-00107-3<pub-id pub-id-type="pmid">32253736</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s43390-020-00107-3</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR123"><label>123.</label><citation-alternatives><element-citation id="ec-CR123" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Granata</surname><given-names>C</given-names></name><name name-style="western"><surname>Merlini</surname><given-names>L</given-names></name><name name-style="western"><surname>Bonfiglioli</surname><given-names>S</given-names></name><name name-style="western"><surname>Marini</surname><given-names>ML</given-names></name><name name-style="western"><surname>Cervellati</surname><given-names>S</given-names></name></person-group><article-title>Spine surgery in spinal muscular atrophy: long-term results</article-title><source>Eur Spine J</source><year>1993</year><volume>2</volume><fpage>190</fpage><lpage>197</lpage><pub-id pub-id-type="doi">10.1007/BF00301412</pub-id><pub-id pub-id-type="pmid">8400861</pub-id></element-citation><mixed-citation id="mc-CR123" publication-type="journal">Granata C, Merlini L, Bonfiglioli S, Marini ML, Cervellati S (1993) Spine surgery in spinal muscular atrophy: long-term results. Eur Spine J 2:190&#8211;197. 10.1007/BF00301412<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0960-8966(93)90061-n</pub-id><pub-id pub-id-type="pmid">8400861</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR124"><label>124.</label><citation-alternatives><element-citation id="ec-CR124" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moss</surname><given-names>H</given-names></name><name name-style="western"><surname>Pfeifer</surname><given-names>C</given-names></name><name name-style="western"><surname>Sands</surname><given-names>K</given-names></name><name name-style="western"><surname>Peavey</surname><given-names>J</given-names></name><name name-style="western"><surname>Chin</surname><given-names>I</given-names></name><name name-style="western"><surname>Jin</surname><given-names>P</given-names></name><name name-style="western"><surname>Mbagwu</surname><given-names>M</given-names></name></person-group><article-title>Comparison of adult vs. pediatric patients with spinal muscular atrophy: an axon registry study (P2&#8211;11.006)</article-title><source>Neurology</source><year>2024</year><pub-id pub-id-type="doi">10.1212/WNL.0000000000205560</pub-id></element-citation><mixed-citation id="mc-CR124" publication-type="journal">Moss H, Pfeifer C, Sands K, Peavey J, Chin I, Jin P, Mbagwu M (2024) Comparison of adult vs. pediatric patients with spinal muscular atrophy: an axon registry study (P2&#8211;11.006). Neurology. 10.1212/WNL.0000000000205560</mixed-citation></citation-alternatives></ref><ref id="CR125"><label>125.</label><citation-alternatives><element-citation id="ec-CR125" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schneider</surname><given-names>C</given-names></name><name name-style="western"><surname>Wassermann</surname><given-names>MK</given-names></name><name name-style="western"><surname>Grether</surname><given-names>NB</given-names></name><name name-style="western"><surname>Fink</surname><given-names>GR</given-names></name><name name-style="western"><surname>Wunderlich</surname><given-names>G</given-names></name><name name-style="western"><surname>Lehmann</surname><given-names>HC</given-names></name></person-group><article-title>Motor unit number estimation in adult patients with spinal muscular atrophy treated with nusinersen</article-title><source>Eur J Neurol</source><year>2021</year><volume>28</volume><fpage>3022</fpage><lpage>3029</lpage><pub-id pub-id-type="doi">10.1111/ene.15005</pub-id><pub-id pub-id-type="pmid">34216082</pub-id></element-citation><mixed-citation id="mc-CR125" publication-type="journal">Schneider C, Wassermann MK, Grether NB, Fink GR, Wunderlich G, Lehmann HC (2021) Motor unit number estimation in adult patients with spinal muscular atrophy treated with nusinersen. Eur J Neurol 28:3022&#8211;3029. 10.1111/ene.15005<pub-id pub-id-type="pmid">34216082</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/ene.15005</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR126"><label>126.</label><citation-alternatives><element-citation id="ec-CR126" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vacchiano</surname><given-names>V</given-names></name><name name-style="western"><surname>Morabito</surname><given-names>F</given-names></name><name name-style="western"><surname>Faini</surname><given-names>C</given-names></name><name name-style="western"><surname>Nocera</surname><given-names>G</given-names></name><name name-style="western"><surname>Not</surname><given-names>R</given-names></name><name name-style="western"><surname>Scarpini</surname><given-names>G</given-names></name><name name-style="western"><surname>Romagnoli</surname><given-names>M</given-names></name><name name-style="western"><surname>Pini</surname><given-names>A</given-names></name><name name-style="western"><surname>Liguori</surname><given-names>R</given-names></name></person-group><article-title>Motor unit number estimation via MSCANFIT MUNE in spinal muscular atrophy</article-title><source>Muscle Nerve</source><year>2024</year><volume>70</volume><fpage>71</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1002/mus.28091</pub-id><pub-id pub-id-type="pmid">38549445</pub-id></element-citation><mixed-citation id="mc-CR126" publication-type="journal">Vacchiano V, Morabito F, Faini C, Nocera G, Not R, Scarpini G, Romagnoli M, Pini A, Liguori R (2024) Motor unit number estimation via MSCANFIT MUNE in spinal muscular atrophy. Muscle Nerve 70:71&#8211;81. 10.1002/mus.28091<pub-id pub-id-type="pmid">38549445</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mus.28091</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR127"><label>127.</label><citation-alternatives><element-citation id="ec-CR127" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vacchiano</surname><given-names>V</given-names></name><name name-style="western"><surname>Morabito</surname><given-names>F</given-names></name><name name-style="western"><surname>Bonan</surname><given-names>L</given-names></name><name name-style="western"><surname>Teodorani</surname><given-names>L</given-names></name><name name-style="western"><surname>Faini</surname><given-names>C</given-names></name><name name-style="western"><surname>Rizzo</surname><given-names>G</given-names></name><name name-style="western"><surname>Liguori</surname><given-names>R</given-names></name></person-group><article-title>Reverse split hand as a neurophysiological hallmark of spinal muscular atrophy</article-title><source>J Clin Med</source><year>2024</year><volume>13</volume><fpage>6881</fpage><pub-id pub-id-type="doi">10.3390/jcm13226881</pub-id><pub-id pub-id-type="pmid">39598025</pub-id><pub-id pub-id-type="pmcid">PMC11594792</pub-id></element-citation><mixed-citation id="mc-CR127" publication-type="journal">Vacchiano V, Morabito F, Bonan L, Teodorani L, Faini C, Rizzo G, Liguori R (2024) Reverse split hand as a neurophysiological hallmark of spinal muscular atrophy. J Clin Med 13:6881. 10.3390/jcm13226881<pub-id pub-id-type="pmid">39598025</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/jcm13226881</pub-id><pub-id pub-id-type="pmcid">PMC11594792</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR128"><label>128.</label><citation-alternatives><element-citation id="ec-CR128" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Elsheikh</surname><given-names>B</given-names></name><name name-style="western"><surname>Severyn</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>S</given-names></name><name name-style="western"><surname>Kline</surname><given-names>D</given-names></name><name name-style="western"><surname>Linsenmayer</surname><given-names>M</given-names></name><name name-style="western"><surname>Kelly</surname><given-names>K</given-names></name><name name-style="western"><surname>Tellez</surname><given-names>M</given-names></name><name name-style="western"><surname>Bartlett</surname><given-names>A</given-names></name><name name-style="western"><surname>Heintzman</surname><given-names>S</given-names></name><name name-style="western"><surname>Reynolds</surname><given-names>J</given-names></name><name name-style="western"><surname>Sterling</surname><given-names>G</given-names></name><name name-style="western"><surname>Weaver</surname><given-names>T</given-names></name><name name-style="western"><surname>Rajneesh</surname><given-names>K</given-names></name><name name-style="western"><surname>Kolb</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Arnold</surname><given-names>WD</given-names></name></person-group><article-title>Safety, tolerability, and effect of nusinersen in non-ambulatory adults with spinal muscular atrophy</article-title><source>Front Neurol</source><year>2021</year><volume>12</volume><fpage>650532</fpage><pub-id pub-id-type="doi">10.3389/fneur.2021.650532</pub-id><pub-id pub-id-type="pmid">33935949</pub-id><pub-id pub-id-type="pmcid">PMC8085528</pub-id></element-citation><mixed-citation id="mc-CR128" publication-type="journal">Elsheikh B, Severyn S, Zhao S, Kline D, Linsenmayer M, Kelly K, Tellez M, Bartlett A, Heintzman S, Reynolds J, Sterling G, Weaver T, Rajneesh K, Kolb SJ, Arnold WD (2021) Safety, tolerability, and effect of nusinersen in non-ambulatory adults with spinal muscular atrophy. Front Neurol 12:650532. 10.3389/fneur.2021.650532<pub-id pub-id-type="pmid">33935949</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fneur.2021.650532</pub-id><pub-id pub-id-type="pmcid">PMC8085528</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR129"><label>129.</label><citation-alternatives><element-citation id="ec-CR129" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Elsheikh</surname><given-names>B</given-names></name><name name-style="western"><surname>Severyn</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>S</given-names></name><name name-style="western"><surname>Kline</surname><given-names>D</given-names></name><name name-style="western"><surname>Linsenmayer</surname><given-names>M</given-names></name><name name-style="western"><surname>Kelly</surname><given-names>K</given-names></name><name name-style="western"><surname>Tellez</surname><given-names>M</given-names></name><name name-style="western"><surname>Bartlett</surname><given-names>A</given-names></name><name name-style="western"><surname>Heintzman</surname><given-names>S</given-names></name><name name-style="western"><surname>Reynolds</surname><given-names>J</given-names></name><name name-style="western"><surname>Sterling</surname><given-names>G</given-names></name><name name-style="western"><surname>Weaver</surname><given-names>T</given-names></name><name name-style="western"><surname>Rajneesh</surname><given-names>K</given-names></name><name name-style="western"><surname>Kolb</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Arnold</surname><given-names>WD</given-names></name></person-group><article-title>Safety, tolerability, and effect of nusinersen treatment in ambulatory adults with 5q-SMA</article-title><source>Front Neurol</source><year>2021</year><volume>12</volume><fpage>650535</fpage><pub-id pub-id-type="doi">10.3389/fneur.2021.650535</pub-id><pub-id pub-id-type="pmid">34093395</pub-id><pub-id pub-id-type="pmcid">PMC8174580</pub-id></element-citation><mixed-citation id="mc-CR129" publication-type="journal">Elsheikh B, Severyn S, Zhao S, Kline D, Linsenmayer M, Kelly K, Tellez M, Bartlett A, Heintzman S, Reynolds J, Sterling G, Weaver T, Rajneesh K, Kolb SJ, Arnold WD (2021) Safety, tolerability, and effect of nusinersen treatment in ambulatory adults with 5q-SMA. Front Neurol 12:650535. 10.3389/fneur.2021.650535<pub-id pub-id-type="pmid">34093395</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fneur.2021.650535</pub-id><pub-id pub-id-type="pmcid">PMC8174580</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR130"><label>130.</label><citation-alternatives><element-citation id="ec-CR130" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kessler</surname><given-names>T</given-names></name><name name-style="western"><surname>Sam</surname><given-names>G</given-names></name><name name-style="western"><surname>Wick</surname><given-names>W</given-names></name><name name-style="western"><surname>Weiler</surname><given-names>M</given-names></name></person-group><article-title>Evaluation of risdiplam efficacy in 5q spinal muscular atrophy: a systematic comparison of electrophysiologic with clinical outcome measures</article-title><source>Eur J Neurol</source><year>2024</year><volume>31</volume><fpage>e16099</fpage><pub-id pub-id-type="doi">10.1111/ene.16099</pub-id><pub-id pub-id-type="pmid">37823715</pub-id><pub-id pub-id-type="pmcid">PMC11235981</pub-id></element-citation><mixed-citation id="mc-CR130" publication-type="journal">Kessler T, Sam G, Wick W, Weiler M (2024) Evaluation of risdiplam efficacy in 5q spinal muscular atrophy: a systematic comparison of electrophysiologic with clinical outcome measures. Eur J Neurol 31:e16099. 10.1111/ene.16099<pub-id pub-id-type="pmid">37823715</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/ene.16099</pub-id><pub-id pub-id-type="pmcid">PMC11235981</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR131"><label>131.</label><citation-alternatives><element-citation id="ec-CR131" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>G&#252;nther</surname><given-names>R</given-names></name><name name-style="western"><surname>Neuwirth</surname><given-names>C</given-names></name><name name-style="western"><surname>Koch</surname><given-names>JC</given-names></name><name name-style="western"><surname>Lingor</surname><given-names>P</given-names></name><name name-style="western"><surname>Braun</surname><given-names>N</given-names></name><name name-style="western"><surname>Untucht</surname><given-names>R</given-names></name><name name-style="western"><surname>Petzold</surname><given-names>D</given-names></name><name name-style="western"><surname>Weber</surname><given-names>M</given-names></name><name name-style="western"><surname>Hermann</surname><given-names>A</given-names></name></person-group><article-title>Motor unit number index (MUNIX) of hand muscles is a disease biomarker for adult spinal muscular atrophy</article-title><source>Clin Neurophysiol</source><year>2019</year><volume>130</volume><fpage>315</fpage><lpage>319</lpage><pub-id pub-id-type="doi">10.1016/j.clinph.2018.11.009</pub-id><pub-id pub-id-type="pmid">30528741</pub-id></element-citation><mixed-citation id="mc-CR131" publication-type="journal">G&#252;nther R, Neuwirth C, Koch JC, Lingor P, Braun N, Untucht R, Petzold D, Weber M, Hermann A (2019) Motor unit number index (MUNIX) of hand muscles is a disease biomarker for adult spinal muscular atrophy. Clin Neurophysiol 130:315&#8211;319. 10.1016/j.clinph.2018.11.009<pub-id pub-id-type="pmid">30528741</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.clinph.2018.11.009</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR132"><label>132.</label><citation-alternatives><element-citation id="ec-CR132" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Querin</surname><given-names>G</given-names></name><name name-style="western"><surname>Lenglet</surname><given-names>T</given-names></name><name name-style="western"><surname>Debs</surname><given-names>R</given-names></name><name name-style="western"><surname>Stojkovic</surname><given-names>T</given-names></name><name name-style="western"><surname>Behin</surname><given-names>A</given-names></name><name name-style="western"><surname>Salachas</surname><given-names>F</given-names></name><name name-style="western"><surname>Le Forestier</surname><given-names>N</given-names></name><name name-style="western"><surname>Amador</surname><given-names>MDM</given-names></name><name name-style="western"><surname>Lacomblez</surname><given-names>L</given-names></name><name name-style="western"><surname>Meininger</surname><given-names>V</given-names></name><name name-style="western"><surname>Bruneteau</surname><given-names>G</given-names></name><name name-style="western"><surname>Lafor&#234;t</surname><given-names>P</given-names></name><name name-style="western"><surname>Blancho</surname><given-names>S</given-names></name><name name-style="western"><surname>Marchand-Pauvert</surname><given-names>V</given-names></name><name name-style="western"><surname>Bede</surname><given-names>P</given-names></name><name name-style="western"><surname>Hogrel</surname><given-names>JY</given-names></name><name name-style="western"><surname>Pradat</surname><given-names>PF</given-names></name></person-group><article-title>The motor unit number index (MUNIX) profile of patients with adult spinal muscular atrophy</article-title><source>Clin Neurophysiol</source><year>2018</year><volume>129</volume><fpage>2333</fpage><lpage>2340</lpage><pub-id pub-id-type="doi">10.1016/j.clinph.2018.08.025</pub-id><pub-id pub-id-type="pmid">30248623</pub-id></element-citation><mixed-citation id="mc-CR132" publication-type="journal">Querin G, Lenglet T, Debs R, Stojkovic T, Behin A, Salachas F, Le Forestier N, Amador MDM, Lacomblez L, Meininger V, Bruneteau G, Lafor&#234;t P, Blancho S, Marchand-Pauvert V, Bede P, Hogrel JY, Pradat PF (2018) The motor unit number index (MUNIX) profile of patients with adult spinal muscular atrophy. Clin Neurophysiol 129:2333&#8211;2340. 10.1016/j.clinph.2018.08.025<pub-id pub-id-type="pmid">30248623</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.clinph.2018.08.025</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR133"><label>133.</label><citation-alternatives><element-citation id="ec-CR133" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barp</surname><given-names>A</given-names></name><name name-style="western"><surname>Carraro</surname><given-names>E</given-names></name><name name-style="western"><surname>Salmin</surname><given-names>F</given-names></name><name name-style="western"><surname>Lizio</surname><given-names>A</given-names></name><name name-style="western"><surname>Cheli</surname><given-names>M</given-names></name><name name-style="western"><surname>Sansone</surname><given-names>V</given-names></name></person-group><article-title>Facial nerve vulnerability in spinal muscular atrophy and motor unit number index of the orbicularis oculi muscle</article-title><source>Muscle Nerve</source><year>2023</year><volume>67</volume><fpage>401</fpage><lpage>406</lpage><pub-id pub-id-type="doi">10.1002/mus.27809</pub-id><pub-id pub-id-type="pmid">36861214</pub-id></element-citation><mixed-citation id="mc-CR133" publication-type="journal">Barp A, Carraro E, Salmin F, Lizio A, Cheli M, Sansone V (2023) Facial nerve vulnerability in spinal muscular atrophy and motor unit number index of the orbicularis oculi muscle. Muscle Nerve 67:401&#8211;406. 10.1002/mus.27809<pub-id pub-id-type="pmid">36861214</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mus.27809</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR134"><label>134.</label><citation-alternatives><element-citation id="ec-CR134" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Otto</surname><given-names>LAM</given-names></name><name name-style="western"><surname>Van Der Pol</surname><given-names>W</given-names></name><name name-style="western"><surname>Schlaffke</surname><given-names>L</given-names></name><name name-style="western"><surname>Wijngaarde</surname><given-names>CA</given-names></name><name name-style="western"><surname>Stam</surname><given-names>M</given-names></name><name name-style="western"><surname>Wadman</surname><given-names>RI</given-names></name><name name-style="western"><surname>Cuppen</surname><given-names>I</given-names></name><name name-style="western"><surname>Van Eijk</surname><given-names>RPA</given-names></name><name name-style="western"><surname>Asselman</surname><given-names>F</given-names></name><name name-style="western"><surname>Bartels</surname><given-names>B</given-names></name><name name-style="western"><surname>Van Der Woude</surname><given-names>D</given-names></name><name name-style="western"><surname>Hendrikse</surname><given-names>J</given-names></name><name name-style="western"><surname>Froeling</surname><given-names>M</given-names></name></person-group><article-title>Quantitative MRI of skeletal muscle in a cross-sectional cohort of patients with spinal muscular atrophy types 2 and 3</article-title><source>NMR Biomed</source><year>2020</year><volume>33</volume><fpage>e4357</fpage><pub-id pub-id-type="doi">10.1002/nbm.4357</pub-id><pub-id pub-id-type="pmid">32681555</pub-id><pub-id pub-id-type="pmcid">PMC7507182</pub-id></element-citation><mixed-citation id="mc-CR134" publication-type="journal">Otto LAM, Van Der Pol W, Schlaffke L, Wijngaarde CA, Stam M, Wadman RI, Cuppen I, Van Eijk RPA, Asselman F, Bartels B, Van Der Woude D, Hendrikse J, Froeling M (2020) Quantitative MRI of skeletal muscle in a cross-sectional cohort of patients with spinal muscular atrophy types 2 and 3. NMR Biomed 33:e4357. 10.1002/nbm.4357<pub-id pub-id-type="pmid">32681555</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/nbm.4357</pub-id><pub-id pub-id-type="pmcid">PMC7507182</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR135"><label>135.</label><citation-alternatives><element-citation id="ec-CR135" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Otto</surname><given-names>LAM</given-names></name><name name-style="western"><surname>Froeling</surname><given-names>M</given-names></name><name name-style="western"><surname>Van Eijk</surname><given-names>RPA</given-names></name><name name-style="western"><surname>Asselman</surname><given-names>F</given-names></name><name name-style="western"><surname>Wadman</surname><given-names>R</given-names></name><name name-style="western"><surname>Cuppen</surname><given-names>I</given-names></name><name name-style="western"><surname>Hendrikse</surname><given-names>J</given-names></name><name name-style="western"><surname>Van Der Pol</surname><given-names>W</given-names></name></person-group><article-title>Quantification of disease progression in spinal muscular atrophy with muscle MRI-a pilot study</article-title><source>NMR Biomed</source><year>2021</year><volume>34</volume><fpage>e4473</fpage><pub-id pub-id-type="doi">10.1002/nbm.4473</pub-id><pub-id pub-id-type="pmid">33480130</pub-id><pub-id pub-id-type="pmcid">PMC7988555</pub-id></element-citation><mixed-citation id="mc-CR135" publication-type="journal">Otto LAM, Froeling M, Van Eijk RPA, Asselman F, Wadman R, Cuppen I, Hendrikse J, Van Der Pol W (2021) Quantification of disease progression in spinal muscular atrophy with muscle MRI-a pilot study. NMR Biomed 34:e4473. 10.1002/nbm.4473<pub-id pub-id-type="pmid">33480130</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/nbm.4473</pub-id><pub-id pub-id-type="pmcid">PMC7988555</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR136"><label>136.</label><citation-alternatives><element-citation id="ec-CR136" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hooijmans</surname><given-names>MT</given-names></name><name name-style="western"><surname>Habets</surname><given-names>LE</given-names></name><name name-style="western"><surname>Van Den Berg-Faay</surname><given-names>SAM</given-names></name><name name-style="western"><surname>Froeling</surname><given-names>M</given-names></name><name name-style="western"><surname>Asselman</surname><given-names>F</given-names></name><name name-style="western"><surname>Strijkers</surname><given-names>GJ</given-names></name><name name-style="western"><surname>Jeneson</surname><given-names>JAL</given-names></name><name name-style="western"><surname>Bartels</surname><given-names>B</given-names></name><name name-style="western"><surname>Nederveen</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Van Der Pol</surname><given-names>WL</given-names></name></person-group><article-title>Multi-parametric quantitative magnetic resonance imaging of the upper arm muscles of patients with spinal muscular atrophy</article-title><source>NMR Biomed</source><year>2022</year><volume>35</volume><fpage>e4696</fpage><pub-id pub-id-type="doi">10.1002/nbm.4696</pub-id><pub-id pub-id-type="pmid">35052014</pub-id><pub-id pub-id-type="pmcid">PMC9286498</pub-id></element-citation><mixed-citation id="mc-CR136" publication-type="journal">Hooijmans MT, Habets LE, Van Den Berg-Faay SAM, Froeling M, Asselman F, Strijkers GJ, Jeneson JAL, Bartels B, Nederveen AJ, Van Der Pol WL (2022) Multi-parametric quantitative magnetic resonance imaging of the upper arm muscles of patients with spinal muscular atrophy. NMR Biomed 35:e4696. 10.1002/nbm.4696<pub-id pub-id-type="pmid">35052014</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/nbm.4696</pub-id><pub-id pub-id-type="pmcid">PMC9286498</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR137"><label>137.</label><citation-alternatives><element-citation id="ec-CR137" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Durmus</surname><given-names>H</given-names></name><name name-style="western"><surname>Yilmaz</surname><given-names>R</given-names></name><name name-style="western"><surname>Gulsen-Parman</surname><given-names>Y</given-names></name><name name-style="western"><surname>Oflazer-Serdaroglu</surname><given-names>P</given-names></name><name name-style="western"><surname>Cuttini</surname><given-names>M</given-names></name><name name-style="western"><surname>Dursun</surname><given-names>M</given-names></name><name name-style="western"><surname>Deymeer</surname><given-names>F</given-names></name></person-group><article-title>Muscle magnetic resonance imaging in spinal muscular atrophy type 3: selective and progressive involvement</article-title><source>Muscle Nerve</source><year>2017</year><volume>55</volume><fpage>651</fpage><lpage>656</lpage><pub-id pub-id-type="doi">10.1002/mus.25385</pub-id><pub-id pub-id-type="pmid">27543937</pub-id></element-citation><mixed-citation id="mc-CR137" publication-type="journal">Durmus H, Yilmaz R, Gulsen-Parman Y, Oflazer-Serdaroglu P, Cuttini M, Dursun M, Deymeer F (2017) Muscle magnetic resonance imaging in spinal muscular atrophy type 3: selective and progressive involvement. Muscle Nerve 55:651&#8211;656. 10.1002/mus.25385<pub-id pub-id-type="pmid">27543937</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mus.25385</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR138"><label>138.</label><citation-alternatives><element-citation id="ec-CR138" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barp</surname><given-names>A</given-names></name><name name-style="western"><surname>Carraro</surname><given-names>E</given-names></name><name name-style="western"><surname>Albamonte</surname><given-names>E</given-names></name><name name-style="western"><surname>Salmin</surname><given-names>F</given-names></name><name name-style="western"><surname>Lunetta</surname><given-names>C</given-names></name><name name-style="western"><surname>Comi</surname><given-names>GP</given-names></name><name name-style="western"><surname>Messina</surname><given-names>C</given-names></name><name name-style="western"><surname>Albano</surname><given-names>D</given-names></name><name name-style="western"><surname>Chianca</surname><given-names>V</given-names></name><name name-style="western"><surname>Sconfienza</surname><given-names>LM</given-names></name><name name-style="western"><surname>Mercuri</surname><given-names>EM</given-names></name><name name-style="western"><surname>Sansone</surname><given-names>VA</given-names></name></person-group><article-title>Muscle MRI in two SMA patients on nusinersen treatment: a two years follow-up</article-title><source>J Neurol Sci</source><year>2020</year><volume>417</volume><fpage>117067</fpage><pub-id pub-id-type="doi">10.1016/j.jns.2020.117067</pub-id><pub-id pub-id-type="pmid">32745721</pub-id><pub-id pub-id-type="pmcid">PMC7388822</pub-id></element-citation><mixed-citation id="mc-CR138" publication-type="journal">Barp A, Carraro E, Albamonte E, Salmin F, Lunetta C, Comi GP, Messina C, Albano D, Chianca V, Sconfienza LM, Mercuri EM, Sansone VA (2020) Muscle MRI in two SMA patients on nusinersen treatment: a two years follow-up. J Neurol Sci 417:117067. 10.1016/j.jns.2020.117067<pub-id pub-id-type="pmid">32745721</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jns.2020.117067</pub-id><pub-id pub-id-type="pmcid">PMC7388822</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR139"><label>139.</label><citation-alternatives><element-citation id="ec-CR139" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gallone</surname><given-names>A</given-names></name><name name-style="western"><surname>Mazzi</surname><given-names>F</given-names></name><name name-style="western"><surname>Bonanno</surname><given-names>S</given-names></name><name name-style="western"><surname>Zanin</surname><given-names>R</given-names></name><name name-style="western"><surname>Moscatelli</surname><given-names>M</given-names></name><name name-style="western"><surname>Aquino</surname><given-names>D</given-names></name><name name-style="western"><surname>Maggi</surname><given-names>L</given-names></name></person-group><article-title>Muscle quantitative MRI in adult SMA patients on nusinersen treatment: a longitudinal study</article-title><source>Acta Myol</source><year>2022</year><volume>41</volume><fpage>76</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.36185/2532-1900-074</pub-id><pub-id pub-id-type="pmid">35832502</pub-id><pub-id pub-id-type="pmcid">PMC9237750</pub-id></element-citation><mixed-citation id="mc-CR139" publication-type="journal">Gallone A, Mazzi F, Bonanno S, Zanin R, Moscatelli M, Aquino D, Maggi L (2022) Muscle quantitative MRI in adult SMA patients on nusinersen treatment: a longitudinal study. Acta Myol 41:76&#8211;83. 10.36185/2532-1900-074<pub-id pub-id-type="pmid">35832502</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.36185/2532-1900-074</pub-id><pub-id pub-id-type="pmcid">PMC9237750</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR140"><label>140.</label><citation-alternatives><element-citation id="ec-CR140" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pelosi</surname><given-names>L</given-names></name><name name-style="western"><surname>Rodrigues</surname><given-names>M</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>C</given-names></name><name name-style="western"><surname>Patel</surname><given-names>S</given-names></name><name name-style="western"><surname>Roxburgh</surname><given-names>R</given-names></name></person-group><article-title>Quantitative muscle ultrasound in adult spinal muscular atrophy: a pilot study</article-title><source>Muscle Nerve</source><year>2024</year><volume>69</volume><fpage>349</fpage><lpage>353</lpage><pub-id pub-id-type="doi">10.1002/mus.28034</pub-id><pub-id pub-id-type="pmid">38158390</pub-id></element-citation><mixed-citation id="mc-CR140" publication-type="journal">Pelosi L, Rodrigues M, Zhong C, Patel S, Roxburgh R (2024) Quantitative muscle ultrasound in adult spinal muscular atrophy: a pilot study. Muscle Nerve 69:349&#8211;353. 10.1002/mus.28034<pub-id pub-id-type="pmid">38158390</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mus.28034</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR141"><label>141.</label><citation-alternatives><element-citation id="ec-CR141" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rich</surname><given-names>KA</given-names></name><name name-style="western"><surname>Fox</surname><given-names>A</given-names></name><name name-style="western"><surname>Yalvac</surname><given-names>M</given-names></name><name name-style="western"><surname>Heintzman</surname><given-names>S</given-names></name><name name-style="western"><surname>Tellez</surname><given-names>M</given-names></name><name name-style="western"><surname>Bartlett</surname><given-names>A</given-names></name><name name-style="western"><surname>Severyn</surname><given-names>S</given-names></name><name name-style="western"><surname>Linsenmayer</surname><given-names>M</given-names></name><name name-style="western"><surname>Kelly</surname><given-names>K</given-names></name><name name-style="western"><surname>Reynolds</surname><given-names>J</given-names></name><name name-style="western"><surname>Sterling</surname><given-names>GB</given-names></name><name name-style="western"><surname>Weaver</surname><given-names>T</given-names></name><name name-style="western"><surname>Rajneesh</surname><given-names>K</given-names></name><name name-style="western"><surname>Pino</surname><given-names>MG</given-names></name><name name-style="western"><surname>Arnold</surname><given-names>WD</given-names></name><name name-style="western"><surname>Elsheikh</surname><given-names>B</given-names></name><name name-style="western"><surname>Kolb</surname><given-names>SJ</given-names></name></person-group><article-title>Neurofilament levels in CSF and serum in an adult SMA cohort treated with nusinersen</article-title><source>J Neuromuscul Dis</source><year>2022</year><volume>9</volume><fpage>111</fpage><lpage>119</lpage><pub-id pub-id-type="doi">10.3233/JND-210735</pub-id><pub-id pub-id-type="pmid">34776417</pub-id></element-citation><mixed-citation id="mc-CR141" publication-type="journal">Rich KA, Fox A, Yalvac M, Heintzman S, Tellez M, Bartlett A, Severyn S, Linsenmayer M, Kelly K, Reynolds J, Sterling GB, Weaver T, Rajneesh K, Pino MG, Arnold WD, Elsheikh B, Kolb SJ (2022) Neurofilament levels in CSF and serum in an adult SMA cohort treated with nusinersen. J Neuromuscul Dis 9:111&#8211;119. 10.3233/JND-210735<pub-id pub-id-type="pmid">34776417</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JND-210735</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR142"><label>142.</label><citation-alternatives><element-citation id="ec-CR142" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wurster</surname><given-names>CD</given-names></name><name name-style="western"><surname>G&#252;nther</surname><given-names>R</given-names></name><name name-style="western"><surname>Steinacker</surname><given-names>P</given-names></name><name name-style="western"><surname>Dreyhaupt</surname><given-names>J</given-names></name><name name-style="western"><surname>Wollinsky</surname><given-names>K</given-names></name><name name-style="western"><surname>Uzelac</surname><given-names>Z</given-names></name><name name-style="western"><surname>Witzel</surname><given-names>S</given-names></name><name name-style="western"><surname>Kocak</surname><given-names>T</given-names></name><name name-style="western"><surname>Winter</surname><given-names>B</given-names></name><name name-style="western"><surname>Koch</surname><given-names>JC</given-names></name><name name-style="western"><surname>Lingor</surname><given-names>P</given-names></name><name name-style="western"><surname>Petri</surname><given-names>S</given-names></name><name name-style="western"><surname>Ludolph</surname><given-names>AC</given-names></name><name name-style="western"><surname>Hermann</surname><given-names>A</given-names></name><name name-style="western"><surname>Otto</surname><given-names>M</given-names></name></person-group><article-title>Neurochemical markers in CSF of adolescent and adult SMA patients undergoing nusinersen treatment</article-title><source>Ther Adv Neurol Disord</source><year>2019</year><volume>12</volume><fpage>1756286419846058</fpage><pub-id pub-id-type="doi">10.1177/1756286419846058</pub-id><pub-id pub-id-type="pmid">31205491</pub-id><pub-id pub-id-type="pmcid">PMC6535708</pub-id></element-citation><mixed-citation id="mc-CR142" publication-type="journal">Wurster CD, G&#252;nther R, Steinacker P, Dreyhaupt J, Wollinsky K, Uzelac Z, Witzel S, Kocak T, Winter B, Koch JC, Lingor P, Petri S, Ludolph AC, Hermann A, Otto M (2019) Neurochemical markers in CSF of adolescent and adult SMA patients undergoing nusinersen treatment. Ther Adv Neurol Disord 12:1756286419846058. 10.1177/1756286419846058<pub-id pub-id-type="pmid">31205491</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/1756286419846058</pub-id><pub-id pub-id-type="pmcid">PMC6535708</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR143"><label>143.</label><citation-alternatives><element-citation id="ec-CR143" publication-type="journal"><person-group person-group-type="author"><collab>The MND-Net</collab><name name-style="western"><surname>Wurster</surname><given-names>CD</given-names></name><name name-style="western"><surname>Steinacker</surname><given-names>P</given-names></name><name name-style="western"><surname>G&#252;nther</surname><given-names>R</given-names></name><name name-style="western"><surname>Koch</surname><given-names>JC</given-names></name><name name-style="western"><surname>Lingor</surname><given-names>P</given-names></name><name name-style="western"><surname>Uzelac</surname><given-names>Z</given-names></name><name name-style="western"><surname>Witzel</surname><given-names>S</given-names></name><name name-style="western"><surname>Wollinsky</surname><given-names>K</given-names></name><name name-style="western"><surname>Winter</surname><given-names>B</given-names></name><name name-style="western"><surname>Osmanovic</surname><given-names>A</given-names></name><name name-style="western"><surname>Schreiber-Katz</surname><given-names>O</given-names></name><name name-style="western"><surname>Al Shweiki</surname><given-names>R</given-names></name><name name-style="western"><surname>Ludolph</surname><given-names>AC</given-names></name><name name-style="western"><surname>Petri</surname><given-names>S</given-names></name><name name-style="western"><surname>Hermann</surname><given-names>A</given-names></name><name name-style="western"><surname>Otto</surname><given-names>M</given-names></name></person-group><article-title>Neurofilament light chain in serum of adolescent and adult SMA patients under treatment with nusinersen</article-title><source>J Neurol</source><year>2020</year><volume>267</volume><fpage>36</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1007/s00415-019-09547-y</pub-id><pub-id pub-id-type="pmid">31552549</pub-id></element-citation><mixed-citation id="mc-CR143" publication-type="journal">The MND-Net, Wurster CD, Steinacker P, G&#252;nther R, Koch JC, Lingor P, Uzelac Z, Witzel S, Wollinsky K, Winter B, Osmanovic A, Schreiber-Katz O, Al Shweiki R, Ludolph AC, Petri S, Hermann A, Otto M (2020) Neurofilament light chain in serum of adolescent and adult SMA patients under treatment with nusinersen. J Neurol 267:36&#8211;44. 10.1007/s00415-019-09547-y<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00415-019-09547-y</pub-id><pub-id pub-id-type="pmid">31552549</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR144"><label>144.</label><citation-alternatives><element-citation id="ec-CR144" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Faravelli</surname><given-names>I</given-names></name><name name-style="western"><surname>Meneri</surname><given-names>M</given-names></name><name name-style="western"><surname>Saccomanno</surname><given-names>D</given-names></name><name name-style="western"><surname>Velardo</surname><given-names>D</given-names></name><name name-style="western"><surname>Abati</surname><given-names>E</given-names></name><name name-style="western"><surname>Gagliardi</surname><given-names>D</given-names></name><name name-style="western"><surname>Parente</surname><given-names>V</given-names></name><name name-style="western"><surname>Petrozzi</surname><given-names>L</given-names></name><name name-style="western"><surname>Ronchi</surname><given-names>D</given-names></name><name name-style="western"><surname>Stocchetti</surname><given-names>N</given-names></name><name name-style="western"><surname>Calderini</surname><given-names>E</given-names></name><name name-style="western"><surname>D'Angelo</surname><given-names>G</given-names></name><name name-style="western"><surname>Chidini</surname><given-names>G</given-names></name><name name-style="western"><surname>Prandi</surname><given-names>E</given-names></name><name name-style="western"><surname>Ricci</surname><given-names>G</given-names></name><name name-style="western"><surname>Siciliano</surname><given-names>G</given-names></name><name name-style="western"><surname>Bresolin</surname><given-names>N</given-names></name><name name-style="western"><surname>Comi</surname><given-names>GP</given-names></name><name name-style="western"><surname>Corti</surname><given-names>S</given-names></name><name name-style="western"><surname>Magri</surname><given-names>F</given-names></name><etal/></person-group><article-title>Nusinersen treatment and cerebrospinal fluid neurofilaments: An explorative study on spinal muscular atrophy type 3 patients</article-title><source>J Cell Mol Med</source><year>2020</year><volume>24</volume><fpage>3034</fpage><lpage>3039</lpage><pub-id pub-id-type="doi">10.1111/jcmm.14939</pub-id><pub-id pub-id-type="pmid">32032473</pub-id><pub-id pub-id-type="pmcid">PMC7077557</pub-id></element-citation><mixed-citation id="mc-CR144" publication-type="journal">Faravelli I, Meneri M, Saccomanno D, Velardo D, Abati E, Gagliardi D, Parente V, Petrozzi L, Ronchi D, Stocchetti N, Calderini E, D&#8217;Angelo G, Chidini G, Prandi E, Ricci G, Siciliano G, Bresolin N, Comi GP, Corti S, Magri F et al (2020) Nusinersen treatment and cerebrospinal fluid neurofilaments: An explorative study on spinal muscular atrophy type 3 patients. J Cell Mol Med 24:3034&#8211;3039. 10.1111/jcmm.14939<pub-id pub-id-type="pmid">32032473</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jcmm.14939</pub-id><pub-id pub-id-type="pmcid">PMC7077557</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR145"><label>145.</label><citation-alternatives><element-citation id="ec-CR145" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Totzeck</surname><given-names>A</given-names></name><name name-style="western"><surname>Stolte</surname><given-names>B</given-names></name><name name-style="western"><surname>Kizina</surname><given-names>K</given-names></name><name name-style="western"><surname>Bolz</surname><given-names>S</given-names></name><name name-style="western"><surname>Schlag</surname><given-names>M</given-names></name><name name-style="western"><surname>Thimm</surname><given-names>A</given-names></name><name name-style="western"><surname>Kleinschnitz</surname><given-names>C</given-names></name><name name-style="western"><surname>Hagenacker</surname><given-names>T</given-names></name></person-group><article-title>Neurofilament heavy chain and tau protein are not elevated in cerebrospinal fluid of adult patients with spinal muscular atrophy during loading with nusinersen</article-title><source>Int J Mol Sci</source><year>2019</year><volume>20</volume><fpage>5397</fpage><pub-id pub-id-type="doi">10.3390/ijms20215397</pub-id><pub-id pub-id-type="pmid">31671515</pub-id><pub-id pub-id-type="pmcid">PMC6862027</pub-id></element-citation><mixed-citation id="mc-CR145" publication-type="journal">Totzeck A, Stolte B, Kizina K, Bolz S, Schlag M, Thimm A, Kleinschnitz C, Hagenacker T (2019) Neurofilament heavy chain and tau protein are not elevated in cerebrospinal fluid of adult patients with spinal muscular atrophy during loading with nusinersen. Int J Mol Sci 20:5397. 10.3390/ijms20215397<pub-id pub-id-type="pmid">31671515</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms20215397</pub-id><pub-id pub-id-type="pmcid">PMC6862027</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR146"><label>146.</label><citation-alternatives><element-citation id="ec-CR146" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Andr&#233;s-Benito</surname><given-names>P</given-names></name><name name-style="western"><surname>V&#225;zquez-Costa</surname><given-names>JF</given-names></name><name name-style="western"><surname>&#209;ungo Garz&#243;n</surname><given-names>NC</given-names></name><name name-style="western"><surname>Colomina</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Marco</surname><given-names>C</given-names></name><name name-style="western"><surname>Gonz&#225;lez</surname><given-names>L</given-names></name><name name-style="western"><surname>Terrafeta</surname><given-names>C</given-names></name><name name-style="western"><surname>Dom&#237;nguez</surname><given-names>R</given-names></name><name name-style="western"><surname>Ferrer</surname><given-names>I</given-names></name><name name-style="western"><surname>Povedano</surname><given-names>M</given-names></name></person-group><article-title>Neurodegeneration biomarkers in adult spinal muscular atrophy (SMA) patients treated with nusinersen</article-title><source>Int J Mol Sci</source><year>2024</year><volume>25</volume><fpage>3810</fpage><pub-id pub-id-type="doi">10.3390/ijms25073810</pub-id><pub-id pub-id-type="pmid">38612621</pub-id><pub-id pub-id-type="pmcid">PMC11011665</pub-id></element-citation><mixed-citation id="mc-CR146" publication-type="journal">Andr&#233;s-Benito P, V&#225;zquez-Costa JF, &#209;ungo Garz&#243;n NC, Colomina MJ, Marco C, Gonz&#225;lez L, Terrafeta C, Dom&#237;nguez R, Ferrer I, Povedano M (2024) Neurodegeneration biomarkers in adult spinal muscular atrophy (SMA) patients treated with nusinersen. Int J Mol Sci 25:3810. 10.3390/ijms25073810<pub-id pub-id-type="pmid">38612621</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms25073810</pub-id><pub-id pub-id-type="pmcid">PMC11011665</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR147"><label>147.</label><citation-alternatives><element-citation id="ec-CR147" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Milella</surname><given-names>G</given-names></name><name name-style="western"><surname>Introna</surname><given-names>A</given-names></name><name name-style="western"><surname>D'Errico</surname><given-names>E</given-names></name><name name-style="western"><surname>Fraddosio</surname><given-names>A</given-names></name><name name-style="western"><surname>Scaglione</surname><given-names>G</given-names></name><name name-style="western"><surname>Morea</surname><given-names>A</given-names></name><name name-style="western"><surname>Ucci</surname><given-names>M</given-names></name><name name-style="western"><surname>Ruggieri</surname><given-names>M</given-names></name><name name-style="western"><surname>Mastrapasqua</surname><given-names>M</given-names></name><name name-style="western"><surname>Megna</surname><given-names>M</given-names></name><name name-style="western"><surname>Puntillo</surname><given-names>F</given-names></name><name name-style="western"><surname>Simone</surname><given-names>IL</given-names></name></person-group><article-title>Cerebrospinal fluid and clinical profiles in adult type 2&#8211;3 spinal muscular atrophy patients treated with nusinersen: an 18-month single-centre experience</article-title><source>Clin Drug Investig</source><year>2021</year><volume>41</volume><fpage>775</fpage><lpage>784</lpage><pub-id pub-id-type="doi">10.1007/s40261-021-01071-0</pub-id><pub-id pub-id-type="pmid">34389971</pub-id><pub-id pub-id-type="pmcid">PMC8390404</pub-id></element-citation><mixed-citation id="mc-CR147" publication-type="journal">Milella G, Introna A, D&#8217;Errico E, Fraddosio A, Scaglione G, Morea A, Ucci M, Ruggieri M, Mastrapasqua M, Megna M, Puntillo F, Simone IL (2021) Cerebrospinal fluid and clinical profiles in adult type 2&#8211;3 spinal muscular atrophy patients treated with nusinersen: an 18-month single-centre experience. Clin Drug Investig 41:775&#8211;784. 10.1007/s40261-021-01071-0<pub-id pub-id-type="pmid">34389971</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40261-021-01071-0</pub-id><pub-id pub-id-type="pmcid">PMC8390404</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR148"><label>148.</label><citation-alternatives><element-citation id="ec-CR148" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cordts</surname><given-names>I</given-names></name><name name-style="western"><surname>Fuetterer</surname><given-names>C</given-names></name><name name-style="western"><surname>Wachinger</surname><given-names>A</given-names></name><name name-style="western"><surname>Von Heynitz</surname><given-names>R</given-names></name><name name-style="western"><surname>Kessler</surname><given-names>T</given-names></name><name name-style="western"><surname>Freigang</surname><given-names>M</given-names></name><name name-style="western"><surname>Quinten</surname><given-names>AL</given-names></name><name name-style="western"><surname>Bjelica</surname><given-names>B</given-names></name><name name-style="western"><surname>Brakemeier</surname><given-names>S</given-names></name><name name-style="western"><surname>Hobbiebrunken</surname><given-names>E</given-names></name><name name-style="western"><surname>Hagenacker</surname><given-names>T</given-names></name><name name-style="western"><surname>Petri</surname><given-names>S</given-names></name><name name-style="western"><surname>Koch</surname><given-names>JC</given-names></name><name name-style="western"><surname>Hahn</surname><given-names>A</given-names></name><name name-style="western"><surname>Lingor</surname><given-names>P</given-names></name><name name-style="western"><surname>Deschauer</surname><given-names>M</given-names></name><name name-style="western"><surname>G&#252;nther</surname><given-names>R</given-names></name><name name-style="western"><surname>Weiler</surname><given-names>M</given-names></name><name name-style="western"><surname>Haller</surname><given-names>B</given-names></name><name name-style="western"><surname>Feneberg</surname><given-names>E</given-names></name></person-group><article-title>Long-term dynamics of CSF and serum neurofilament light chain in adult patients with 5q spinal muscular atrophy treated with nusinersen</article-title><source>Neurology</source><year>2025</year><volume>104</volume><fpage>e213371</fpage><pub-id pub-id-type="doi">10.1212/WNL.0000000000213371</pub-id><pub-id pub-id-type="pmid">39946662</pub-id><pub-id pub-id-type="pmcid">PMC11837849</pub-id></element-citation><mixed-citation id="mc-CR148" publication-type="journal">Cordts I, Fuetterer C, Wachinger A, Von Heynitz R, Kessler T, Freigang M, Quinten AL, Bjelica B, Brakemeier S, Hobbiebrunken E, Hagenacker T, Petri S, Koch JC, Hahn A, Lingor P, Deschauer M, G&#252;nther R, Weiler M, Haller B, Feneberg E (2025) Long-term dynamics of CSF and serum neurofilament light chain in adult patients with 5q spinal muscular atrophy treated with nusinersen. Neurology 104:e213371. 10.1212/WNL.0000000000213371<pub-id pub-id-type="pmid">39946662</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0000000000213371</pub-id><pub-id pub-id-type="pmcid">PMC11837849</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR149"><label>149.</label><citation-alternatives><element-citation id="ec-CR149" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sumner</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Kolb</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Harmison</surname><given-names>GG</given-names></name><name name-style="western"><surname>Jeffries</surname><given-names>NO</given-names></name><name name-style="western"><surname>Schadt</surname><given-names>K</given-names></name><name name-style="western"><surname>Finkel</surname><given-names>RS</given-names></name><name name-style="western"><surname>Dreyfuss</surname><given-names>G</given-names></name><name name-style="western"><surname>Fischbeck</surname><given-names>KH</given-names></name></person-group><article-title>SMN mRNA and protein levels in peripheral blood: biomarkers for SMA clinical trials</article-title><source>Neurology</source><year>2006</year><volume>66</volume><fpage>1067</fpage><lpage>1073</lpage><pub-id pub-id-type="doi">10.1212/01.wnl.0000201929.56928.13</pub-id><pub-id pub-id-type="pmid">16481599</pub-id></element-citation><mixed-citation id="mc-CR149" publication-type="journal">Sumner CJ, Kolb SJ, Harmison GG, Jeffries NO, Schadt K, Finkel RS, Dreyfuss G, Fischbeck KH (2006) SMN mRNA and protein levels in peripheral blood: biomarkers for SMA clinical trials. Neurology 66:1067&#8211;1073. 10.1212/01.wnl.0000201929.56928.13<pub-id pub-id-type="pmid">16481599</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/01.wnl.0000201929.56928.13</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR150"><label>150.</label><citation-alternatives><element-citation id="ec-CR150" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brichta</surname><given-names>L</given-names></name><name name-style="western"><surname>Holker</surname><given-names>I</given-names></name><name name-style="western"><surname>Haug</surname><given-names>K</given-names></name><name name-style="western"><surname>Klockgether</surname><given-names>T</given-names></name><name name-style="western"><surname>Wirth</surname><given-names>B</given-names></name></person-group><article-title>In vivo activation of SMN in spinal muscular atrophy carriers and patients treated with valproate</article-title><source>Ann Neurol</source><year>2006</year><volume>59</volume><fpage>970</fpage><lpage>975</lpage><pub-id pub-id-type="doi">10.1002/ana.20836</pub-id><pub-id pub-id-type="pmid">16607616</pub-id></element-citation><mixed-citation id="mc-CR150" publication-type="journal">Brichta L, Holker I, Haug K, Klockgether T, Wirth B (2006) In vivo activation of SMN in spinal muscular atrophy carriers and patients treated with valproate. Ann Neurol 59:970&#8211;975. 10.1002/ana.20836<pub-id pub-id-type="pmid">16607616</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ana.20836</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR151"><label>151.</label><citation-alternatives><element-citation id="ec-CR151" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Simard</surname><given-names>LR</given-names></name><name name-style="western"><surname>B&#233;langer</surname><given-names>MC</given-names></name><name name-style="western"><surname>Morissette</surname><given-names>S</given-names></name><name name-style="western"><surname>Wride</surname><given-names>M</given-names></name><name name-style="western"><surname>Prior</surname><given-names>TW</given-names></name><name name-style="western"><surname>Swoboda</surname><given-names>KJ</given-names></name></person-group><article-title>Preclinical validation of a multiplex real-time assay to quantify SMN mRNA in patients with SMA</article-title><source>Neurology</source><year>2007</year><volume>68</volume><fpage>451</fpage><lpage>456</lpage><pub-id pub-id-type="doi">10.1212/01.wnl.0000252934.70676.ab</pub-id><pub-id pub-id-type="pmid">17283322</pub-id><pub-id pub-id-type="pmcid">PMC3273325</pub-id></element-citation><mixed-citation id="mc-CR151" publication-type="journal">Simard LR, B&#233;langer MC, Morissette S, Wride M, Prior TW, Swoboda KJ (2007) Preclinical validation of a multiplex real-time assay to quantify SMN mRNA in patients with SMA. Neurology 68:451&#8211;456. 10.1212/01.wnl.0000252934.70676.ab<pub-id pub-id-type="pmid">17283322</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/01.wnl.0000252934.70676.ab</pub-id><pub-id pub-id-type="pmcid">PMC3273325</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR152"><label>152.</label><citation-alternatives><element-citation id="ec-CR152" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Czech</surname><given-names>C</given-names></name><name name-style="western"><surname>Tang</surname><given-names>W</given-names></name><name name-style="western"><surname>Bugawan</surname><given-names>T</given-names></name><name name-style="western"><surname>Mano</surname><given-names>C</given-names></name><name name-style="western"><surname>Horn</surname><given-names>C</given-names></name><name name-style="western"><surname>Iglesias</surname><given-names>VA</given-names></name><name name-style="western"><surname>Fr&#246;hner</surname><given-names>S</given-names></name><name name-style="western"><surname>Zaworski</surname><given-names>PG</given-names></name><name name-style="western"><surname>Paushkin</surname><given-names>S</given-names></name><name name-style="western"><surname>Chen</surname><given-names>K</given-names></name><name name-style="western"><surname>Kremer</surname><given-names>T</given-names></name></person-group><article-title>Biomarker for spinal muscular atrophy: expression of SMN in peripheral blood of SMA patients and healthy controls</article-title><source>PLoS ONE</source><year>2015</year><volume>10</volume><fpage>e0139950</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0139950</pub-id><pub-id pub-id-type="pmid">26468953</pub-id><pub-id pub-id-type="pmcid">PMC4607439</pub-id></element-citation><mixed-citation id="mc-CR152" publication-type="journal">Czech C, Tang W, Bugawan T, Mano C, Horn C, Iglesias VA, Fr&#246;hner S, Zaworski PG, Paushkin S, Chen K, Kremer T (2015) Biomarker for spinal muscular atrophy: expression of SMN in peripheral blood of SMA patients and healthy controls. PLoS ONE 10:e0139950. 10.1371/journal.pone.0139950<pub-id pub-id-type="pmid">26468953</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0139950</pub-id><pub-id pub-id-type="pmcid">PMC4607439</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR153"><label>153.</label><citation-alternatives><element-citation id="ec-CR153" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zaworski</surname><given-names>P</given-names></name><name name-style="western"><surname>von Herrmann</surname><given-names>KM</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>S</given-names></name><name name-style="western"><surname>Sunshine</surname><given-names>SS</given-names></name><name name-style="western"><surname>McCarthy</surname><given-names>K</given-names></name><name name-style="western"><surname>Risher</surname><given-names>N</given-names></name><name name-style="western"><surname>Newcomb</surname><given-names>T</given-names></name><name name-style="western"><surname>Weetall</surname><given-names>M</given-names></name><name name-style="western"><surname>Prior</surname><given-names>TW</given-names></name><name name-style="western"><surname>Swoboda</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Chen</surname><given-names>KS</given-names></name><name name-style="western"><surname>Paushkin</surname><given-names>S</given-names></name></person-group><article-title>SMN protein can be reliably measured in whole blood with an electrochemiluminescence (ECL) immunoassay: implications for clinical trials</article-title><source>PLoS ONE</source><year>2016</year><volume>11</volume><fpage>e0150640</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0150640</pub-id><pub-id pub-id-type="pmid">26953792</pub-id><pub-id pub-id-type="pmcid">PMC4783032</pub-id></element-citation><mixed-citation id="mc-CR153" publication-type="journal">Zaworski P, von Herrmann KM, Taylor S, Sunshine SS, McCarthy K, Risher N, Newcomb T, Weetall M, Prior TW, Swoboda KJ, Chen KS, Paushkin S (2016) SMN protein can be reliably measured in whole blood with an electrochemiluminescence (ECL) immunoassay: implications for clinical trials. PLoS ONE 11:e0150640. 10.1371/journal.pone.0150640<pub-id pub-id-type="pmid">26953792</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0150640</pub-id><pub-id pub-id-type="pmcid">PMC4783032</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR154"><label>154.</label><citation-alternatives><element-citation id="ec-CR154" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alves</surname><given-names>CRR</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>R</given-names></name><name name-style="western"><surname>Johnstone</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Garner</surname><given-names>R</given-names></name><name name-style="western"><surname>Eichelberger</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Lepez</surname><given-names>SDSD</given-names></name><name name-style="western"><surname>Yi</surname><given-names>V</given-names></name><name name-style="western"><surname>Stevens</surname><given-names>V</given-names></name><name name-style="western"><surname>Poxson</surname><given-names>R</given-names></name><name name-style="western"><surname>Schwartz</surname><given-names>R</given-names></name><name name-style="western"><surname>Zaworski</surname><given-names>P</given-names></name><name name-style="western"><surname>Swoboda</surname><given-names>KJ</given-names></name></person-group><article-title>Whole blood survival motor neuron protein levels correlate with severity of denervation in spinal muscular atrophy</article-title><source>Muscle Nerve</source><year>2020</year><volume>62</volume><fpage>351</fpage><lpage>357</lpage><pub-id pub-id-type="doi">10.1002/mus.26995</pub-id><pub-id pub-id-type="pmid">32511765</pub-id><pub-id pub-id-type="pmcid">PMC7496476</pub-id></element-citation><mixed-citation id="mc-CR154" publication-type="journal">Alves CRR, Zhang R, Johnstone AJ, Garner R, Eichelberger EJ, Lepez SDSD, Yi V, Stevens V, Poxson R, Schwartz R, Zaworski P, Swoboda KJ (2020) Whole blood survival motor neuron protein levels correlate with severity of denervation in spinal muscular atrophy. Muscle Nerve 62:351&#8211;357. 10.1002/mus.26995<pub-id pub-id-type="pmid">32511765</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mus.26995</pub-id><pub-id pub-id-type="pmcid">PMC7496476</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR155"><label>155.</label><citation-alternatives><element-citation id="ec-CR155" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>X</given-names></name><name name-style="western"><surname>Li</surname><given-names>YN</given-names></name><name name-style="western"><surname>Fan</surname><given-names>YB</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>HH</given-names></name><name name-style="western"><surname>Li</surname><given-names>L</given-names></name><name name-style="western"><surname>Lu</surname><given-names>C</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>LH</given-names></name><name name-style="western"><surname>Niu</surname><given-names>Q</given-names></name></person-group><article-title>Cytokines in cerebrospinal fluid as a prognostic predictor after treatment of nusinersen in SMA patients</article-title><source>Clin Neurol Neurosurg</source><year>2024</year><volume>244</volume><fpage>108462</fpage><pub-id pub-id-type="doi">10.1016/j.clineuro.2024.108462</pub-id><pub-id pub-id-type="pmid">39047390</pub-id></element-citation><mixed-citation id="mc-CR155" publication-type="journal">Cheng X, Li YN, Fan YB, Zhao HH, Li L, Lu C, Zhu LH, Niu Q (2024) Cytokines in cerebrospinal fluid as a prognostic predictor after treatment of nusinersen in SMA patients. Clin Neurol Neurosurg 244:108462. 10.1016/j.clineuro.2024.108462<pub-id pub-id-type="pmid">39047390</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.clineuro.2024.108462</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR156"><label>156.</label><citation-alternatives><element-citation id="ec-CR156" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Belan&#269;i&#263;</surname><given-names>A</given-names></name><name name-style="western"><surname>Jankovi&#263;</surname><given-names>T</given-names></name><name name-style="western"><surname>Gkrinia</surname><given-names>EMM</given-names></name><name name-style="western"><surname>Kristi&#263;</surname><given-names>I</given-names></name><name name-style="western"><surname>Raji&#269; Bumber</surname><given-names>J</given-names></name><name name-style="western"><surname>Ra&#269;ki</surname><given-names>V</given-names></name><name name-style="western"><surname>Pilipovi&#263;</surname><given-names>K</given-names></name><name name-style="western"><surname>Vitezi&#263;</surname><given-names>D</given-names></name><name name-style="western"><surname>Mr&#353;i&#263;-Pel&#269;i&#263;</surname><given-names>J</given-names></name></person-group><article-title>Glial cells in spinal muscular atrophy: speculations on non-cell-autonomous mechanisms and therapeutic implications</article-title><source>Neurol Int</source><year>2025</year><volume>17</volume><fpage>41</fpage><pub-id pub-id-type="doi">10.3390/neurolint17030041</pub-id><pub-id pub-id-type="pmid">40137462</pub-id><pub-id pub-id-type="pmcid">PMC11944370</pub-id></element-citation><mixed-citation id="mc-CR156" publication-type="journal">Belan&#269;i&#263; A, Jankovi&#263; T, Gkrinia EMM, Kristi&#263; I, Raji&#269; Bumber J, Ra&#269;ki V, Pilipovi&#263; K, Vitezi&#263; D, Mr&#353;i&#263;-Pel&#269;i&#263; J (2025) Glial cells in spinal muscular atrophy: speculations on non-cell-autonomous mechanisms and therapeutic implications. Neurol Int 17:41. 10.3390/neurolint17030041<pub-id pub-id-type="pmid">40137462</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/neurolint17030041</pub-id><pub-id pub-id-type="pmcid">PMC11944370</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR157"><label>157.</label><citation-alternatives><element-citation id="ec-CR157" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>TH</given-names></name><name name-style="western"><surname>Chang</surname><given-names>SH</given-names></name><name name-style="western"><surname>Wu</surname><given-names>YF</given-names></name><name name-style="western"><surname>Yen</surname><given-names>YP</given-names></name><name name-style="western"><surname>Hsu</surname><given-names>FY</given-names></name><name name-style="western"><surname>Chen</surname><given-names>YC</given-names></name><name name-style="western"><surname>Ming</surname><given-names>Y</given-names></name><name name-style="western"><surname>Hsu</surname><given-names>HC</given-names></name><name name-style="western"><surname>Su</surname><given-names>YC</given-names></name><name name-style="western"><surname>Wong</surname><given-names>ST</given-names></name><name name-style="western"><surname>Hung</surname><given-names>JH</given-names></name><name name-style="western"><surname>Chiou</surname><given-names>SH</given-names></name><name name-style="western"><surname>Jong</surname><given-names>YJ</given-names></name><name name-style="western"><surname>Chen</surname><given-names>JA</given-names></name></person-group><article-title>MiR34 contributes to spinal muscular atrophy and AAV9-mediated delivery of MiR34a ameliorates the motor deficits in SMA mice</article-title><source>Mol Ther Nucleic Acids</source><year>2023</year><volume>32</volume><fpage>144</fpage><lpage>160</lpage><pub-id pub-id-type="doi">10.1016/j.omtn.2023.03.005</pub-id><pub-id pub-id-type="pmid">37064776</pub-id><pub-id pub-id-type="pmcid">PMC10090489</pub-id></element-citation><mixed-citation id="mc-CR157" publication-type="journal">Chen TH, Chang SH, Wu YF, Yen YP, Hsu FY, Chen YC, Ming Y, Hsu HC, Su YC, Wong ST, Hung JH, Chiou SH, Jong YJ, Chen JA (2023) MiR34 contributes to spinal muscular atrophy and AAV9-mediated delivery of MiR34a ameliorates the motor deficits in SMA mice. Mol Ther Nucleic Acids 32:144&#8211;160. 10.1016/j.omtn.2023.03.005<pub-id pub-id-type="pmid">37064776</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.omtn.2023.03.005</pub-id><pub-id pub-id-type="pmcid">PMC10090489</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR158"><label>158.</label><citation-alternatives><element-citation id="ec-CR158" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Catapano</surname><given-names>F</given-names></name><name name-style="western"><surname>Zaharieva</surname><given-names>I</given-names></name><name name-style="western"><surname>Scoto</surname><given-names>M</given-names></name><name name-style="western"><surname>Marrosu</surname><given-names>E</given-names></name><name name-style="western"><surname>Morgan</surname><given-names>J</given-names></name><name name-style="western"><surname>Muntoni</surname><given-names>F</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>H</given-names></name></person-group><article-title>Altered levels of microRNA-9, -206, and -132 in spinal muscular atrophy and their response to antisense oligonucleotide therapy</article-title><source>Mol Ther Nucleic Acids</source><year>2016</year><volume>5</volume><fpage>e331</fpage><pub-id pub-id-type="doi">10.1038/mtna.2016.47</pub-id><pub-id pub-id-type="pmid">27377135</pub-id><pub-id pub-id-type="pmcid">PMC5014531</pub-id></element-citation><mixed-citation id="mc-CR158" publication-type="journal">Catapano F, Zaharieva I, Scoto M, Marrosu E, Morgan J, Muntoni F, Zhou H (2016) Altered levels of microRNA-9, -206, and -132 in spinal muscular atrophy and their response to antisense oligonucleotide therapy. Mol Ther Nucleic Acids 5:e331. 10.1038/mtna.2016.47<pub-id pub-id-type="pmid">27377135</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/mtna.2016.47</pub-id><pub-id pub-id-type="pmcid">PMC5014531</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR159"><label>159.</label><citation-alternatives><element-citation id="ec-CR159" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Malacarne</surname><given-names>C</given-names></name><name name-style="western"><surname>Galbiati</surname><given-names>M</given-names></name><name name-style="western"><surname>Giagnorio</surname><given-names>E</given-names></name><name name-style="western"><surname>Cavalcante</surname><given-names>P</given-names></name><name name-style="western"><surname>Salerno</surname><given-names>F</given-names></name><name name-style="western"><surname>Andreetta</surname><given-names>F</given-names></name><name name-style="western"><surname>Cagnoli</surname><given-names>C</given-names></name><name name-style="western"><surname>Taiana</surname><given-names>M</given-names></name><name name-style="western"><surname>Nizzardo</surname><given-names>M</given-names></name><name name-style="western"><surname>Corti</surname><given-names>S</given-names></name><name name-style="western"><surname>Pensato</surname><given-names>V</given-names></name><name name-style="western"><surname>Venerando</surname><given-names>A</given-names></name><name name-style="western"><surname>Gellera</surname><given-names>C</given-names></name><name name-style="western"><surname>Fenu</surname><given-names>S</given-names></name><name name-style="western"><surname>Pareyson</surname><given-names>D</given-names></name><name name-style="western"><surname>Masson</surname><given-names>R</given-names></name><name name-style="western"><surname>Maggi</surname><given-names>L</given-names></name><name name-style="western"><surname>Dalla Bella</surname><given-names>E</given-names></name><name name-style="western"><surname>Lauria</surname><given-names>G</given-names></name><name name-style="western"><surname>Mantegazza</surname><given-names>R</given-names></name><etal/></person-group><article-title>Dysregulation of muscle-specific microRNAs as common pathogenic feature associated with muscle atrophy in ALS, SMA and SBMA: evidence from animal models and human patients</article-title><source>Int J Mol Sci</source><year>2021</year><volume>22</volume><fpage>5673</fpage><pub-id pub-id-type="doi">10.3390/ijms22115673</pub-id><pub-id pub-id-type="pmid">34073630</pub-id><pub-id pub-id-type="pmcid">PMC8198536</pub-id></element-citation><mixed-citation id="mc-CR159" publication-type="journal">Malacarne C, Galbiati M, Giagnorio E, Cavalcante P, Salerno F, Andreetta F, Cagnoli C, Taiana M, Nizzardo M, Corti S, Pensato V, Venerando A, Gellera C, Fenu S, Pareyson D, Masson R, Maggi L, Dalla Bella E, Lauria G, Mantegazza R et al (2021) Dysregulation of muscle-specific microRNAs as common pathogenic feature associated with muscle atrophy in ALS, SMA and SBMA: evidence from animal models and human patients. Int J Mol Sci 22:5673. 10.3390/ijms22115673<pub-id pub-id-type="pmid">34073630</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms22115673</pub-id><pub-id pub-id-type="pmcid">PMC8198536</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR160"><label>160.</label><citation-alternatives><element-citation id="ec-CR160" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Welby</surname><given-names>E</given-names></name><name name-style="western"><surname>Rehborg</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Harmelink</surname><given-names>M</given-names></name><name name-style="western"><surname>Ebert</surname><given-names>AD</given-names></name></person-group><article-title>Assessment of cerebral spinal fluid biomarkers and microRNA-mediated disease mechanisms in spinal muscular atrophy patient samples</article-title><source>Hum Mol Genet</source><year>2022</year><volume>31</volume><fpage>1830</fpage><lpage>1843</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddab365</pub-id><pub-id pub-id-type="pmid">34919695</pub-id></element-citation><mixed-citation id="mc-CR160" publication-type="journal">Welby E, Rehborg RJ, Harmelink M, Ebert AD (2022) Assessment of cerebral spinal fluid biomarkers and microRNA-mediated disease mechanisms in spinal muscular atrophy patient samples. Hum Mol Genet 31:1830&#8211;1843. 10.1093/hmg/ddab365<pub-id pub-id-type="pmid">34919695</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/hmg/ddab365</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR161"><label>161.</label><citation-alternatives><element-citation id="ec-CR161" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Magen</surname><given-names>I</given-names></name><name name-style="western"><surname>Aharoni</surname><given-names>S</given-names></name><name name-style="western"><surname>Yacovzada</surname><given-names>NS</given-names></name><name name-style="western"><surname>Tokatly Latzer</surname><given-names>I</given-names></name><name name-style="western"><surname>Alves</surname><given-names>CRR</given-names></name><name name-style="western"><surname>Sagi</surname><given-names>L</given-names></name><name name-style="western"><surname>Fattal-Valevski</surname><given-names>A</given-names></name><name name-style="western"><surname>Swoboda</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Katz</surname><given-names>J</given-names></name><name name-style="western"><surname>Bruckheimer</surname><given-names>E</given-names></name><name name-style="western"><surname>Nevo</surname><given-names>Y</given-names></name><name name-style="western"><surname>Hornstein</surname><given-names>E</given-names></name></person-group><article-title>Muscle microRNAs in the cerebrospinal fluid predict clinical response to nusinersen therapy in type II and type III spinal muscular atrophy patients</article-title><source>Eur J Neurol</source><year>2022</year><volume>29</volume><fpage>2420</fpage><lpage>2430</lpage><pub-id pub-id-type="doi">10.1111/ene.15382</pub-id><pub-id pub-id-type="pmid">35510740</pub-id><pub-id pub-id-type="pmcid">PMC9544362</pub-id></element-citation><mixed-citation id="mc-CR161" publication-type="journal">Magen I, Aharoni S, Yacovzada NS, Tokatly Latzer I, Alves CRR, Sagi L, Fattal-Valevski A, Swoboda KJ, Katz J, Bruckheimer E, Nevo Y, Hornstein E (2022) Muscle microRNAs in the cerebrospinal fluid predict clinical response to nusinersen therapy in type II and type III spinal muscular atrophy patients. Eur J Neurol 29:2420&#8211;2430. 10.1111/ene.15382<pub-id pub-id-type="pmid">35510740</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/ene.15382</pub-id><pub-id pub-id-type="pmcid">PMC9544362</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR162"><label>162.</label><citation-alternatives><element-citation id="ec-CR162" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Babi&#263;</surname><given-names>M</given-names></name><name name-style="western"><surname>Banovi&#263;</surname><given-names>M</given-names></name><name name-style="western"><surname>Bere&#269;i&#263;</surname><given-names>I</given-names></name><name name-style="western"><surname>Bani&#263;</surname><given-names>T</given-names></name><name name-style="western"><surname>Babi&#263; Leko</surname><given-names>M</given-names></name><name name-style="western"><surname>Ulamec</surname><given-names>M</given-names></name><name name-style="western"><surname>Junakovi&#263;</surname><given-names>A</given-names></name><name name-style="western"><surname>Kopi&#263;</surname><given-names>J</given-names></name><name name-style="western"><surname>Serti&#263;</surname><given-names>J</given-names></name><name name-style="western"><surname>Bari&#353;i&#263;</surname><given-names>N</given-names></name><name name-style="western"><surname>&#352;imi&#263;</surname><given-names>G</given-names></name></person-group><article-title>Molecular biomarkers for the diagnosis, prognosis, and pharmacodynamics of spinal muscular atrophy</article-title><source>J Clin Med</source><year>2023</year><volume>12</volume><fpage>5060</fpage><pub-id pub-id-type="doi">10.3390/jcm12155060</pub-id><pub-id pub-id-type="pmid">37568462</pub-id><pub-id pub-id-type="pmcid">PMC10419842</pub-id></element-citation><mixed-citation id="mc-CR162" publication-type="journal">Babi&#263; M, Banovi&#263; M, Bere&#269;i&#263; I, Bani&#263; T, Babi&#263; Leko M, Ulamec M, Junakovi&#263; A, Kopi&#263; J, Serti&#263; J, Bari&#353;i&#263; N, &#352;imi&#263; G (2023) Molecular biomarkers for the diagnosis, prognosis, and pharmacodynamics of spinal muscular atrophy. J Clin Med 12:5060. 10.3390/jcm12155060<pub-id pub-id-type="pmid">37568462</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/jcm12155060</pub-id><pub-id pub-id-type="pmcid">PMC10419842</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR163"><label>163.</label><citation-alternatives><element-citation id="ec-CR163" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garofalo</surname><given-names>M</given-names></name><name name-style="western"><surname>Bonanno</surname><given-names>S</given-names></name><name name-style="western"><surname>Marcuzzo</surname><given-names>S</given-names></name><name name-style="western"><surname>Pandini</surname><given-names>C</given-names></name><name name-style="western"><surname>Scarian</surname><given-names>E</given-names></name><name name-style="western"><surname>Dragoni</surname><given-names>F</given-names></name><name name-style="western"><surname>Di Gerlando</surname><given-names>R</given-names></name><name name-style="western"><surname>Bordoni</surname><given-names>M</given-names></name><name name-style="western"><surname>Parravicini</surname><given-names>S</given-names></name><name name-style="western"><surname>Gellera</surname><given-names>C</given-names></name><name name-style="western"><surname>Masson</surname><given-names>R</given-names></name><name name-style="western"><surname>Dosi</surname><given-names>C</given-names></name><name name-style="western"><surname>Zanin</surname><given-names>R</given-names></name><name name-style="western"><surname>Pansarasa</surname><given-names>O</given-names></name><name name-style="western"><surname>Cereda</surname><given-names>C</given-names></name><name name-style="western"><surname>Berardinelli</surname><given-names>A</given-names></name><name name-style="western"><surname>Gagliardi</surname><given-names>S</given-names></name></person-group><article-title>Preliminary insights into RNA in CSF of pediatric SMA patients after 6 months of nusinersen</article-title><source>Biol Direct</source><year>2023</year><volume>18</volume><fpage>57</fpage><pub-id pub-id-type="doi">10.1186/s13062-023-00413-6</pub-id><pub-id pub-id-type="pmid">37705059</pub-id><pub-id pub-id-type="pmcid">PMC10498611</pub-id></element-citation><mixed-citation id="mc-CR163" publication-type="journal">Garofalo M, Bonanno S, Marcuzzo S, Pandini C, Scarian E, Dragoni F, Di Gerlando R, Bordoni M, Parravicini S, Gellera C, Masson R, Dosi C, Zanin R, Pansarasa O, Cereda C, Berardinelli A, Gagliardi S (2023) Preliminary insights into RNA in CSF of pediatric SMA patients after 6 months of nusinersen. Biol Direct 18:57. 10.1186/s13062-023-00413-6<pub-id pub-id-type="pmid">37705059</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13062-023-00413-6</pub-id><pub-id pub-id-type="pmcid">PMC10498611</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR164"><label>164.</label><citation-alternatives><element-citation id="ec-CR164" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leo</surname><given-names>M</given-names></name><name name-style="western"><surname>Schmitt</surname><given-names>LI</given-names></name><name name-style="western"><surname>Mairinger</surname><given-names>F</given-names></name><name name-style="western"><surname>Roos</surname><given-names>A</given-names></name><name name-style="western"><surname>Hansmann</surname><given-names>C</given-names></name><name name-style="western"><surname>Hezel</surname><given-names>S</given-names></name><name name-style="western"><surname>Skuljec</surname><given-names>J</given-names></name><name name-style="western"><surname>Pul</surname><given-names>R</given-names></name><name name-style="western"><surname>Schara-Schmidt</surname><given-names>U</given-names></name><name name-style="western"><surname>Kleinschnitz</surname><given-names>C</given-names></name><name name-style="western"><surname>Hagenacker</surname><given-names>T</given-names></name></person-group><article-title>Analysis of free circulating messenger ribonucleic acids in serum samples from late-onset spinal muscular atrophy patients using nCounter NanoString technology</article-title><source>Cells</source><year>2023</year><volume>12</volume><fpage>2374</fpage><pub-id pub-id-type="doi">10.3390/cells12192374</pub-id><pub-id pub-id-type="pmid">37830588</pub-id><pub-id pub-id-type="pmcid">PMC10572204</pub-id></element-citation><mixed-citation id="mc-CR164" publication-type="journal">Leo M, Schmitt LI, Mairinger F, Roos A, Hansmann C, Hezel S, Skuljec J, Pul R, Schara-Schmidt U, Kleinschnitz C, Hagenacker T (2023) Analysis of free circulating messenger ribonucleic acids in serum samples from late-onset spinal muscular atrophy patients using nCounter NanoString technology. Cells 12:2374. 10.3390/cells12192374<pub-id pub-id-type="pmid">37830588</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cells12192374</pub-id><pub-id pub-id-type="pmcid">PMC10572204</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR165"><label>165.</label><citation-alternatives><element-citation id="ec-CR165" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Panicucci</surname><given-names>C</given-names></name><name name-style="western"><surname>Sahin</surname><given-names>E</given-names></name><name name-style="western"><surname>Bartolucci</surname><given-names>M</given-names></name><name name-style="western"><surname>Casalini</surname><given-names>S</given-names></name><name name-style="western"><surname>Brolatti</surname><given-names>N</given-names></name><name name-style="western"><surname>Pedemonte</surname><given-names>M</given-names></name><name name-style="western"><surname>Baratto</surname><given-names>S</given-names></name><name name-style="western"><surname>Pintus</surname><given-names>S</given-names></name><name name-style="western"><surname>Principi</surname><given-names>E</given-names></name><name name-style="western"><surname>D'Amico</surname><given-names>A</given-names></name><name name-style="western"><surname>Pane</surname><given-names>M</given-names></name><name name-style="western"><surname>Sframeli</surname><given-names>M</given-names></name><name name-style="western"><surname>Messina</surname><given-names>S</given-names></name><name name-style="western"><surname>Albamonte</surname><given-names>E</given-names></name><name name-style="western"><surname>Sansone</surname><given-names>VA</given-names></name><name name-style="western"><surname>Mercuri</surname><given-names>E</given-names></name><name name-style="western"><surname>Bertini</surname><given-names>E</given-names></name><name name-style="western"><surname>Sezerman</surname><given-names>U</given-names></name><name name-style="western"><surname>Petretto</surname><given-names>A</given-names></name><name name-style="western"><surname>Bruno</surname><given-names>C</given-names></name></person-group><article-title>Proteomics profiling and machine learning in nusinersen-treated patients with spinal muscular atrophy</article-title><source>Cell Mol Life Sci</source><year>2024</year><volume>81</volume><fpage>393</fpage><pub-id pub-id-type="doi">10.1007/s00018-024-05426-6</pub-id><pub-id pub-id-type="pmid">39254732</pub-id><pub-id pub-id-type="pmcid">PMC11387582</pub-id></element-citation><mixed-citation id="mc-CR165" publication-type="journal">Panicucci C, Sahin E, Bartolucci M, Casalini S, Brolatti N, Pedemonte M, Baratto S, Pintus S, Principi E, D&#8217;Amico A, Pane M, Sframeli M, Messina S, Albamonte E, Sansone VA, Mercuri E, Bertini E, Sezerman U, Petretto A, Bruno C (2024) Proteomics profiling and machine learning in nusinersen-treated patients with spinal muscular atrophy. Cell Mol Life Sci 81:393. 10.1007/s00018-024-05426-6<pub-id pub-id-type="pmid">39254732</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00018-024-05426-6</pub-id><pub-id pub-id-type="pmcid">PMC11387582</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR166"><label>166.</label><citation-alternatives><element-citation id="ec-CR166" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Faravelli</surname><given-names>I</given-names></name><name name-style="western"><surname>Gagliardi</surname><given-names>D</given-names></name><name name-style="western"><surname>Abati</surname><given-names>E</given-names></name><name name-style="western"><surname>Meneri</surname><given-names>M</given-names></name><name name-style="western"><surname>Ongaro</surname><given-names>J</given-names></name><name name-style="western"><surname>Magri</surname><given-names>F</given-names></name><name name-style="western"><surname>Parente</surname><given-names>V</given-names></name><name name-style="western"><surname>Petrozzi</surname><given-names>L</given-names></name><name name-style="western"><surname>Ricci</surname><given-names>G</given-names></name><name name-style="western"><surname>Far&#232;</surname><given-names>F</given-names></name><name name-style="western"><surname>Garrone</surname><given-names>G</given-names></name><name name-style="western"><surname>Fontana</surname><given-names>M</given-names></name><name name-style="western"><surname>Caruso</surname><given-names>D</given-names></name><name name-style="western"><surname>Siciliano</surname><given-names>G</given-names></name><name name-style="western"><surname>Comi</surname><given-names>GP</given-names></name><name name-style="western"><surname>Govoni</surname><given-names>A</given-names></name><name name-style="western"><surname>Corti</surname><given-names>S</given-names></name><name name-style="western"><surname>Ottoboni</surname><given-names>L</given-names></name></person-group><article-title>Multi-omics profiling of CSF from spinal muscular atrophy type 3 patients after nusinersen treatment: a 2-year follow-up multicenter retrospective study</article-title><source>Cell Mol Life Sci</source><year>2023</year><volume>80</volume><fpage>241</fpage><pub-id pub-id-type="doi">10.1007/s00018-023-04885-7</pub-id><pub-id pub-id-type="pmid">37543540</pub-id><pub-id pub-id-type="pmcid">PMC10404194</pub-id></element-citation><mixed-citation id="mc-CR166" publication-type="journal">Faravelli I, Gagliardi D, Abati E, Meneri M, Ongaro J, Magri F, Parente V, Petrozzi L, Ricci G, Far&#232; F, Garrone G, Fontana M, Caruso D, Siciliano G, Comi GP, Govoni A, Corti S, Ottoboni L (2023) Multi-omics profiling of CSF from spinal muscular atrophy type 3 patients after nusinersen treatment: a 2-year follow-up multicenter retrospective study. Cell Mol Life Sci 80:241. 10.1007/s00018-023-04885-7<pub-id pub-id-type="pmid">37543540</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00018-023-04885-7</pub-id><pub-id pub-id-type="pmcid">PMC10404194</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR167"><label>167.</label><citation-alternatives><element-citation id="ec-CR167" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pant</surname><given-names>DC</given-names></name><name name-style="western"><surname>Verma</surname><given-names>S</given-names></name></person-group><article-title>Identifying novel response markers for spinal muscular atrophy revealed by targeted proteomics following gene therapy</article-title><source>Gene Ther</source><year>2025</year><pub-id pub-id-type="doi">10.1038/s41434-025-00513-0</pub-id><pub-id pub-id-type="pmid">39794476</pub-id></element-citation><mixed-citation id="mc-CR167" publication-type="journal">Pant DC, Verma S (2025) Identifying novel response markers for spinal muscular atrophy revealed by targeted proteomics following gene therapy. Gene Ther. 10.1038/s41434-025-00513-0<pub-id pub-id-type="pmid">39794476</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41434-025-00513-0</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR168"><label>168.</label><citation-alternatives><element-citation id="ec-CR168" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>M</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>Sun</surname><given-names>N</given-names></name><name name-style="western"><surname>Huang</surname><given-names>S</given-names></name><name name-style="western"><surname>Yang</surname><given-names>L</given-names></name><name name-style="western"><surname>Li</surname><given-names>D</given-names></name></person-group><article-title>Metabolomics of cerebrospinal fluid reveals candidate diagnostic biomarkers to distinguish between spinal muscular atrophy type II and type III</article-title><source>CNS Neurosci Ther</source><year>2024</year><volume>30</volume><fpage>e14718</fpage><pub-id pub-id-type="doi">10.1111/cns.14718</pub-id><pub-id pub-id-type="pmid">38615366</pub-id><pub-id pub-id-type="pmcid">PMC11016346</pub-id></element-citation><mixed-citation id="mc-CR168" publication-type="journal">Lu M, Wang X, Sun N, Huang S, Yang L, Li D (2024) Metabolomics of cerebrospinal fluid reveals candidate diagnostic biomarkers to distinguish between spinal muscular atrophy type II and type III. CNS Neurosci Ther 30:e14718. 10.1111/cns.14718<pub-id pub-id-type="pmid">38615366</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/cns.14718</pub-id><pub-id pub-id-type="pmcid">PMC11016346</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR169"><label>169.</label><citation-alternatives><element-citation id="ec-CR169" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saffari</surname><given-names>A</given-names></name><name name-style="western"><surname>Niesert</surname><given-names>M</given-names></name><name name-style="western"><surname>Cannet</surname><given-names>C</given-names></name><name name-style="western"><surname>Blaschek</surname><given-names>A</given-names></name><name name-style="western"><surname>Hahn</surname><given-names>A</given-names></name><name name-style="western"><surname>Johannsen</surname><given-names>J</given-names></name><name name-style="western"><surname>Kockaya</surname><given-names>M</given-names></name><name name-style="western"><surname>K&#246;lbel</surname><given-names>H</given-names></name><name name-style="western"><surname>Hoffmann</surname><given-names>GF</given-names></name><name name-style="western"><surname>Claus</surname><given-names>P</given-names></name><name name-style="western"><surname>K&#246;lker</surname><given-names>S</given-names></name><name name-style="western"><surname>M&#252;ller-Felber</surname><given-names>W</given-names></name><name name-style="western"><surname>Roos</surname><given-names>A</given-names></name><name name-style="western"><surname>Schara-Schmidt</surname><given-names>U</given-names></name><name name-style="western"><surname>Trefz</surname><given-names>FK</given-names></name><name name-style="western"><surname>Vill</surname><given-names>K</given-names></name><name name-style="western"><surname>Wick</surname><given-names>W</given-names></name><name name-style="western"><surname>Weiler</surname><given-names>M</given-names></name><name name-style="western"><surname>Okun</surname><given-names>JG</given-names></name><name name-style="western"><surname>Ziegler</surname><given-names>A</given-names></name></person-group><article-title>Identification of biochemical determinants for diagnosis and prediction of severity in 5q spinal muscular atrophy using <sup>1</sup>H-nuclear magnetic resonance metabolic profiling in patient-derived biofluids</article-title><source>Int J Mol Sci</source><year>2024</year><volume>25</volume><fpage>12123</fpage><pub-id pub-id-type="doi">10.3390/ijms252212123</pub-id><pub-id pub-id-type="pmid">39596191</pub-id><pub-id pub-id-type="pmcid">PMC11594255</pub-id></element-citation><mixed-citation id="mc-CR169" publication-type="journal">Saffari A, Niesert M, Cannet C, Blaschek A, Hahn A, Johannsen J, Kockaya M, K&#246;lbel H, Hoffmann GF, Claus P, K&#246;lker S, M&#252;ller-Felber W, Roos A, Schara-Schmidt U, Trefz FK, Vill K, Wick W, Weiler M, Okun JG, Ziegler A (2024) Identification of biochemical determinants for diagnosis and prediction of severity in 5q spinal muscular atrophy using <sup>1</sup>H-nuclear magnetic resonance metabolic profiling in patient-derived biofluids. Int J Mol Sci 25:12123. 10.3390/ijms252212123<pub-id pub-id-type="pmid">39596191</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms252212123</pub-id><pub-id pub-id-type="pmcid">PMC11594255</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR170"><label>170.</label><citation-alternatives><element-citation id="ec-CR170" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Errico</surname><given-names>F</given-names></name><name name-style="western"><surname>Marino</surname><given-names>C</given-names></name><name name-style="western"><surname>Grimaldi</surname><given-names>M</given-names></name><name name-style="western"><surname>Nuzzo</surname><given-names>T</given-names></name><name name-style="western"><surname>Bassareo</surname><given-names>V</given-names></name><name name-style="western"><surname>Valsecchi</surname><given-names>V</given-names></name><name name-style="western"><surname>Panicucci</surname><given-names>C</given-names></name><name name-style="western"><surname>Di Schiavi</surname><given-names>E</given-names></name><name name-style="western"><surname>Mazza</surname><given-names>T</given-names></name><name name-style="western"><surname>Bruno</surname><given-names>C</given-names></name><name name-style="western"><surname>D'Amico</surname><given-names>A</given-names></name><name name-style="western"><surname>Carta</surname><given-names>M</given-names></name><name name-style="western"><surname>D'Ursi</surname><given-names>AM</given-names></name><name name-style="western"><surname>Bertini</surname><given-names>E</given-names></name><name name-style="western"><surname>Pellizzoni</surname><given-names>L</given-names></name><name name-style="western"><surname>Usiello</surname><given-names>A</given-names></name></person-group><article-title>Nusinersen induces disease-severity-specific neurometabolic effects in spinal muscular atrophy</article-title><source>Biomolecules</source><year>2022</year><volume>12</volume><fpage>1431</fpage><pub-id pub-id-type="doi">10.3390/biom12101431</pub-id><pub-id pub-id-type="pmid">36291640</pub-id><pub-id pub-id-type="pmcid">PMC9599672</pub-id></element-citation><mixed-citation id="mc-CR170" publication-type="journal">Errico F, Marino C, Grimaldi M, Nuzzo T, Bassareo V, Valsecchi V, Panicucci C, Di Schiavi E, Mazza T, Bruno C, D&#8217;Amico A, Carta M, D&#8217;Ursi AM, Bertini E, Pellizzoni L, Usiello A (2022) Nusinersen induces disease-severity-specific neurometabolic effects in spinal muscular atrophy. Biomolecules 12:1431. 10.3390/biom12101431<pub-id pub-id-type="pmid">36291640</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/biom12101431</pub-id><pub-id pub-id-type="pmcid">PMC9599672</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR171"><label>171.</label><citation-alternatives><element-citation id="ec-CR171" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Srivastava</surname><given-names>T</given-names></name><name name-style="western"><surname>Darras</surname><given-names>BT</given-names></name><name name-style="western"><surname>Wu</surname><given-names>JS</given-names></name><name name-style="western"><surname>Rutkove</surname><given-names>SB</given-names></name></person-group><article-title>Machine learning algorithms to classify spinal muscular atrophy subtypes</article-title><source>Neurology</source><year>2012</year><volume>79</volume><fpage>358</fpage><lpage>364</lpage><pub-id pub-id-type="doi">10.1212/WNL.0b013e3182604395</pub-id><pub-id pub-id-type="pmid">22786588</pub-id><pub-id pub-id-type="pmcid">PMC3400094</pub-id></element-citation><mixed-citation id="mc-CR171" publication-type="journal">Srivastava T, Darras BT, Wu JS, Rutkove SB (2012) Machine learning algorithms to classify spinal muscular atrophy subtypes. Neurology 79:358&#8211;364. 10.1212/WNL.0b013e3182604395<pub-id pub-id-type="pmid">22786588</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0b013e3182604395</pub-id><pub-id pub-id-type="pmcid">PMC3400094</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR172"><label>172.</label><citation-alternatives><element-citation id="ec-CR172" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vu-Han</surname><given-names>TL</given-names></name><name name-style="western"><surname>Schettino</surname><given-names>RB</given-names></name><name name-style="western"><surname>Wei&#223;</surname><given-names>C</given-names></name><name name-style="western"><surname>Perka</surname><given-names>C</given-names></name><name name-style="western"><surname>Winkler</surname><given-names>T</given-names></name><name name-style="western"><surname>Sunkara</surname><given-names>V</given-names></name><name name-style="western"><surname>Pumberger</surname><given-names>M</given-names></name></person-group><article-title>An interpretable data-driven prediction model to anticipate scoliosis in spinal muscular atrophy in the era of (gene-) therapies</article-title><source>Sci Rep</source><year>2024</year><volume>14</volume><fpage>11838</fpage><pub-id pub-id-type="doi">10.1038/s41598-024-62720-w</pub-id><pub-id pub-id-type="pmid">38783003</pub-id><pub-id pub-id-type="pmcid">PMC11116550</pub-id></element-citation><mixed-citation id="mc-CR172" publication-type="journal">Vu-Han TL, Schettino RB, Wei&#223; C, Perka C, Winkler T, Sunkara V, Pumberger M (2024) An interpretable data-driven prediction model to anticipate scoliosis in spinal muscular atrophy in the era of (gene-) therapies. Sci Rep 14:11838. 10.1038/s41598-024-62720-w<pub-id pub-id-type="pmid">38783003</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-024-62720-w</pub-id><pub-id pub-id-type="pmcid">PMC11116550</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR173"><label>173.</label><citation-alternatives><element-citation id="ec-CR173" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pane</surname><given-names>M</given-names></name><name name-style="western"><surname>Donati</surname><given-names>MA</given-names></name><name name-style="western"><surname>Cutrona</surname><given-names>C</given-names></name><name name-style="western"><surname>De Sanctis</surname><given-names>R</given-names></name><name name-style="western"><surname>Pirinu</surname><given-names>M</given-names></name><name name-style="western"><surname>Coratti</surname><given-names>G</given-names></name><name name-style="western"><surname>Ricci</surname><given-names>M</given-names></name><name name-style="western"><surname>Palermo</surname><given-names>C</given-names></name><name name-style="western"><surname>Berti</surname><given-names>B</given-names></name><name name-style="western"><surname>Leone</surname><given-names>D</given-names></name><name name-style="western"><surname>Ticci</surname><given-names>C</given-names></name><name name-style="western"><surname>Sacchini</surname><given-names>M</given-names></name><name name-style="western"><surname>Cerboneschi</surname><given-names>M</given-names></name><name name-style="western"><surname>Capasso</surname><given-names>A</given-names></name><name name-style="western"><surname>Cicala</surname><given-names>G</given-names></name><name name-style="western"><surname>Pera</surname><given-names>MC</given-names></name><name name-style="western"><surname>Bravetti</surname><given-names>C</given-names></name><name name-style="western"><surname>Abiusi</surname><given-names>E</given-names></name><name name-style="western"><surname>Vaisfeld</surname><given-names>A</given-names></name><name name-style="western"><surname>Vento</surname><given-names>G</given-names></name><name name-style="western"><surname>Tiziano</surname><given-names>FD</given-names></name><name name-style="western"><surname>Mercuri</surname><given-names>E</given-names></name></person-group><article-title>Neurological assessment of newborns with spinal muscular atrophy identified through neonatal screening</article-title><source>Eur J Pediatr</source><year>2022</year><volume>181</volume><fpage>2821</fpage><lpage>2829</lpage><pub-id pub-id-type="doi">10.1007/s00431-022-04470-3</pub-id><pub-id pub-id-type="pmid">35522315</pub-id><pub-id pub-id-type="pmcid">PMC9192449</pub-id></element-citation><mixed-citation id="mc-CR173" publication-type="journal">Pane M, Donati MA, Cutrona C, De Sanctis R, Pirinu M, Coratti G, Ricci M, Palermo C, Berti B, Leone D, Ticci C, Sacchini M, Cerboneschi M, Capasso A, Cicala G, Pera MC, Bravetti C, Abiusi E, Vaisfeld A, Vento G, Tiziano FD, Mercuri E (2022) Neurological assessment of newborns with spinal muscular atrophy identified through neonatal screening. Eur J Pediatr 181:2821&#8211;2829. 10.1007/s00431-022-04470-3<pub-id pub-id-type="pmid">35522315</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00431-022-04470-3</pub-id><pub-id pub-id-type="pmcid">PMC9192449</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article>
        
    </metadata>
</record>
    </GetRecord>

</OAI-PMH>